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Summary 
ardiac valve replacement is the second most common heart operation in the 
Western World. Valve replacements currently available are poorly adapted for 
use in young patients who typically require multiple re-operations as they grow, 
resulting in increased morbidity and mortality. Tissue-engineering a living heart valve 
replacement would be an ideal substitute as it would not require drug therapies or re- 
operation. Bone marrow-derived mesenchymal stem cells have been shown to be 
capable of differentiating into a variety of lineages and may be advantageous as a cell 
source for tissue engineering applications. 
Attempts were made to isolate human and porcine mesenchymal stem cells (MSC) from 
the respective bone marrows using gradient-centrifugation to separate the cells and 
complete Dulbecco"s Modified Eagle's Medium (DMEM) to culture the cells. The 
cellular material from one bone marrow was transferred to one 25CM2 tissue Culture 
flask. Cell differentiation was attempted by supplementing complete culture medium 
with growth factors and biochemicals. The phenotype of the human MSC (hMSC) was 
then examined by FACS analysis. A previously developed decellularised porcine aortic 
valve matrix was biochemically characterised to ensure that the major matrix 
components had not been removed by the decellularisation procedure. Furthermore the 
biocompatibility of the decellularised. tissue compared to fresh tissue was assessed by 
subcutaneous implantation into mice (n--4). hMSC were then seeded onto the 
decellularised porcine aortic valve matrices in vitro and the ability of the cells to 
migrate into the tissue compared to smooth muscle cells in a static culture system was 
assessed. 
I 
Summary 
Putative porcine MSC (pMSC) and hMSC were successfully isolated from their 
respective bone marrows. Putative pMSC were found to have a cell doubling time 
(CDT) of 106 hours and hMSC had a CDT of 151 hours. A failure to successfully 
culture pMSC was found to be due to a change in the supplier of DMEM used. Attempts 
to differentiate porcine MSC (pMSC) produced adipogenic cells but failed to produce 
osteogenic, chondrogenic, neurogenic, myogenic or smooth muscle lineage cells. hMSC 
were successfully differentiated into cells of the adipogenic, myogenic and neurogenic 
lineage. However, attempts to clone the cells were unsuccessful. FACS analysis of 
hMSC indicated that the cells were CD45-,, CD13 +, D7FIB + 1, CD 105 
+, CD I 0+/-il 
LNGFe-,, CD55 + 1, BNT- and AP+'-. Analysis of hydroxyproline, sulphated 
proteoglycan and DNA content of the decellularised porcine valve tissue indicated no 
change in collagen or GAG content and removal of cellular DNA. Implanted 
decellularised tissues were accepted by the mice in comparison to fresh tissue and 
appeared to be undergoing regeneration. Furthen-nore, the cell infiltrate into the matrices 
was favourable, being low in T-cells but more macrophages and endothelial cells. 
Seeding the decellulansed matrix with hMSC showed that the cells migrated into the 
tissue to up to 2% of the cell density found in native valve tissue compared to 0% of the 
smooth muscle cells. 
Failure to clone hMSC meant that differentiation could have been a result of multiple 
cell precursors being present in the bone marrow rather than a stem cell population. 
Biochemical and biocompatibility analyses of the decellularised porcine valve matrix 
-I- snowed that the tissue was unaltered by the procedure and biocompatible. hMSC were 
also observed to migrate into the tissue under static seeding conditions. 
11 . 
Summary 
In conclusion,, mesenchymal stem cells represent a promising cell source for tissue 
engineering a living aortic heart valve. However, more research is required to further 
characterise the cells and optimise their growth and differentiation. The decellularised 
porcine valve matrix developed by shows potential as a matrix for tissue engineering an 
aortic heart valve. 
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CHAPTER ONE: 
Introduction 
0 CHAPTER 19 
IntrOdUction 
C ardiovascular disease is the leading cause of death in the Western World, with an 
estimated 62 million sufferers in the US and an additional 40,000 children 
suffering from congenital heart defects [Perry & Roth, 2003]. Some 20,000 people are 
thought to die in the United States alone as a result of heart valve dysfunction [Shinoka 
et aL, 1997]. If caught in the earliest stages therapies can be implemented to help 
alleviate the problems, however, the most severe cases will ultimately require some 
form of transplant, be it a whole heart, or just an individual valve. The availability of 
these replacements is restricted and unpredictable, leading to long waiting lists of 
patients requiring transplants, many of whom die before a replacement becomes 
available. Mitral valves are most frequently repaired rather than replaced, and the 
current techniques give favourable results. For aortic heart valves, mechanical and 
bioprosthetic alternatives are available, but these are not adequate for all patients, since 
they are unable to grow and repair, often requiring drugs to maintain their longevity. 
Thus, an altertiative is required to overcome these problems, particularly for paediatric 
patients who currently require multiple reoperations as they grow. 
1.1. The Human Heart 
The human heart beats over 100,000 times a day, circulating a volume of approximately 
5 litres of blood through, what is estimated to be nearly 100,000 miles of 
blood vessels 
in the average adult. In order to do this effectively, the pressure of the 
blood as it travels 
through the heart, particularly as it leaves through the aorta, is considerable. To 
I 
CLr 4pRI 
facilitate efficient blood flow in the correct direction there are four valves that prevent 
blood regurgitation between the chambers and major vessels of the heart during the 
resting phase of the cardiac cycle. The tricuspid valve separates the right atrium and 
ventricle; the mitral valve separates the left atrium and ventricle; the pulmonar-Y ý, alve 
separates the pulmonary artery from the right ventricle and the aortic valve separates the 
aorta from the left ventricle. An explanatory diagram can be seen in Figure 1.1. 
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Figure 1.1. A diagram of the human heart 
[http-: //www. pediheart. org/kidzone/The_heart/Anatomy/anatomy. html]. 
After coronary artery bypass grafting, valve replacement is the second most common 
major heart operation in the western world. Any one of the four valves in the heart may 
require repair (valvotomy) or, more commonly, replacement as a result Of congenital 
problems or age and disease related degeneration of the valve tissue 
[Carabello & 
Crawford,, 1997]. This results in progressive calcification, which can bring about 
stenosis, or valve failure, which induces valvular prolapse and 
blood regurgitation. This 
leads to a range of symptoms depending on the severity of malfunction, including 
shortness of breath, chest pain, tachycardia, palpitations, atrial 
fibrillation and orthopnea 
[Merck Manual of Medical Information (online), 2003]. 
Symptoms can also manifest in 
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other forms such as strokes, as thromboembolisms that originated in the heart valve 
become dislodged and move through the body's blood vessels before they become 
lodged elsewhere. In certain cases, such as endocarditis, death can result in a matter of 
days if surgical intervention is not rapidly implemented. 
The most critical and most prone to failure of the four valves is the aortic valve. It is 
here that blood pressure is highest and the largest forces are applied to the fissues. This 
makes the valve very difficult to repair and adds to the complexity of creating a suitable 
replacement. Prior to a description of attempts to tissue engineer an aortic valve 
replacement, it is first important to understand the structure and function of the native 
tissue. 
1.2. Aortic Valve Structure 
The aortic valve is composed of three leaflets (or cusps), which can be identified as 
being the left-coronary, right-coronary, or non-coronary leaflet (Figure 1.2. ). They are 
distinguished by the presence of coronary arteries just above the leaflets on the right and 
left coronary leaflets, which supply the heart tissue itself with 
blood. The non-coronary 
leaflet (NCL) has no such artery and the right (RCL) and left coronary 
leaflets (LCL) 
can be distinguished by the attachment of muscle near 
to the base of the right-coronary 
leaflet whilst there in none on the left (Figure 
1.2. ) [Sutton et aL, 1995]. 
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Figure 1.2. Schematic diagram identifying the individual leaflets of the aortic 
valve. NCL non-coronary leaflet, LCL left coronary leaflet, RCL right coronary leaflet. 
The ovals represent the coronary arteries. Muscle is found at the base of the RCL, 
making it distinct from the LCL 
[http: //medlib. med. utah. edu/WebPath/CVHTML/CVIDX. htm1]. 
When the valve is open, the leaflets bend outwards to let the blood flow through and 
upon closing each leaflet meets its neighbour along a junction extending from the 
periphery to the centre of the valve orifice to fully occlude the aorta and prevent blood 
regurgitation [Sutton et aL, 1995]. 
1.2.1. Tissue Layers 
There are three well-defined tissue layers within each leaflet (Figure 1.3. ) [Schoen, 
1999]: 
1. The ventricularis faces the inflow surface and is predominantly collagenous with 
radially aligned elastin fibres; 
2. The centrally located spongiosa is composed of loosely arranged collagen and 
has an abundance of glycosoaminoglycans (GAGs); and 
3. The fibrosa faces the outflow surface and is composed predominantly of 
circumferentially aligned, macroscopically crimped, and 
densely packed 
collagen fibres; largely arranged parallel to the 
leaflet's free edge. 
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Figure 1.3. The three-layered structure of the valve leaflet [Vesely, 1998]. 
Within the leaflet layers, the structural elements are arranged in a non-random 
orientation,, leading to properties that are highly anisotropic [Schoen, 1999]. Several 
structural features enable leaflets to be a) extremely soft and pliable when unloaded, b) 
virtually inextensible when back-pressure is applied, and c) to have a much higher tissue 
compliance in the radial direction than in the circumferential direction. These include 1) 
gross corrugations of the fibrosa, which produce a visible surface rippling in systole but 
disappear during diastole; ii) an abundance of collagen cords in the fibrosa which 
radiate primarily from the commissures and confer strength, and ill) cr-imping of the 
collagen fibres. During closure, the crimping expands in the radial direction, permitting 
an initial increase in size with minimal stress. The stiffening induced by fully extended 
collagen crimps and taut collagen cords prevents excessive sagging of the leaflet centres 
when the valve is closed and thereby prevents leaflet prolapse [Schoen, 1999]. The 
elastin of the ventricularis extends when the leaflets stretch to enlarge the coaption area 
but recoils to make the leaflet smaller when the valve is open. 
The function of the 
spongiosa is poorly understood, but it is likely that shear stresses and 
flexion-fatigue 
caused by the differential movements of the layers and the shock of valve closure are 
both dissipated by the ability of the outer layers to glide upon this intervening spongy 
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layer, thus relieving the effect of compression forces on the fibrosa, and tensile forces 
on the ventricularts of flexing leaflet segments [Davila, 1989; Schoen, 1999]. 
Therefore, the collagen. gives the leaflets tensile strength, the elastin allows for flexion 
and deformation, and the spongy connective tissue of the spongiosa pertnits the 
necessary movement of all elements withm the leaflet body [Davila, 19891. 
1.2.2. Aortic Valve Cells 
Two cell types are present within the leaflets: an outer layer of endothelial cells and a 
layer of deep interstitial cells [Schoen, 1999]. Morphologically, heart valve interstitial 
cells have characteristics of both fibroblasts and smooth muscle cells [Messier et aL, 
1994]. It is not clear, however, whether these cells represent a single cell type 
(myofibroblast) or whether there are two populations of cells Within the valve [Lester et 
al, 1988; Mulholland & Gotheb, 1996; Roy et aL, 2000]. Amongst others Taylor et a/. 
(2000), however, have found that two distinct populations of cells exist within the 
interstitium. of porcine valve leaflets, one characterised by prominent stress fibres and 
the other by prominent synthetic and secretory organelles. Of the cells they examined, 
some had abundant Golgi complexes and rough endoplasmic reticulum Wtb few 
filaments or microtubules, whilst others showed dense bundles of microfilaments 
throughout the cytoplasm with less rough endoplasmic reticulum and Golgi complexes 
present in the body of the cell. The bundles of m1crofilaments were most prominent 
along the periphery and extended into the long cell processes. 
In contrast, Rabkin et al. 
(2002), described the cells singularly as being myofibroblasts, but went on to 
demonstrate that the cells showed a varied protein expression that changed when a 
construct consisting of cells grown on a synthetic scaffold in vitro was implanted in 
vivo. To complicate matters ftirther, Lester et al. 
(1988) have described electron dense 
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structures occurring along the microfilament bundles. Other features of interstitial cells 
include the presence of functional gap junctions between the cells. Gap junctions haý e 
been identified by electron microscopy of valve tissue [Lester et al., 19885 Messier C1 
al, 1994; Mulholland & Gotlieb, 1996], suggesting that cells in the valve interstitium 
might be in communication with each other. 
The outer surfaces of the valve leaflets also possess an endothelial cell lining. This cell 
layer plays a vital role in preventing platelet adhesion and subsequent embolus 
formation. It is also responsible for responding to and regulating the secretion and 
molecular transport of growth factors, cytokines and horTnones in order to regulate 
perffision and permeability in the microcirculation [Bachetti & Morbidelli, 20001. 
1.2.3. Other Cellular Features of Aortic Valves 
Motor nerve terminals have been found in close juxtaposition to the valvular interstitial 
cells, mostly towards the base of the leaflets, although theIr relevance s currently 
unknown [Mulholland & Gotlieb, 1996]. In a study of the vasculature of the leaflets, 
Weind et aL (2000) found that of 15 porcine aortic valves examined, nine valves had 
vasculature in all three leaflets and two valves were completely avascular. Vessels were 
found predominantly in the basal third of the leaflets and extended in 
from the 
commissures almost to the level of the free edge. Thus it is possible that a non-nally 
functioning aortic valve receives oxygen from the oxygen-rich 
blood passing across its 
surfaces, but at the base diflusion distances exceed metabolic requirements 
and a 
compensatory microcirculation develops [Weind et aL, 
2000]. 
1.2.4. Aortic Valve Function 
It is thought that no flow or pressure gradient across the valve Is required to open the 
valve initially and purposeful contraction of the valve leaflets has been postulated 
[Messier et aL, 1994]. Higashidate et aL (1995) believed that the aortic valve opens 
before the onset of aortic blood flow because of the increase in the restoring force that 
tends to make a valve orifice triangular, owing to the increase in the distances between 
the commissures without forward flow. The reason for this can be deduced from the fact 
that the left ventricular pressure elevation induces aortic root expansion, subsequent 
commissure separation, and stretching of the free edges of the valve leaflet [Higashidate 
et aL , 1995]. Therefore it is believed that the valve has an intrinsic potential to open - 
Aortic heart valves are subjected to enonnous stresses (botb tensile and flexion) during 
over 100,, 000 cardiac cycles per day, and as a consequence of these forces, some 
internal damage must occur through cell shearing and general wear and tear of the 
tissues [Deck et aL, 1988]. Normal valve tissue has been shown to have a considerable 
metabolic activity [Weind et at., 2000], and this most probably represents an active 
repair mechanism to maintain the structural integrity of the valve leaflets. The fact that 
vascularisation is found predominantly in the basal regions of the leaflets corresponds 
with the fact that this region endures the majority of the flexural stress imposed on the 
valve during the cardiac cycle, and therefore it will be the area that suffers the greatest 
structural damage [Weind et al., 2000]. Deck et al, (1988) have shown a Positive 
correlation between turnover rates of matrix components such as proteins and 
glycosoaminoglycans (GAGs) and the amount of stress measured in 
distinct regions of 
rat aortic valves during the cardiac cycle. This lends support to 
the Idea Of Ongoing 
repair within the tissue. The myofibroblastic cells within the interstitial 
layer in aortic 
valves are thought to play an important role 
in wound healing, and their presence 
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supports the concept of an active repair mechanism [Weind et al, 2000]. The need for 
continual turnover within valve tissue could help explain the failure associated NNIth 
gluteraidehyde-fixed bioprosthetic valves, which contain no viable cells [Weind et al., 
2000]. 
There remains considerable variability in the current understanding and characterisation 
of the heart valve leaflets. Of the information discussed here, 
- there is much ambiguity in 
the reports written so far and these issues need to be addressed to fully understand the 
tissue and cell functions of the valves and maximise the potential benefits of tissue 
engineering replacement valves. For example, Weind et al. (2000) stated that 
vasculature although present in the majority of the leaflets they examined, was not 
ubiquitous in all the samples. This presents a potential problem to the success for all 
future tissue engineered valves because if vasculature is required and is not included 
during the engineering of the valves, all attempts will ultimately fail if the seeded cells 
die. However, if it is not required, much time could be saved in the production of the 
valves. It is also essential to assess the full importance of the motor nerve terminals 
found by Mulholland & Gotlieb (1996) as again there could be potential functional 
failure of any tissue engineered valve it they are not taken into account. Overall, further 
study and characterisation of aortic valve leaflets is essential. 
1.3. Currently Available Heart Valve Replacements 
Throughout the world, 95% of all valve replacements are performed for mitral and 
aortic valves, the vast majority of which are aortic valve replacements. 
There are 
approximately 225,000 heart valve procedures performed world-Wide each year 
[St Jude 
Medical Inc., 2003]. and replacement heart valves are estimated to be a $259.1 billion 
industry [Gangireddy et al- 2001]. This market is expected to continue to grow due to 
9 
r, y Y, ný I 
the ageing population and the emergence of a need for the replacements in developing 
countries. Many different designs of prosthetic valves have been created since the 1950s 
and the replacement procedures all have a high success rate. The different types and 
numbers of single open valve replacement surgeries performed in the UK in 2000-2001 
are shown in Figure 1.4. 
1600 
In 
1200 
1000 
E 800 
600 
400 
200 
0 
Figure 1.4. The different types and numbers of single open valve replacement 
surgery performed in the UK in 2000-2001 without coronary artery bypass 
grafting (CABG) [Data included in the National Audit Cardiac Surgical Report 2000- 
2001: hftp: //www. scts. orgl. 
1.3.1. Mechanical Valves 
1.3.1.1. Ball Valves 
The first artificial heart valve was implanted by Charles Hufnagel In 
1952 to aid a 
poorly functioning natural heart valve [DeWall et aL, 
20001. This device consisted of a 
methacrylate ball contained in a methacrylate tube. 
The ball was situated at the proximal 
end of the tube during diastole, and three bulbous pouches 
that opened around the ball 
in its systolic position at the distal portion of the 
tube allowed blood to flow in one 
direction. The valve was sited in the descending thoracic aorta, 
secured by nylon rings 
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containing teeth on its inner surface to hold the aorta to the prosthesis. The valve was 
designed for use in patients with aortic insufficiency and was a major breakthrough for 
valvular disease. 
Modifications and improvements on this design brought the Starr-Edwards ball and 
cage valve, which became available in the early 1960s (Figure 1.5. ) [Senthilnathan et 
al., 1999]. This device consisted of a rubber ball in a cage In which the ball moved to 
close the valve under back-pressure. Although effective and durable as a valve, it 
altered the haemodynamics of the blood flowing over it because the ball had to be larger 
than the valve opening in order for it to effectively seal the valve when it was shut, and 
this partially obstructed blood flow, even when the valve was open. This resulted in a 
tendency for blood clotting; leading to thrombosis and ultimately heart failure. 
Subsequent models of this type aimed to reduce the size of the ball and use different 
materials. Although these initial valves functioned appropriately in the mechanical 
sense, they were totally different to the natural valve. Consequently, despite eliminating 
the original valve failure, they frequently induced additional problems. Therefore, 
despite these designs being some of the most durable designs developed, ball and cage 
valves are rarely implanted today. 
Cage 
Figure 1.5. Starr-Edwards Ball and Cage valve, (selOOO), 1960 [Cedars-Sinai Health 
System, 2003]. 
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1.3.1.2. Single Leaflet Disc Valves 
The next mechanical valves to be developed were the single leaflet disc valves. The 
most historically important single leaflet valve and initially one of the most successful, 
was the original Bj6rk-Shiley valve (Figure 1.6. ) of the late 1960s [Cedars-Sinai Health 
System, 2003]. The Bjbrk-Shiley valve is a tilting disc valve with a single disc that is 
held in place by two small C-shaped metal inflow struts and an outflow strut. Tens of 
thousands have been implanted in the United States and across the world. The original 
model of the Bj6rk-Shiley valve was an extremely reliable and durable valve. It had 
good haemodynamics and a low rate of thromboembolism, making it a very successful 
and durable design [Senthilnathan et al., 1999; Cedars-Sinai Health System, 2003]. 
Unfortunately, attempts to improve the haemodynamics of the original Bj6rk-Shiley 
valve by redesigning it led to disaster. Certain models of the Bj6rk-Shiley valve 
developed strut fractures resulting in thromboemboli forming on the disc. This led to all 
models of the Bj6rk-Shiley valve being removed from the United States valve market, 
although it is still available today in some countries [Cedars-Sinai Health System, 
2003]. 
- Sewing ring 
C-shaped struts 
Disc 
Figure 1.6. Bj6rk-Shiley Convexo-Concave UR valve, 1975 [Cedars-Sinai Health 
System, 2003]. 
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1.3.1.3. Bileaflet Heart Valves 
Bileaflet heart valves were first developed in the late 1970s and one of the first and by 
far the most successful bileaflet valves has been the St. Jude Valve, shown in Figure 
1.7, [Wang, 1989]. The leaflets and inner ring of the St. Jude Medical mechanical heart 
valve are made of graphite and coated with pyrolytic carbon. Pyrolytic carbon was 
chosen for the coating because of its hardness, strength, and durability. It is also 
resistant to platelet adhesion, which helps to minimise the risk of blood clot formation. 
The outer ring of the valve is a polyester cuff that is sewn into the remaining tissue of 
the heart. Since 1977, more than one million people have received St. Jude Medical 
mechanical heart valves [St. Jude Medical Inc., 2003]. It has excellent durability, good 
haemodynamics and is currently the most commonly implanted valve in the United 
States, with over 90% of valves being of this design [Senthilnathan et al., 1999; Cedars- 
Sinai Health System, 2003]. Indeed it is regarded as the gold standard to which all other 
prosthetic valves are compared. The valve leaflets open easily, offer minimum 
resistance to flow, and when closed have insignificant regurgitation [Senthilnathan et 
al. , 19991. 
Leaflets 
Sewing ring 
Hinge 
Figure 1.7. St Jude bileaflet heart valve, 1977 [Cedars-Sinai Health System, 20031. 
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1.3.2. Bioprosthetic Valves 
The late 1960s saw the development of bioprosthetic valves in an attempt to overcome 
the haemodynamic problems of their mechanical counterparts. Bloprosthetic valves are 
usually hybrid structures consisting of either porcine cuspal tissue or bovine pericardial 
tissue,, usually cross-linked with aldehydes, and a synthetic stent and sewing ring. 
Essentially, valve tissue is sewn onto a metal wire stent, which is bent to form three 'U' 
shaped prongs. A cloth (Dacron) sewing skirt is attached to the base of the wire stent 
and the stents are also covered with cloth. Non-stented valves are also available and are 
either completely or nearly completely composed of tissue and are sewn directly into 
the surgically prepared aortic valve sites [Schoen, 1999]. These implanted animal tissue 
valves are referred to as xenografts or heterografts. An example can be seen in Figure 
1.8. Gluteraldehyde-fixed bioprosthetic valves were first introduced in 1969 in an 
attempt to reduce tissue immunogenicity and mechanical valve related 
thromboembolism and the subsequent risk of haemoffhage [Korossis et aL , 
2000]. Such 
was the interest in these valves; about 60% of all valves inserted in the 1970s were of 
this type. Unfortunately tissue valves were subsequently found to have a high incidence 
of structural deterioration, [Senthilnathan et aL, 1999]. The ftmction and success of 
these valves largely depends on the type, source, preservation and handling of the tissue 
and the method of tissue attachment and support, but the ma or problem is tissue failure; i 
-C, -- - frequently beginning within ten years. This is mainly a result of the harsh 
gluteraldehyde treatment that is required to reduce the immunogenicity of the valves. 
This makes the valve leaflets much more rigid and less flexible than the natural valve, 
leading them to experience greater stresses and therefore wear out sooner [Vesely et aL, 
1995]. Alternative fixative chemicals such as genipin, and altering other variables such 
as the fixation pressure on the valve leaflets have yet to provide leaflets with mechanical 
properties comparable to the natural leaflets [Sung et aL, 1999]. 
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Figure 1.8. Carpentier-Edwards porcine aortic valve (CE2625), 1975 [Cedars-Sinai 
Health System, 2003]. 
1.3.3. Human Tissue Valves 
Valvular tissue can be transplanted between persons and from one site to another in the 
same individual. Homografts are valves transplanted from another human (Figure 1.9. ). 
A valve is removed from a human cadaveric donor and preserved in liquid nitrogen 
(cryopreserved) until needed. The valve must be thawed overnight prior to being 
transplanted into the recipient. This means that a surgeon must know in advance what 
size and type of valve he or she is going to use. Homograft valves tend to have good 
haemodynamics and good durability but are also technically harder to implant than 
standard bioprosthetic valves such as the Carpentier-Edwards valve [Cedars-Sinai 
Health System, 2003]. A major problem, as with all organ transplants, is that homograft 
availability is limited by donor availability. 
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Figure 1.9. A human aortic homograft valve. 
Autografts are valves taken from the same patient in which the valve is implanted. The 
most common autograft procedure is the Ross procedure developed by Mr. Donald Ross 
(Figure 1.10. ), [Dohmen et al., 2002a]. The abnormal aortic valve is removed and the 
patient's own pulmonary valve is transplanted to the aortic position to take its place. A 
homograft pulmonary valve is then used to replace the patient's pulmonary valve. 
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Figure 1.10. The Ross procedure [Cedars-Sinai Health System, 2003]. 
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The main advantage of the Ross procedure is that the patient receives a living valve in 
the aortic position that will continue to grow and repair. This is particularly useful If the 
patient is a child as the valve can continue to grow and develop with the child so no 
reoperation is required. Other potential benefits are improved haemodynamics (there is 
essentially no pressure drop across the valve) and good durability [Dohmen et aL , 
2002a]. The Ross procedure, however, is a very technically difficult procedure and 
involves considerable skill and time. The pulmonary valve must be carefully measured 
and sculpted to fit the aortic root and the replacement pulmonary homograft must 
similarly be shaped to fit the pulmonary root. There are many potential complications, 
the most common of which is aortic regurgitation [Dohmen et aL, 2002a]. Many 
patients have small amounts of aortic regurgitation but some have moderate or even 
severe amounts and require a second operation for valve replacement. Other problems 
include stenosis of a coronary artery, right-sided endocarditis (since a homograft valve 
has been implanted in the pulmonary position) as well as the usual difficulties of valve 
replacement discussed below. In addition, the pulmonary valve will not grow and so 
will need replacing in young patients as they grow and develop. Also it remains unclear 
whether the durability of the autograft is better than standard porcine or pericardial 
valves [Dohmen et aL, 2002a]. 
1.4. Complications of Replacement Heart Valves 
Although the currently available heart valve replacements enhance the quality of life 
and increase the longevity of many patients with severe valvular heart disease 
[Gnmkemeier & Rahimtoola, 1990; Staff et al, 2002], there is no ideal replacement for 
children as they lack the ability to grow with the child and therefore need replacing 
regularly to keep pace with the child's development. Even when the child has stopped 
Igowing, the valuable lifetime of the valves is frequently less than ten years before they 
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need to be replaced. Also, there may well be prosthetic valve related complications. 
Replacement associated problems necessitate re-operation or cause death within ten 
years postoperative y in at least 50-60% of patients undergoing heart valve replacement 
surgery [Schoen et aL, 1992,1999; Korossis et aL , 2000]. The most common 
replacement related conditions include [Grunkemeier & Rahimtoola, 
.1 
1990; Schoen, 
1999; Korossis et aL , 
2000]: 
i. Thromboembolism, thrombosis and anticoagulation related haemorrhage; 
ii. Non-structural dysfunction, including dehiscence (the separation of the 
prosthetic valve suture line from the heart,, leading to para-valvular 
leakage, seen mainly in the immediate postoperative period), peri- 
valvular leak, disproportion (occurring when the prosthetic valve is not 
fitted well, leading to deficient blood flow), haemolysis, tissue 
overgrowth, and other extrinsic interactions of host tissues with the 
prosthesis; 
iii. Structural failure (degeneration of the prosthesis biomaterials); and 
iv. Prosthetic valve endocarditis. 
Prosthetic valve endocarditis is particularly problematic in this situation as the bacteria 
responsible readily colonise the prosthetic valve and form a biofilm. This occurs when 
the bacteria irreversibly attach to the prosthesis and surround themselves with an 
extracellular polymeric substance that protects them from the effects of the host immune 
system and antimicrobial therapeutic agents administered to combat the infection 
[Donlan & Costerton, 2002]. Consequently the infection becomes very difficult to 
eradicate. 
Clinical studies have indicated that the composite rates of valve related complications 
are similar for both mechanical and bioprosthetic valve replacements [Korossis, et aL, 
18 
CHAPTER 1 
2000; Starr et al, 2002]. The frequency and nature of specific valve related condifions, 
however, can vary with the type of prosthesis, model , implantation site and patient 
characteristics. The main disadvantage of mechanical prosthetic valves is the substantial 
risk of systemic thromboemboli and local tbirombotic occlusion [Grunkemeier & 
Rahimtoola, 1990; Schoen et aL , 
1992], which requires chronic anticoagulation therapy 
as a preventative measure. The rate of thrombosis per patient per year for the St. Jude 
valve, for example, is approximately 5% [Wang, 1989]. Therefore in 20 years, a patient 
with one of these valves is essentially guaranteed to have some form of thromboembolic 
event. Chronic oral anticoagulation itself carries a risk of haemorrhage with a frequency 
of approXimately 4% per patient per year, particularly retroperitoneal, gastrointestinal or 
cerebral, 15-25% of these events are fatal [Schoen et aL, 1992]. However, mechanical 
valves do offer patients extended durability, which limits the mortality and morbidity 
risks associated with reoperation for replacement of degenerated bioprostheses [Fradet 
et aL, 1995]. In contrast, since tissue valves maintain a low rate of thromboembolism 
without anticoagulation, their recipients are generally not anticoagulated and therefore 
have a superior quality of life. The main disadvantage with tissue valves, however, is 
structural failure due to progressive tissue deterioration (via both calcification and non- 
calcification mechanisms) [Butany & Leask, 20011. Prosthetic valve endocarditis and 
non-structural dysfunction affect both tissue and mechanical valves almost equally. 
Unexpectedly, perhaps, noise can also be a problem with mechanical valves as they can 
be heard to make a ticking sound as they shut during the heart cycle, some valves being 
louder than others [Blome-Eberwein et aL, 1996]. 
Moreover, the cost of treating valve complications is not inconsequential. The average 
costs in the US of treating an episode of care for valve related complications in 1996 
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ranged from $8,699 for the medical management of structural dysfunction to $84,750 
for the lifetime management of an embolism [Caro et aL , 1996]. 
1.4.1. Choice of Replacement Aortic Valve 
Aortic valve replacement is performed primarily for degenerative valve disease in 
increasingly older patients [Birkmeyer et aL, 2000]. In elderly patients, mechanical 
valves may be less favourable because risks of anticoagulation-related bleeding increase 
with age. In addition, tissue valve failure, which typically occurs 10 to 15 years after 
valve implantation, may be less of a concern for older patients who have lower valve 
failure rates and shorter life expectancies [Grunkemeier & Rahimtoola, 1990; 
Birkmeyer et aL, 2000]. Therefore the optimal valve prosthesis depends on patient age, 
reflecting the time-dependent nature of trade-offs between mechanical and tissue valves. 
Consequently, although mechanical valves are associated with greater life-expectancy in 
younger patients, tissue valves confer greater benefit for the majority of patients 
undergoing valve replacement who are 60 years of age and older [Birkmeyer et aL, 
2000]. 
The use of prosthetic devices for aortic valve replacement in infants and children with 
congenital heart valve defects is associated with numerous short-term and long-term 
complications and, in most cases, is considered palliative [Vitale et aL, 1999]. In short, 
tissue valves gradually deteriorate over time and mechanical valves, require 
anticoagulation therapy, which is especially undesirable in children [Turrentine et aL, 
2001]. Of particular importance, neither is capable of growth and development and as 
such, multiple reoperations are frequently required as the child ages. Consequently, the 
Ross procedure has become the primary choice for aortic valve replacement in 
paediatric patients because of the growth potential, optimal haemodynamic 
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performance, and lack of the need for anticoagulation [LaudIto et aL, 200 1 ]. However, 
this also has drawbacks as concerns pers'st due to potential dilatation of the autograft, 
the incidence of reoperation for autograft dysfunction and the residual or increasing 
autograft insufficiency. It is for these reasons that an alternative must be sought that 
possesses the capability to adaptively grow and remodel without compromising other 
heart valves or necessitating further reoperation or drug therapies. 
1.5. Ten Commandmentsfor the Prosthedc Valve 
An alternative heart valve prosthesis is therefore required that is suitable for all patients; 
particularly children. Harken (1989) defined ten commandments for the prosthetic 
valve: 
It must not propagate emboli. 
2. It must be chemically inert and not damage blood elements. 
3. It must offer no resistance to physiological flows. 
4. It must close promptly (less than 0.05 seconds). 
5. It must remain closed during the appropriate phase of the cardiac cycle. 
6. It must have lasting physical and geometric features. 
7. It must be inserted in a physiological site (generally the normal anatomical site). 
8. It must be capable of permanent fixation. 
9. It must not annoy the patient. 
10. It must be technically practical to insert. 
No mechanical or bioprosthetic valve to date has completely 
fulfilled all of these 
objectives. To achieve these standards, the valve must resemble the natural 
living valve 
as closely as possible and so the most promising route is through the tissue engineering 
of a living aortic heart valve. 
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Tissue Engineering 
Tissue engineering is a rapidly developing field that combines biological and 
engineering principles in an attempt to create replacement organs or structures from 
cells and biological or synthetic scaffolds to restore, maintain,, or improve tissue 
function. Although the technology is still in its infancy, the potential of this field is vast, 
and the research is driven by the intrinsic problems of current techniques for repair and 
replacement of tissues, such as limited donor availability and poorly compatible 
materials. In the United States alone, approximately 7.5 million patients reqwre 
artificial biological implants each year [Cassell et al., 2002]. 
There are multiple challenges for the tissue engineering approach to aortic valve 
replacement. The physical and biological properties of the natural tissue must be 
recapitulated, and any synthetic materials used must be tolerated by the body and 
adequately degraded as the new tissue develops and remodels. The basic principle 
involves seeding cells onto a matrix scaffold. However, there are a number of ways of 
creating a suitable matrix scaffold and many potential cell sources. 
There are four key processes occurring during the in vitro or in vivo phases of tissue 
formation and maturation [Rabkin & Schoen, 20021: 
(1) Cell proliferation and differentiation; 
(2) Extracellular matrix production; 
(3) Degradation of the scaffold; and 
(4) Remodelling and potentially growth of the tissue. 
Once combined in the correct manner, it has been proposed that a dynamic and 
interactive cell phenotype and extracellular matrix could be produced which would 
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ultimately develop a microarchitecture comparable to a native valve [Rabkin et al. 
2002]. This should then be able to grow, develop, repair and remodel itself just as the 
native valve tissue. 
There has been considerable interest in the tissue engineering approach for designing 
cardiac valve substitutes, typically using a synthetic scaffold construct. [Bader ef aL, 
1998; Hoerstrup et aL, 1999; O'Brien et aL , 1999; 2002; Sodian et aL, 2000a; Elkins et 
aL , 200 1 a; Jockenhoevel et aL , 200 1; Kim et aL . 200 1; Cebotari et aL , 2002; Rabkin ef 
aL, 2002; Rothenburger et aL, 2002; Shinoka, 2002; Taylor et aL, 2002; Perry & Roth, 
2003]. 
1.6.1. Polymeric Scaffolds 
There are a number of different biodegradable materials with minimal immuriogenicity 
currently being investigated. Scaffolds must possess sufficient structural integrity to 
temporarily Withstand ftmctional loading in vitro and in vivo. These scaffolds are 
usually designed to gradually degrade over time and be replaced with new host tissue 
and cells. Consequently, it must be ensured that materials used are non-immunogenic,, 
non-toxic and are adequately reabsorbed by the body. 
1.6.1.1. Fibrin gel scaffold 
Fibrin gel is derived from blood and can be prepared in an autologous manner to negate 
immunogenicity problems. It can be polymerised and moulded into a valve structure to 
create a completely autologous and biodegradable scaffold. Histological investigations 
of cell seeding onto fibrin scaffolds by Jockenhoevel et aL (2001) have demonstrated 
good tissue development with viable fibroblasts surrounded by collagen bundles. 
However, fibroblasts surrounded by collagen bundles are a long way from a tri-laminar 
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tissue structure capable of withstanding the forces generated in the aortic valve. 
Moreover, a scaffold made from fibrin gel would lack the necessary mechanical 
strength and when placed into the aortic Position would almost certainly disintegrate 
long before any cells could lay down a new extracellular matrix. 
1.6.1.2. Collagen matrix 
Synthetic type I collagen has been used by Rothenburger et aL (200 1; 2002) and Taylor 
et aL (2002) to construct a biodegradable, biocompatible sponge-like matrix which was 
reseeded in vitro. Taylor et al. (2002) showed that seeded valve interstitial cells 
developed a molecular phenotype similar to those of skeletal, cardiac, and smooth 
muscle cells,, which may be valuable functional qualities for a tissue-engineered valve. 
However, although collagen is a fundamental part of the heart valve structure, Without 
the damping effects of the glycosaminoglycans, and the elastic effects of the elastin, any 
scaffold made from collagen alone would be likely to deteriorate and degenerate very 
quickly as a result of the in vivo forces affecting the heart valve. 
1.6.1.3. Other Polymeric Scaffolds 
ZOnd et aL (1997) have combined polyglycolic acid (PGA) with polylactic acid (PLA) 
in a sandwiched copolymer for their scaffold material and seeded it with both 
fibroblasts and endothelial cells from an ovine source. They reported that after 14 days 
the construct was histologically similar to a native valve. However, no mention was 
made of any mechanical testing, which is an essential part of any analysis of a tissue 
engineered aortic heart valve construct. 
Comparable studies have also been carried out by Shinoka et al. 
(1996; 1997; 1998) 
using a PGA/polyglactin sandwich scaffold implanted 
into a lamb model. They too 
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reported the generation of a 'proper' matrix, and in their case the scaffold was 
completely degraded after 8 weeks. However, they reported problems with polymer 
stiffness when it was first implanted, which meant that cells were subjected to greater 
forces and the leaflets were more Prone to structural problems. 
Sodian et aL (2000b) produced a scaffold fabricated from porous polyhydroxyalkanoate 
and seeded it with autologous cells prior to implantation in the pulmonary position in a 
lamb model for up to 17 weeks. They indicated that cell numbers increased and 
capillaries fortned in the new scaffold, which was gradually overtaken by new host 
tissue as the seeded cells produced their own matrix. However, they reported 
insufficient degradation of the scaffold which meant that the cells were not able to 
remodel the scaffold as readily as expected. 
Rabkin et aL (2002) have shown the potential of a PGA polymer by successfully 
creating an in vitro valve construct seeded with endothelial cells. However, whilst this 
appeared successful on gross morphological evaluation, immunohistochemical analysis 
showed that despite apparent proteoglycan accumulation and the presence of an 
appropriate three-layered architecture, the absence of elastin fibres and weak staining 
for collagen indicated limitations in the construct as these are the main strength and 
flexibility-giving qualities required for a suitable valve replacement. 
Problems with PGA polymers have been noted by other researchers, however, as they 
may give toxic by-products upon degradation, and may be poorly reabsorbed by the 
body [Ye et aL, 2000]. Research into the use of chemical polymers and synthetic 
materials to produce tissue-engineered heart valves is in its infancy and both the 
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mechanical stability and potential complications of implanting the polý,, meric 
compounds used in scaffolds are currently unknown. 
Each of these polymers has advantages and disadvantages. However, on the whole, they 
are severely limited when compared with the native tissue. Any synthetic material used 
must be designed to be as similar to the native tri-laminar structure as possible if it is to 
withstand the forces in vivo while new extracellular matrix is laid down and remodelled 
by the seeded cells. Concentrating simply on creating the correct polymer stiff-hess is 
not sufficient. The forces applied to the synthetic material must be adequately dissipated 
within the leaflet, and ideally the construct should have elastic propertles to give a 
greater flexibility whilst maintaining polymer strength in order that the leaflet can 
effectively occlude the valve during backpressure whilst maintaining a minimal profile 
when the valve is open. These are all properties of the native valve tissue that have been 
honed through evolution to give the most effective design, and consequently it is the 
xenogeneic or allogeneic equivalent which represents the most promising route to 
creating a viable aortic heart valve. However, as with homografts, the allogeneic 
scaffold is beset with donor shortage problems. 
1.6.2. Xenogeneic scaffolds 
Developing a heart valve tissue substitute from a naturally occurring decellularised 
biological matrix is an altemative strategy that would provide a ready-made scaffold, 
which already possesses optimal mechanical and biochemical qualities and 
characteristics. There is also an immediate distinct advantage in that there should be 
minimal host response to a naturally occurring extracellular matrix [Badylak, 2002]. 
Methods for producing acellular matrices typically use a combination of enzymes and 
detergents to remove the cells from a xenogeneic valve [Bader et al., 1998; Booth et al., 
('74APTV)? 1 
20021. This approach could offer an unlimited source of valve matrices, N"'hich could 
then be reseeded with autologous cells from the valve recipient, to gwe a non- 
immunogenic product. The difficulty with this technique, however, lies in the 
decellularisation process: all of the cells must be completely removed, whilst not 
damaging the tissue matrix so that mechanical and structural properties are maintained 
as much as possible. Remaining cell fragments could readily act as nucleation points for 
calcification to occur, resulting in rapid stiffening and irreparable damage to any 
implanted tissues [Dohmen et aL, 2002b]. Any chemicals used in this process must be 
completely removed to ensure biocompatibility with cells and host fissue upon 
implantation. Also, questions remain as to the suitability of unfixed animal sources for 
human implantation due to the risks of transmitting animal viruses and prions, which are 
difficult to screen for and adequately remove if detected. 
One important attempt at making a valve using a xenogeneic scaffold was the 
SYNERGRAFTI'll valve produced by Cryolife Inc. This valve was made from 
decellularised porcine valve tissue stitched into a valve shape. The decellularisation 
process was reported to give a completely acellular matrix and biomecharucal testing 
showed results comparable to those of a native human aorfic valve. Despite favourable 
findings when the valves were implanted in an ovine model [O'Brien et aL, 19991, 
implantation of the valves into four paediatric patients resulted in catastrophic failure 
leading to the deaths of three patients and rapid replacement of the valve in the 
remaining recipient [Simon et aL, 20031. It was reported that the collagen matrix 
induced a severe inflammatory response, which subsequently led to early development 
of a thick fibrous sheath both on the inside and the outside of the graft. Consequently, 
due to the sheep model failing to predict the failure of the valves in humansl it 
has been 
recommended that the implantation of these valves be stopped pending the development 
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of appropriate test models. It is possible that the failure of this valve was due to a lack 
of cells. Had the constructed been reseeded in vitro prior to implantation, the 
remodelling carried out by the cells may have strengthened the construct and also 
remodelled any damaged areas of the matrix, thereby reducing the immune response by 
the host. 
A patented method has been developed at the University of Leeds for the 
decellularisation of aortic valve leaflets using the detergent sodium dodecyl sulphate 
SDS). Histological analysis showed that the matrix components remained intact (Booth 
et al, . 2002), whilst mechanical testing demonstrated that the SDS treatment produced 
valves with equal strength, competence under physiological pressures (120mmHg) and 
greater extensibility than untreated fresh valves (Korossis et aL, 2002). 
1.6.3. Cell Source 
In any tissue engineering strategy to produce a living aortic heart valve an appropriate 
source of suitable cells has to be established that have similar properties to the cells of 
the native tissue. It may be that multiple cell sources are required, i. e. endothelial and 
smooth muscle cells, in order that an endothelial lining is established to prevent 
thrombus formation,, whilst smooth muscle cells can penetrate and remodel the tissue. 
Using MSC could be potentially better than terminally differentiated cells as they have 
the potential to differentiate into multiple cell phenotypes, potentially resulting in a cell 
lineage far closer to that of the native valve cells. Also, MSC could,, in theory, be 
propagated indefinitely in culture, enabling vast numbers of cells to be grown in vitrO 
without the loss of cell function seen in tenninally differentiated cells [Hayflick, 1965]. 
The use of autologous, cells would give the advantage of a functional tissue that would 
be an identical human leukocyte associated (BLA) antigen match, and therefore non- 
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immunogenic. In contrast,, allogeneic cells would necessitate immunosuppressive 
therapy to prevent rejection, which has a high risk of morbidity and mortality [Adler & 
Turka, 2002]. 
It is thought that once a tissue-engineered product is implanted, host cells would 
gradually infiltrate and migrate through it over many weeks or months, thereby further 
remodelling the tissue and replacing the seeded cells. Therefore it could be argued that 
seeding cells prior to implantation is not strictly necessary. However, due to the high 
pressures and forces exerted on to heart valve tissue in situ, a lack of cells to undertake 
the ongoing repair that is required in order to maintain a native heart valve may well 
result in the tissue becoming irreparably damaged before any cells can reach the valve 
leaflets by migrating in from the surrounding tissues. 
A Brief History of Stem Cells 
Mammalian tissues were first described to be composed of cells in the 19"' century. This 
led Virchow and Schwan to the claim that cells originate exclusively from other cells 
( 64 ominis cellula a cellula"), [Wulf et aL, 2001]. Analysis of the phylogeny of 
baematopoiesis in the bone marrow by morphological observation led to the concept of 
tissue stem cells being the basis for tissue regeneration at the beginning of the 
20'h 
century. Pappenheirn deduced the existence of an undifferentiated stem cell that gave 
rise to the plethora of blood cells via an intermediate state of progenitor cell 
[Wulf et 
aL , 200 1 
]. In the 1950s, several groups corroborated the existence of the 
haematopoietic 
stem cell in the bone marrow by showing haernatopoietic recovery 
from transplanted 
bone marrow after irradiation damage [Wulf et al., 2001]. Till and 
McCulloch (1961) 
later traced haernatopoietic repopulation capacity to clonogenic cells establishing spleen 
colony forming units and in 1976 expenments by Freidenstein et aL 
first brought 
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attention to a second population of stem cells within the bone marrow, mesenchymal 
stem cells. These findings led to the concept of tissue regeneration from a small 
population of resident tissue stem cells being widely accepted, and was extended to 
other tissues, such as gut and skin [Potten & Loeffler,, 1990]. 
The principle of directed cellular proliferation was also used in the understanding of the 
early stages of embryogenesis, and led to the discovery of morphogenesis via germ 
layers in the early embryo [Wulf et aL, 2001]. Emerging technologies led to the 
functional isolation of stem cells with the capacity to differentiate into all tissues of the 
adult organism from pre-implantation embryos of mice in 1981 [Evans & Kaufman, 
1981]. Thomson et aL followed this in 1998 by the isolation of the human equivalent 
These cells were termed embryonic stem (ES) cells. 
The successful cloning of a mammal by implanting the nucleus of an adult tissue cell 
into an enucleated fertilised ovum in 1997 [Wilmut et al., 1997] established that the 
nuclei of at least some adult cells were capable of being reprogrammed. This spurred 
many groups to return to examining the differentiation capacity of adult tissue stem 
cells, and the credence of earlier postulations of the existence of adult tissue stem cells 
took on a new importance, which led to a vast increase in research in this area. It is now 
thought that adult stem cells may reside in all organs having a connective tissue 
component where they function as a source of cells for wound healing, tissue repair and 
regeneration [Calcutt et aL, 1993; Young et aL, 1995; Mackenzie & Flake, 200 1 a]. 
These include (in order of discovery) haematopoietic stem cells [Till and McCulloch, 
1961], keratinocyte stem cells [Green et al , 
1979], gastrointestinal stem cells [Potten el 
aL. 1997; Potten & Booth, 2000], neural stem cells [McKay, 1997; Prockop, 
1997; 
Solter & Gearhart 1999; Temple, 1999; Kennea & Memhet, 2002; Peterson, 2002], 
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hepatic stem cells [Alison, 1998; Strain & Crosby, 2000], muscle stem cells [Miller et 
al., 2001; Asakura et al, 2001; Zammit & Beauchamp, 2001, Goldnng et aL, 2002. 
Wada et aL,, 2002], amniotic fluid stem cells [Prusa, & Hengstschiager, 2002], cardiac 
stem cells [Hughes, 2002.1, lung epithelial. stem cells [Otto, 20021, pancreatic stem cells 
[Bonner-Weir & Sharma, 2002], and prostatic stem cells [Foster et aL, 2002]. 
1.8. Adult versus Embryonic Stem Cells 
Both adult stem (AS) cells and embryonic stem (ES) cells have advantages and 
disadvantages in their potential use in tissue engineering. A comparison of ES and AS 
cells is shown in Table 1.1. At first, it seemed as though ES cells had the most potential 
as they have the capacity to differentiate into every cell in the human body once the 
correct conditions are established (totipotent), whereas it was originally thought that AS 
cells had some constraints on their developmental capacity (multipotent). However, AS 
cells continue to show a potential overlap in their functions and it is possible that in the 
future their capacity for differentiation will be shown to be equal to or almost equal to 
that of ES cells [Grompe, 2002]. In favour of AS cells, immunological problems can be 
overcome by extracting AS cells from the intended recipient of the final tissue 
engineered product, whereas ES cells will express the histocompatibility antigens of the 
parents and thus will be allogeneic. Without HLA matching, genetic manipulation or 
immunosuppression of the recipient they would be rejected. Hence there are 
considerable advantages of utilising AS cells, which can be extracted at any point 
through the life of the person. 
I 
CHAPTER I 
EMBRYONIC STEM CELLS ADULT STEM CELLS 
ADVANTAGES Can be propagated indefinitely 
Pluripotent differentiation 
capacity. 
Absence of any potential 
effects of age. 
DISADVANTAGES Need to be grown on mouse 
feeder cells. 
Can give rise to 
Autologous derivation. 
Respond to developmental 
signals in the injury 
environment and differentiate. 
Easy to obtain. 
Not plunpotent. 
May be donor-age-associated 
changes in proliferative and 
teratocarcinomas. differentiative capacity. 
Epigenetic instability, Current culture conditions do 
Allogeneic derivation. not maintain multipotency. 
Table 1 .1. Comparing the advantages and disadvantages of ES and AS cells. 
The main drawback to the use of ES cells, however,, remains an ethical one. With the 
currently available technology, extraction of ES cells for research purposes necessitates 
the death of the embryo from which they are harvested. This ethically contentious 
practice has promoted widespread public concem [Doerflinger, 1999]. Furthermore, 
confus' II ion propagated by unhelpful publicity in the media n relation to human cloning, 
the use of hurnan organs for research and a poor understanding of the concepts and 
potential of this kind of research have led to many countries implementing legislation to 
block or greatly limit the majority of ES cell research [Pedersen, 1999]. This has left a 
much clearer path open for research into AS cells, and has led to a huge surge in interest 
in this area. 
1.9. Definition of a Stem Cell 
To date, there is no universally accepted definition of a stem cell. Since there are no cell 
markers specific for stem cells, they are typically defined by virtue of their functional 
attributes. However, in order to assess whether a cell is a stem cell or not requires 
its properties. So in real' manipulation of the cell, which in turn changes i ity, assessments 
have to be based on a population of cells clonally derived from a single cell that can be 
used in multiple experiments. When Till & McCulloch first identified haematopoietic 
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stem cells in 1961, they defined stem cells simply as clonogenic cells capable of both 
self-renewal and multilineage differentiation. Potten & Loeffler (1990) offered the 
definition as undifferentiated cells capable of 
a) Proliferation; 
b) Self-maintenance; 
c) The production of a large number of differentiated functional progeny, 
d) Regenerating tissue after injury; and 
e) A flexibility in the use of these options. 
A more recent definition ftom. Verfaillie [2002] states the minimal criteria for a stem 
cell to be: 
1. The ability to self renew; 
2. The ability for a single cell to differentiate into cells of the tissue of origin and 
into at least one cell type different from the tissue of origin; and 
3. The ability to functionally differentiate in vivo into cells of the tissue of origin 
and at least one cell type of a tissue other than the tissue of origin. 
These definitions are further complicated by the nature of stem cells as it seems that 
stem cells can be divided into a long-term subset, capable of indefinite self-renewal, as 
well as a short-term subset that self-renews for a defined interval [Weissman, 2000]. 
These stem cells then give rise to non-self renewing progenitor cells, which in turn give 
rise to more restricted progeny that become terminally differentiated fully functional 
mature cells (Figure 1.11). Therefore stem cell division is widely thought to be an 
asymmetrical process, which enables a constant number of self-renewing stem cells to 
be maintained whilst generating progenitor cells to undergo a differentiation process. 
This offers an explanation for the typically heterogeneous nature of freshly 
isolated 
adult stem cells, since they are likely to be a mixture of self-renewing cells, and other 
cells at different stages of the differentiation process. 
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LT 
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LT = long term stem cell 
ST = short term stem cell 
PC progenitor cell 
RP restricted progenitor cell 
M= mature cell 
.......... 
PC PC 
RP'-, RP 
ure 1.11. Lineage Progression. Green arrows represent standard 
lineage progression. Short-term stem cell self-renews and produces progenitor cell for 
limited period before producing progenitor cells only (Red arrows). 
1.10. Mesenchymal Stem Cells 
The discovery of a population of adult stem cells in the bone marrow was made by 
Fnedenstein et aL In 1976,, Friedenstein et al. placed samples of murine whole bone 
marrow in plastic culture dishes and, after several hours, changed the culture medium, 
thereby pouring off the cells that had not adhered. In doing this,, most of the 
haematopoietic stem cells and their progeny and any other non-adherent, non- 
haernatopoietic cells were discarded. They reported that the small numbers of adherent 
cells remaining were heterogeneous in appearance, but that most tightly adherent cells 
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were spindle-shaped and formed foci of two to four cells. The cells in the foci remained 
quiescent for a number of days and then began to divide rapidly. After several passages, 
the adherent cells became more homogeneous and uniformly spindle-shaped in 
appearance. Unusually, it was noted that although the cells could remain as spindle- 
shaped precursors, they also had the ability to differentiate into colonies of cells 
resembling small deposits of bone and cartilage. Later, Fnedenstein et al. (1987) went 
on to demonstrate that even after 20 or 30 cell doublings in culture, these cells were still 
capable of differentiating into connective tissue fibroblasts, osteocytes and chondrocytes 
when enclosed in a capsule with a porous membrane and implanted into the peritoneum 
of rats. Since these cells exhibited a high capacity for self-renewal and multipotentiality, 
it was speculated that these cells were the precursors for a number of different 
mesenchymal cell lineages [Caplan, 1994; Minguell et aL, 2000] and hence they have 
been termed mesenchymal stem cells. However, they are also referred to as bone 
marrow stromal. cells, bone marrow stem cells, multipotent adult progenitor cells, 
mesenchymal progenitor cells, bone marrow progenitor cells and non-haematopoietic 
stem cells. Such is the confusion and debate suffounding these cells, they may also have 
been labelled with other names such as circulating endothelial progenitor cells [Hill et 
aL , 
2003], which upon close examination bear more than a striking resemblance to cells 
that others have labelled MSC. 
More recent advances in understanding of the differentiation processes and 
characterisation of mesenchymal phenotypes have led to the acceptance that MSC are 
precursors for a range of connective tissue-related cell types such as osteocytes, 
chondrocytes, adipocytes, myocytes, tenocytes, myofibroblasts, cardiomyocytes,, 
endothelium and haematopoietic-supporting stromal. cells (Figure 1.12. ) [Caplan, 1991 -, 
Pereira et aL , 1995; 
Wakitani et al., 1995; Cassiede et al., 1996; Prockop, 1997; Ferran, 
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et al, 1998; Johnstone et aL, 1998; Nevo et aL. 1998; Makino et al., 1999; Pittenger et 
aL , 1999; Deans & Moseley, 2000; Emura et aL,, 2000; Minguell et aL, 2000; Pittenger 
et aL , 
2000-- Fukuda,. 2002; Hakuno et aL , 
2002; Reyes et aL, 2002). Clonogenic studies 
of rat MSC have shown that multiple differentiation fates can be induced in a population 
of cells derived from a single cell [Young et aL, 200 1 ]. This has been repeated in hw-nan 
MSC (hMSC) using a variety of methods such as ring-cloning [Prockop, 1997; Pittenger 
et al, 1999] and retro-viral marking strategies [Reyes et aL, 2001; Jiang et aL, 2002; 
Schwartz et aL,, 2002]. Although both of these techniques have their limitations (more 
than one cell may reside within a ring, and retroviral marking may cause unknown 
effects on cell DNA), success in each case further demonstrated the multipotent stem 
cell nature of MSC and strongly opposes the possibility of multiple progenitor cells for 
different cell lineages being present in the bone maffow. This extensive differentiation 
capacity, however, is thought to depend on factors such as the harvesting procedure, the 
frequency of MSC in the bone marrow and the condition and age of the donor [Caplan, 
1994; Digorolaino et aL, 1999; Mendes et aL, 2002]. 
There have been increasing numbers of reports that there is some functional overlap 
between different stem cell lineages [Poulsom et aL, 2002], and mesenchymal stem 
cells have been reported to be capable of differentiating into non-mesenchymal cell 
types including astrocytes [Bjorklund & Svendsen, 1999; Woodbury et aL, 2000; Kabos 
et aL, 2002; Mezey et aL, 2003], and hepatocytes [Prockop, 1997; Avital et aL, 2001; 
Poulsom et al., 2002; Theise & Krause, 2002a]. They have also been investigated for 
use in tissue engineering nephrons [Ito et aL, 20011. Meanwhile, haernatopoietic cells 
have been shown capable of differentiating into hepatic oval cells [Petersen et aL , 
1999], neural stem cells into haematopoietic precursors [Bjornson et aL, 1999] and 
dermal stem cells have been differentiated into neurogenic, myogenic and adipogenic 
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cells [Torna et A, 2001]. Indeed, such is the interest in MSC,, a growing number of 
patents have been filed relating to the isolation , identification and differentiation of 
these cells for tissue engineering and other appli I [Caplan, 1996; Caplan & 
Haynesworth, 1996; 2000; Pittenger, 1998; Marshak & Holecek,, 1999; Femdndez & 
.... . ..... . 
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Minguell, 2001]. 
Figure 1.12. Mesenchymal stem cell phenotypes. Solid green arrows represent Gells 
of mesenchyrnal lineage; dashed red arrows represent functional overlap with other 
adult stem cell lineages. 
1.10.1. Characteristics of MSC 
The term,, mesenchyme , is 
derived from the Greek meaning 'middle' (meso) 'Infusion' 
and refers to the ability of mesenchymatous cells to migrate and spread in early 
embryonic development between the ectodermal and endodermal layers [Caplan, 1991 ]. 
This characteristic migratory, space-filling ability is the key element of all wound repair 
in adult organisms involving mesenchymal cells in skin (dermis), bone (penosteum), or 
muscle (perimysium). 
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Human MSC (hMSC) cultures have been shown to have a population doubling time of 
33 hours [Conget et al., 1999]. However, there are conflicting reports over the longevItY 
of hMSC,. with some reports stating that the cells become senescent after only 8 or 9 
passages, whilst others claim to have passaged hMSC in excess of 50 times without any 
change in viability or differentiation potential [Grompe, 2002]. It has been suggested 
that telomerase activity (an enzyme which maintains telomere length, and is widely 
thought to be associated with preventing cell aging) may be an important characteristic 
of stem cells that gives them the ability to self-renew indefinitely without senescence 
[Morrison et aL, 1997]. Banfi et aL (2002) have shown that hMSC do not show any 
telomerase activity in vitro and that telomere length shortens with each cell replication 
at the expected rate for telomerase-negative somatic cells (50-100 base pairs per 
doubling [Zakian, 1997]). Pittenger et aL (1999) have shown hMSC to display 
telomerase activity in vitro, however, the activity found was comparable to normal 
human foreskin fibroblasts,. which have been consistently described by a number of 
investigators to be telomerase-negative [Kim et aL, 1994; Bodnar et aL, 1998]. Lack of 
telomerase activity does contradict the principle that true stem cells should be able to 
replicate indefinitely and suggests that hMSC life span would be no greater than that of 
other terminally differentiated somatic cells. Of course in vrvo conditions may well 
promote telomerase activity and it may well be that current in vitro culture conditions 
do not provide an appropriate environment or stiniWatorY conditions for telomerase 
activity. Simonsen et aL (2002) have addressed this issue by demonstrating that it is 
possible to successfully transfect hMSC with a retroviral vector containing the catalytic 
subunit of the human telomerase gene, whilst maintaining full cell proliferation and 
differentiation functions. 
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The antigenic phenotype of hMSC has shown them to possess features of several cell 
lineages including mesenchymal, endothelial, epithelial and muscle cells fGalmiche et 
aL, 1993; Conget et aL, 1999; Pittenger et aL, 19991. Isolated hMSC have been reported 
to constitute a single, phenotypically distinct population and show the following cluster 
of differentiation (CD) markers: CD44+, CD71+, CD90+, CD95L+, CD106+,, CD120a+, 
and CD 124+ [Fontes & Thomson, 1999]. They have been shown to be CD34-,. CD3 I- 
and CD133-,, making them distinct from cells of the haematopoletic, endothelial and 
neurogenic stem cell lineages respectively. They have also been shown to cross-react 
with the monoclonal antibodies SH2 (anti-CD105/endoglin) and SH3 [Zvaifler et aL, 
2000; Jones et aL, 2002; Lodie et aL, 2002]. 
Despite the fact that the multipotentiality of MSC has been recognised for several 
decades, there are surprisingly large gaps in the information about the cells themselves 
[Prockop, 1997]. MSC remain a very rare cell population within the bone marrow [van 
den Bos et aL,, 1997; Nevo et al., 1998], and it is estimated that less than I in 100,000 
bone marrow cells are MSC [Caplan, 1994]. The cells,, isolated by their adherence to 
plastic, were initially shown to be heterogeneous and have proved difficult to clone. A 
number of groups claim to have produced monoclonal antibodies specific for hMSC 
which could overcome this discrepancy [Simmons & Torok-Storb, 1991; Barry et aL,. 
1999; Caplan & Haynesworth, 2000], however almost as soon as they were produced) 
the monoclonal antibodies were found to cross-react with other non-MSC lineages. 
Cultured hMSC have been shown to synthesise an extracellular matrix that includes 
interstitial type I collagen, fibronectin, and the tyW IV collagen and laminin of 
basement membranes [Caplan, 1991; Clark & Keating, 1995]. A small fraction of the 
cultured cells have been reported to synthesise factor VIII-associated antigen, which is 
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characteristic of endothelial cells. The cells have also been shown to secrete cytokines, 
including interleukin-7 (IL-7), IL-8, EL-1 I and stem cell factor (c-kit ligand) [Prockop, 
19971. 
1.11. Defining Differentiation 
Differentiation can be defined as a qualitative change in the cellular phenotype that is 
the consequence of the onset of synthesis of new gene products and may be recognised 
by a change in the morphology of the cell or by the appearance of changes in enzyme 
activity or protein composition [Potten & Loeffler, 1990]. The specific route of 
transition from one lineage to another is a point of contention. Two groups [Terada et 
aL. ) 
2002; Ying et aL, 20021 have claimed that there is a low incidence of cell fusion 
between murine adult stem cells (MSC and neural stem cells respectively) and host cells 
along side the differentiation of the majority of cells in vivo. In both these cases, donor 
cells were identified using Y-chromosome markers, and fusion was found but at a very 
low frequency. It was suggested that these fused cells could have the potential to 
become a dominant population should they gain a growth or survival advantage over 
their parental cells by supplementing deficient genes. However, in these experiments , it 
happened at a very low frequency in vitro (I in 105 to 106 cells), and might only occur 
in vivo in circumstances of extensive selection pressures in tissues that 'tolerate' 
tetraploidy, such ýas muscle and 
liver (Vefaillie, 2002]. 
There is also the concept of de-differentiation and re-differentiation 
(or nuclear 
reprogramming). De-differentiation has been used to describe the loss of the 
differentiated properties of a tissue when it is grown in culture [Freshney, 
20001. This 
mechanism is thought to underlie the ability of amphibians and 
fish to regenerate limbs 
Spontaneously and can complicate the identification of a stem cell. 
Both chondrocytes 
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and adipocytes are known to de-differentiate in two-dimensional culture, losing the 
properties that normally define them as that cell phenotype, e. g. chondrocytes stop 
producing collagen 11 [Ma et aL, 2003]. Chondrocy-tes can be re-differentiated by 
placing the cells in a three-dimensional culture system, and adipocytes With the correct 
chemical stimulation. It is also thought that there may be a developmental link between 
adipocytes and osteocytes [Bennet et al., 1991] and that culturing them under the 
correct conditions can cause the de-differentiation followed by re-differentiation into the 
other cell phenotype, or back into the original cell phenotype. This may be the situation 
behind the claims of adult stem cells being isolated from adipose tissue [Zuk et aL, 
20011,2002; De Ugarte et aL,, 2003], and unknown similar relationships could be behind 
other reports of MSC differentiation. In other cases , in response to trauma or injury, 
mature cells may lose their differentiated properties and re-enter the cell division cycle. 
In this case, once the necessary repairs are made, cell division stops and differentiation 
is re-induced [Freshney, 2000]. Some investigators use the term "transdifferentiation" in 
describing the change in phenotype from one cell to another, typically referring to 
mature cells [Freshney,, 2000]. 
It is for these reasons and wnbiguities that there is currently no definitive proof that true 
pluripotent stem cells exist in vivo during post-natal life. However , if 
de- and re- 
differentiation is the mechanism involved, the potential benefits and uses of cells 
capable of this process remain unchanged. Whatever the mechanism, it will be vitally 
important to test whether in vitro culture and manipulation will not cause uncontrollable 
proliferation and/or differentiation similar to the teratomas seen when ES cells are 
transplanted in vivo. 
1.11.1. Differentiation by Biochemical Supplementation In Vitro 
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From the earliest days of modem man,, bone has been recognised to have the powerful 
capacity for self-repair [Caplan, 1991]. A variety of factors combine in a complex 
multicellular,, multi-step response in which reparatiVe cells are specifically attracted to 
the repair site. These cells then aggregate, multiply, bridge the bone gap, and 
differentiate into osteoblasts. 
The culture conditions required for differentiating MSC, however, have been found to 
be somewhat species-dependent and influenced by poorly defined variables, such as the 
level of foetal calf serum used. Osteoblasts are thought to be highly orientated cells that 
secrete bone from the side of the cell opposite that which is in contact with the capillary, 
whereas chondrocytes develop away from vasculature [Caplan, 1991]. Therefore, basal 
nutnents, cell density, spatial Organisation, mechanical forces, growth factors and 
cytokines have a profound influence on MSC differentiation [Pittenger et aL, 2000]. 
Chondrocytes have been shown to develop easily when MSC are plated under very 
compact, high-density conditions of approximately 5x 106 chick embryonIc stage-24 
limb mesenchymal cells per 9.6 cm2 dish [Caplan, 1991]. Densities below 
approximately 2x 106 cells per 9.6 CM2 dish have been shown to stimulate the generation 
of osteocytes [Caplan, 1991]. Using chemical methods, MSC from mouse, rat, rabbit 
and human sources have been reported to readily differentiate into colonies of 
osteoblasts under the influence of dexamethasone, P-glycerophosphate and ascorbate in 
the presence of 10% (v/v) foetal bovine serum (FBS). Chondrocyte differentiation has 
been induced by gently centrifuging isolated mesenchymal cells to form a pelleted- 
micromass and culturing the cells without serum and with transforming growth 
factor- 
03 (TGFP3). Treatment with 1-methyl-3-isobutylxanthine, dexamethasone, 
insulin and 
indomethacin has been shown to induce differentiation into adipocytes 
[Friedenstein et 
aL, 1976; Piersma et aL, 1985; Friedenstein et aL, 1987; Caplan, 
1991, Clark 8-' 
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Keating, 1995; Wakitani et al., 1995; Prockop, 1997; Bruder et al., 1998-, Pittenger et 
al., 2000]. In response to 5-azacytidine and amphotericin B or amphotencin B alone. 
murine MSC have been reported to differentiate Into myoblasts that fti-se into 
rhythmically beating myotubes [Wakitani et aL, 1995; Makino et aL, 1999; Emura et 
al, 2000]. Treatment with P-mercaptoethanol has been shown to differentiate hMSC 
into cells of the neurogenic lineage [Woodbury et aL, 2000]. The hMSC cultured in 
each of the differentiation conditions may also produce autocnne and paracrine factors 
that are essential for lineage progression [Pittenger et aL, 1999]. It is thought, however, 
that the osteogenic pathway is the 'default' lineage that these cells can progress through, 
-possibly because of an intrinsic commitment or the in vitro culture conditions 
representing a microenvironment favouring osteogenesis [Muraglia et aL, 2000; Banfi el 
aL., 20021. 
1.11.2. Differentiation by Co-culture 
The capabilities of MSC to differentiate as a result of the conditions created in a co- 
culture system have also been investigated. Emura et aL (2000) were able to 
differentiate hMSC into myofibroblasts by culturing the cells on a feeder layer of 
human colon carcinoma cells. Condorelli et al. (2001) have shown the potential for 
human endothelial cells and neural stem cells to differentiate into beating 
cardiomyocytes in differing degrees when co-cultured on a feeder layer of neonatal rat 
cardiomyocytes. This further demonstrates the plasticity of adult stem cells and also 
adds to the issue questioning the nature of the processes that induce cells to alter their 
-I- phenotype. 
00 1.11.3. Differentiation by Mechanical Stimu ation 
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Altman et aL (2002) have shown that it is possible for hMSC to be differentiated bv 
mechanical stimuli in vitro without biochemical factors being present. In their 
experiments, MSC were stimulated to differentiate into a ligament cell lineage. They 
demonstrated a change in expression of collagens I and III and fibronectin, alignment of 
the cells and a changed morphology. After 14 days, mRNA levels were seen to 
an pproach those of -native ligament cells. To date, this is the only work published 
examining the effects of mechanical stimulation on hMSC. However, the potential 
benefits of enhanced matrix production and cell alignment in response to mechanical 
stimulation have been shown on other cell types such as fibroblasts and aortic 
endothelial cells [Streppeti et aL, 1993; Banes et aL, 1995; Sato et aL, 1995; Eastwood 
et aL. 1998; Hishikawa & Lascher, 1997; Sirois et al., 1998; Breen, 2000; Grinell, 
2000]. In a study on cardiac fibroblasts by Butt & Bishop (1997), it was found that 
mechanical load enhanced procollagen gene transcription in the presence of serum 
growth factors. More specifically, cardiac fibroblast procollagen synthesis in response 
to specific fibrotic cytokines such as TGFOI and IGF-1 was enhanced when the cells 
were simultaneously subjected to mechanical load. These studies demonstrate the 
importance of not only biochemical, but also mechanical stimulation on both cell 
differentiation and cell signalling processes and serves to highlight the significance of 
culturing tissue-engineered products in appropriately designed bioreactors in order to 
accurately simulate the natural environment of the tissue prior to implantation. 
1.11.4. Homing and Differentiation In VIVO 
Both Almeida-Porada et aL (2001) and Liechty et aL (2000) investigated the 
fate of 
hMSC when they were Introduced into foetal sheep early in gestation, 
before and after 
the expected development of immunological competence. Leichty et aL 
(2000) 
demonstrated that hMSC underwent site-specific differentiation into chondrocytes, 
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adipocytes, myocytes and cardiomyocytes, bone marrow stromal cells and thymic 
stroma. The cells were capable of migration across the peritoneal cavity and engrafted 
and persisted in multiple tissues for as long as 13 months after transplantation, even 
when cells were transplanted after the expected development of immunocompetence. 
Devine et aL (2001) went on to investigate the intravenous infusion of baboon-denved 
autologous and allogeneic mesenchymal stem cells combined with haernatopoietic stem 
cells in a lethally irradiated non-human primate model. They found that MSC were 
capable of homing to the bone marrow and persisted for over a year without significant 
toxicity. A control animal that was not irradiated,, but still infused with MSC had cells 
present in its bone marrow up to 442 days post-infusion. 
Mackenzie & Flake, co-authors of Liechty et aL (2000) speculated that the homing 
ni, ability of the cells may be a response to tissue injury, further supporting the idea that 
MSC exist as part of a wound repair mechanism [Mackenzie & Flake, 2001 a; 2001b]. 
Also,, since the cells appeared to be capable of persisting in xenogeneic and allogenelc 
hosts, it may be that the cells possess unusual immunological properties. 
1.11.5. Stem Cell Therapy 
To date, animal studies have the shown the potential usefulness Of lineage-committed 
mesenchymal stem cells in the site-directed repair of cartilage [Wakitani et aL, 1994; 
Grande et aL , 1995; 
Yoo et aL, 1998], skeletal muscle [Saito et aL, 1995], heart muscle 
[Wang et aL, 2000; Tomita et aL, 2002], bone [Kadiyala et aL, 19971, and tendon 
[Young et aL, 1998]. Also, uncommitted MSC have been used in the simultaneous site- 
directed repair of both cartilage and bone [Grande et aL, 1995]. In all cases, MSC were 
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simply injected into the site of interest, and then the tissue excised and examined after 
varying time periods. 
1.12. Do hMSC Possess Immunomodulatory Properties? 
hMSC have been shown to constitutively express a number of molecules required for 
antigen specific interactions with T-cells including major histocompatibility class-I 
(MHC 1), but not MHC class 11 molecules, unless induced by interferon gamma (IFN-y), 
[McIntosh & Bartholomew, 2000; Le Blanc et al, 2003]. They also constitutively 
express intracellular adhesion molecule-I (ICAM-1), ICAM-2, vascular adhesion 
molecule-I (VCAM-1), L-selectin, CD72, and lymphocyte function-associated antigen- 
3 (LFA-3) adhesion molecules [Pittenger et aL, 19991. hMSC typically do not express 
the co-stimulatory molecules B7-1 (CD80) or B7-2 (CD86), although mRNA for B7-1 
has been detected by reverse-transcriptase polymerase chain-reaction (rt-PCR) 
[McIntosh & Bartholomew, 2000]. 
Several groups have shown that hMSC are not stimulatory to alloreactive T-cells 
[McIntosh & Bartholomew, 2000; Le Blanc et al., 2003; Tse et al., 2003]. Culture of 
hMSC with resting allogeneic T-cells failed to elicit T-cell proliferation or the 
expression of T-cell activation molecule CD40-ligand. This was apparently not 
due to a 
lack of co-stimulatory molecule expression, since retroviral. transduction of 
MSC with 
either B7-1 or B7-2 did not result in a significant response. It has also 
been shown that 
although the ability to present antigen in the absence of co-stimulatory molecules might 
result in the induction of T-cell tolerance, MSC appeared not to 
be tolerogen1c, since T- 
cells cultured with allogeneic MSC or donor-matched irradiated peripheral 
blood 
mononuclear cells (PBMC) for seven days and rested for three 
days were able to be re- 
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stimulated with irradiated PBMC with secondary kinetics. This suggests that MSC 
prime T-cells without inducing proliferation. 
In addition to this, some groups have carried out experiments to investigate the effect of 
MSC on mixed lymphocyte reactions (MLR). The MLR is used as an i. n vitro correlate 
of the transplantation reaction. The MLR involves mixing populations of lymphocytes 
froln two allogeneic donors. One donor's cells are irradiated to prevent cell proliferation 
whilst maintaining metabolic activity and are termed the stimulators, and the other 
donor's cells are termed responders. The T-cells of the responder population react with 
the foreign MIFIC on the surface of stimulator antigen presenting cells (APCs) causing 
the T-cells to rapidly proliferate and this can be assayed by measuring tritlated 
thymidine incorporation into the DNA of the dividing cells. The level of T-cell 
proliferation is directly proportional to the degree of human leukocyte antigen (HLA) 
mismatch between the two cell sources: closely matched cells show a minimal T-cell 
proliferation where mismatched cells show a high T-cell proliferation. The MLR was 
previously used to type tissues prior to organ transplantation in order to try to minimise 
organ rejection. Experiments by Klyushnenkova et aL (1999) and Le Blanc et aL (2003) 
suggested that hMSC may suppress activated T-cells, since the addition of MSC to an 
MLR resulted in near complete suppression of T-cell proliferation whether the 
MSC 
were added to the MLR at the initiation culture or midway through a seven 
day culture 
period. Suppression was also shown to be independent of treatment with 
IFN-y and fas- 
ligand, and was not MEC restricted, since MSC from third party 
donors were as equally 
suppressive as autologous MSC matched to responder or stimulator cells 
in the MLR. 
Furthermore, this immunosuppressive effect appeared to be mediated at 
least in part by 
a soluble factor based on the result of MLR cultures undertaken 
in transwells [McIntosh 
& Bartholomew, 2000]. Interestingly, Le Blanc et al. 
[2003] showed that although 
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proliferation activity in the MLR was suppressed with the addition of between 10,000 
and 40,000 MSC, the addition of just 10- 1000 MSC led to a less consistent suppression 
or a marked lymphocyte proliferation, showing the effect to be largely dose dependent. 
However, another interpretation of these results suggest that competition for nutrients 
could cause the reduction in T-cell proliferation since when the MSC were added to the 
MLR,, the volume of tissue culture medium was kept constant, failing to compensate for 
the increased consumption of nutrients by the extra cells. However, no other cel I source 
was used as a control for the experiment therefore there are no means to verify whether 
lack of nutrients was the cause of these results. Moreover,. the wide inconsistency of the 
findings when only 10-1000 cells were added suggests more research is required before 
any real conclusions can be made. More recent experiments by Bartholomew ef UL 
(2002) showed that T-cell suppression was reduced when MSC were added midway 
ý1- - through an MLR and could be partially reversed using interleukin-2 (IL-2), however 
again without adequate experimental controls. They also demonstrated that the 
intravenous introduction of MSC in baboons prolonged the survival time of both an 
MSC donor matched skin graft and a third party skin graft from approximately 7 days to 
approximately II days. 
Despite the short fallings of these experiments, taken together, these data suggest that 
hMSC may possess immunosuppressive effects which may render them either 
"immunoprivileged" or perhaps immunosuppressive in vivo. These findings may 
explain the lack of rejection of xenogeneic, allogeneic, or gene transduced 
MSC 
following their transplantation in large animal models [Devine et al., 2001; Mackenzie 
& Flake, 2001a; 2001b; Liechty et al., 2000]. This offers great potential 
benefits for 
tissue engineering purposes as MSC from any donor could be used to create 
the ideal 
off-the-shelf tissue-engineering product suitable for any recipient, whilst retaining 
the 
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ability to grow and develop. However, the same findings also highlight potentially 
catastrophic consequences: If MSC do cause suppression of T-cell proliferation, then 
should implanted cells become infected with a virus or become neoplastic once 
transplanted, the immune system will be unable to deal with the problem, as cell 
mediated immunity is paramount in host defence against virus infected cells and 
tumours. Therefore, any tissue-engineered product seeded with MSC might be 
unprotected and exempt from the body" s immune surveillance systems. 
1.13. Alternadve Sources of Mesenchymal Stem Cells 
It is possible that MSC may reside in tissues other than the bone marrow. Zuk et aL 
(2001,2002), Gronthos et al. (2001), De Ugarte et al. (2003), Monzono et al. (2003) 
and Winter et aL (2003), for example, claim to have isolated hMSC from adipose 
tissues. If this source of MSC was found to be reliable, it would be a far more useful 
source of cells both for research and future applications as the cells could be readily 
isolated from waste material from liposuction procedures which are increasingly 
common. This would give a far superior supply of cells than procurement from bone 
marrow biopsies which are both painful to the donor and do not provide a great deal of 
material to isolate cells from. It remains to be seen whether this source perhaps 
represents another pool of adult stem cells or if they are in fact MSC. If they are MSC, 
then it could be argued that all adult stem cells are in fact the same and have the same 
capabilities and activities but are merely found in different reservoirs throughout the 
body as a ready source for wound healing. 
Other groups believe that hMSC can be found circulating through the 
blood [Zk, aifler et 
aL, 2000; Blau et aL,, 2001], although others have previously 
disagreed [Lazarus et al., 
1997]. Again this could represent a new source of adult stem cells, although it seems 
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more likely that they have been mobilised from their initial location of the bone 
marrow, perhaps by wound response factors, and are destined for a wound healing role 
in a specific damaged tissue. De Bari et al. (2001) and Jones et aL (2002) claim to have 
isolated hMSC from adult synovial membrane, where again they may provide wound 
healing response to the surface of the joint concerned and could be another form of 
adult stem cell. The presence of hMSC in full term cord blood is still a point of 
contention [Erices et al, 2000; Labat, 2001; Romanov et al, 2003]. hMSC have, 
however, been isolated in first trimester foetal blood, liver and bone marrow, suggesting 
that hMSC migrate during the first trimester of foetal life from the liver to the bone 
marrow [Campagnoli et aL, 200 1 ]. 
14. Mesenchymal Stem Cells and Neoplasia 
number of researchers have noted similarities between adult stem cells and 
metaplastic cells. Both cell types have been shown capable of indefinite proliferation, 
form heterogeneous populations, have the capability to m1grate and differentiate and can 
be tissue specific. This has led a nwnber of people to draw on the possibility that the 
two may well be linked [Reya, et aL, 2001; Alison et aL, 2002; Pathak,, 2002]. Since the 
main functional purpose of adult stem cells are as a source of cells for wound repair, it 
follows that pools of adult stem cells of different sources,, in various locations 
throughout the body, would need to be maintained in some form throughout the life of 
an individual. Since these cells are immortal, their environment would have to be 
stringently controlled to prevent unnecessary proliferation beyond base line levels 
required for maintenance of the cell population while they are in a quiescent state. Th, is 
environment and the rigorous controls placed on the cells could be affected b), the 
I 
ageing and/or health state of an individual, which could ultimately lead to relaxation of 
these strict controls. Under these conditions, the known proliferation and differentiation 
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capabilities of mesenchymal stem cells alone could enable a single pool of de-regulated 
cells to readily differentiate into the broad range of cell phenotypes found in neoplasms 
throughout the body. The recognition that different varieties of adult stem cells may 
display functional overlap in their diversity of differentiation capabilities could easily 
account for most, if not all, varieties of neoplasia. Needless to say, no proof of any link 
currently exists and further investigation is required to link the two, but it would seem to 
be an intriguing coincidence and possibility. 
51 
Aims and Objectives 
Aim 
o date, no valve has completely fulfilled all of the objectives of the ideal aortic 
heart valve replacement as set out by Harken in 1989. The alms of this study 
therefore were to develop methods for the isolation and characterisation of 
mesenchymal stem cells as a cell source for re-seeding a decellularised aortic heart 
valve matrix in order to create a living valve that is capable of growth, repair and 
regeneration. Furthermore, a previously developed decellularised porcine valve matrix 
was further characterised and its biocompatibility assessed prior to being reseeded with 
mesenchymal stem cells. 
Specific objectives 
* To investigate the extraction and isolation of mesenchymal stem cells (MSC) 
rl__ - from porcine and human bone marrow. 
o To characterise porcine and human MSC by means of their differentiation 
capacity and phenotypic analysis. 
To further characterise a previously developed decellulansed porcine aortic 
heart valve matrix. 
To assess the biocompatibility of the decellularised valve matrix in a murine 
model. 
To examine the potential of re-seeding a decellularised aortic 
heart valve matrix 
with human mesenchymal stem cells in vitro. 
0 CHAPTER Two. 
General Materials & Methods 
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General Materials & Methods 
2.1. Equipment& consumables 
2.1.1. Balances 
A Mettler AE50 four-figure balance and a Sartorius BL50 two-figure balance were 
used. 
2.1.2. Centrifuges 
An MSE Mistral 30001 (Fisher Scientific) centrifuge was used for general 
centrifugation. High-speed centrifugation was carried out on samples contained in 
Sorvall 'Oakridge' polycarbonate (50 ml) centrifuge tubes using a Sorvall RC-5B 
refrigerated super-speed centrifuge. 
2.1.3. Class H safety cabinet 
Hazardous procedures, such as handling unscreened tissue, and procedures in which 
workers' protection was required were carried out in a Heraeus 85 Class 11 safety 
cabinet. All items entering the cabinet were sprayed thoroughly with a 70 % (v/v) 
ethanol (VWR International) solution as a surface disinfection step. Gloved 
hands of 
those using the cabinet were also sprayed with alcohol prior to entering the work area 
within the cabinet. 
2.1.4. Microtitre plate reader 
A Dynex MRX plate reader with preloaded software was used. 
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2.1.5. Fluorescence activated cell sorting (FACS) 
FACS analysis was carried out using a Beckman Coulter EPICS XL-MCL model. 
2.1-6. Glassware 
Glassware (beakers, bottles (100 ml, 500 ml, 1000 ml), flasks and measuring cylinders) 
was cleaned by immersion in aI% (v/v) solution of a phosphate-free detergent 
(Neutracono, Decon Laboratories Ltd) overnight. They were then rinsed thoroughly in 
tap water followed by three rinses in distilled water to remove all traces of detergent. 
The glassware was then dried or sterilised (160 T for 2 hours, as required) by dry heat. 
2.1.7. Incubators 
Tissue culture experiments were incubated in a humidified 5% (V/V) C02 incubator 
(Sanyo Gallenkamp) maintained at 37 T. 
2.1.8. Microscopy 
Bright-field and phase contrast microscopy was carried out using a CK40 Olympus 
inverted microscope. Fluorescent microscopy was carried out on the same microscope 
using a CK40-RFA fluorescent vertical illuminator. Cells were photographed by 
attaching an Olympus OM-4Ti Camera using 400 and 800 speed Fuji colour film for 
bright field and fluorescence microscopy respectively and later an Olympus Camedia 
C4040 Zoom digital camera. Photograph negatives were digitally scanned for computer 
manipulation using a Minolta Dimage Image Scanner attached to a personal computer 
using Adobe Photoshop 5.5 software. Latterly, cells and tissues were viewed and 
photographed using an Olympus Inverted IX71 microscope and an 
01yMpus BX51 
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microscope respectively with an Evolution MP Color Digital camera from 
MediaCybernetics attached and controlled through Image Pro Plus imaging soffivare, 
2.1.9. Sterile plastieware 
Flat-bottomed 96-well,, 48-well,, 24-well, 12-well and 6-well plates, and 25 crn2 and 
75cm 2 tissue culture flasks, all Nunc brand,, were purchased from Fisher Scientific. The 
'Stripette' disposable pipettes (2 ml, 5 ml, 10 ml and 25 ml) were supplied by Coming 
Costar. Bibby Sterilin bijou containers (7 ml), universal containers (25 in]) and 
specimen containers (60 ml, 150 ml and 250 ml) were purchased from SLS. 
Finnpipettes and pipette boys were purchased from Scientific Laboratory Supplies. Both 
filter and non-filter tips (2 gl, 20 gl, 200 gl and 1000 ýtl) were purchased from Star 
Labs. 
2.1.10. Dissection 
A size 22 scalpel handle, dissecting scissors, rat-tooth forceps, and standard forceps 
. C-- - were purchased from Fisher Scientific and sterilised with dry heat prior to use. 
Single 
use sterile scalpel blades were also purchased from Fisher Scientfic. 
2.1.11. Measurement of pH 
The pH of solutions was measured using a Jenway 3020 pH meter. 
The pH meter was 
calibrated using solutions of pH 4,7 and 10 made 
from buffer tablets (VWR 
International) dissolved in deionised water. The pH of solutions was measured using 
temperature compensation. To adjust the pH of the solution, 
IM hydrochloric acid 
(HCI, VWR International) or IM sodium hydroxide (NaOH, 
VWR International) was 
added drop-wise with stirring. 
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2.1.12. Microtome and cryostat 
Paraffin sections were cut at 4 pm on a Leica RM2125RTF microtome. Frozen sections 
were cut at 5 gm on a Bright Instruments OTF/AS 88100588 cryostat. 
2.2. Sterilisation 
2.2.1. Dry heat sterilisation 
Items to be sterilised by dry heat were placed in an oven and held at a temperature of 
160 T for I hour. 
2.2.2. Moist heat sterilisation 
Oýjects and solutions not suitable for dry heat sterilisation were stenlised by .F 
autoclaving at 121 T, 15 pounds per square inch (psi) for 20 minutes. 
2.2.3. Filter sterilisation 
Solutions not suitable for autoclaving were sterilised with single use 0.2 ptm filters 
purchased from Schleider and Schuell UK Ltd. 
2.3. General solutions & reagents 
2.3.1. Bovine serum albumin 
Bovine serum albumin (BSA) fraction V (tissue culture tested) was purchased 
from 
Sigma-Aldrich and stored at 4 T. 
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2.3-2. Foetal calf serum 
Foetal calf serum (FCS) of New Zealand origin was supplied b,,,, Invitrogen. 
Complement within the FCS was inactivated by incubation at 56 T for 60 minutes. The 
FCS was then aliquoted and stored at -20 OC until required. 
2.3.3. Formalin solution 
A 40 % (v/v) solution of fonnaidehyde (VWR Intemational) was diluted in phosphate 
buffered saline (PBS) to 4% (v/v) and stored at room temperature. 
2.3.4. L-Glutamine solution 
L-Glutamine was purchased from Sigma-Aldrich at a concentration of 200 mM. The 
solution was aliquoted and stored at -20 T. 
2.3.5. Hanks' balanced salt solution (HBSS) 
Both complete HBSS and calcium and magnesium free HBSS were purchased from 
Sigma-Aldrich and stored at room temperature until required. After opening, HBSS was 
stored at 4 T. 
2.3.6. N-(2-hydroxyethyl)piperazine-N'-(2-ethanulfonic acid) (HEPES) 
AIM solution of BEPES was supplied by Sigma-Aldrich and was stored at room 
temperature until required. Once open, the 14EPES was stored at 4 
T. 
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2.3.7. Pen ic illin/streptomycin solution 
A solution of 100,. 000 Units. ml-1 penicillin and 100,000 pjg. my' streptomycin was 
purchased from Sigma-Aldrich and was aliquoted and stored at -20 T. 
2.3.8. Transport medium 
Transport medium consisted of 100 ml complete I]BSS supplemented with I ml 
penicillin/streptomycin solution, 10 KIU aprotonin (Tyrasol, Leeds General Infinnary 
Pharmacy), and 2 ml 1M HEPES. 
2.3.9. Phosphate buffered saline (PBS) 
Sterile PBS solution for tissue culture experiments was purchased from Sigma-Aldrich. 
PBS for general experiments was prepared from PBS tablets (BR14a OXOtD). One 
tablet for each 100 ml of PBS required was dissolved in distilled water according to the 
manufacturer's instructions and autoclaved. 
2.3.10. Culture medium 
Dulbecco"s modified Eagles medium (DUEM) without L-glutamine and sodium 
pyruvate was purchased ftom Invitrogen up to February 2002 and after October 2002. 
The same DMEM was supplied by Sigma-Aldrich between February and December 
2002. Between August and October 2002, human MSC cells were cultured in Mesencult 
with supplements for human mesenchymal stem cells. One porcine 
MSC sample 
(pBM37) was cultured in Mesencult with supplements for human mesenchymal stem 
cells during December 2002. All culture medium was stored at 
4T and warmed to 37 
OC pnor to use. 
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2.3.11. Gas mixtures 
Laboratory gradeC02was supplied by BOC Ltd. 
2.4. Tissue culture 
2.4.1. Complete medium and standard culture conditions 
DMEM was supplemented with I ml penicillin/streptomycin solution and I ml L- 
glutamine solution per 100 ml, and 10 % (v/v) FCS. This was stored for up to 2 weeks 
at 4 T. Cells were cultured in a humidified Sanyo incubator at 37 T with 5% CO, 
(v/v) in air. 
2.4.2. Cell counting & cell viability 
Materials: An improved Neubauer haemocytometer chamber was purchased from 
Fisher Scientific. Trypan blue solution (4 %w/v) was purchased from Sigma-Aldrich. 
Method: A trypan. blue dye exclusion test was used when counting cells to ensure that 
only viable cells were included. Trypan blue solution was added to a small aliquot of 
cell suspension at a ratio of 1: 1. The plasma membrane of a viable cell did not permit 
entry of the dye substance; therefore viable cells and non-viable cells could be 
distinguished. The sum of the number viable cells visible by bright field microscopy 
within any five of the nine major squares on either side of the central divide of the 
haernocytometer were multiplied by a factor of 
103 to calculate the number of cells in 
Iml of suspension. 
2.4.3. Calculating cell doubling time (CDT) 
Once a confluent cell layer was obtained from the original cell isolation, 5x, 05 Ce, IS 
were transferred to a 75 cm 
2 tissue culture flask. The cells were then cultured further 
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until a confluent monolayer had formed and the time to reach confluence noted. The 
cells were then counted using a haemocytometer as described in section 2.4.2. 
Typically, 5x 105 human mesenchymal stem cells formed a confluent monolayer in a 25 
cm 2 tissue culture flask, and 1.5x 106 cells in a 75 CM2 tissue culture flask. The cell 
doubling time (CDT) in that time period was then calculated using the following 
formula: 
CDT t 
logio (N/N,, ) x 3.33 
Where: t= time in hours for confluent monolayer to form after cells seeded 
N= final number of cells in confluent monolayer 
No = original number of seeded cells 
2.4.4. Passaging cells 
Materials: Trypsin-ethylenediaminetetraacetic acid (I x; EDTA) solution was obtained 
from Sigma-Aldrich. 
Method: Cell culture medium was aspirated and then discarded. The cell layer was then 
rinsed once with calcium and magnesium-free HBSS. Enough trypsin-EDTA was added 
to just cover the cell monolayer (0-5 ml for 25 cm 2 flasks, and I ml for 75 CM2 flasks). 
The flask was then rocked to coat the surface with trypsin-EDTA prior to being 
incubated at 37 T for 10 minutes. The flask was then firmly tapped to assist cell 
detachment from the surface of the tissue culture flask until all the cells were detached. 
Once detached, the cells were resuspended in complete medium and passaged at a 1-3 
ratio. 
2.4.5. Cryopreservation of cells 
Materials: CryOvials and a Nalgene freezing container were obtained from Fisher 
Scientific. Dimethylsulphoxide (DMSO) was obtained from Sigma-Aldrich. Cryo- 
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medium consisted of complete medium containing 20 % (v/v) foetal calf serum and 10 
(v/v) DMSO. 
Method: The cells were trypsinised as described above and resuspended In chilled (4 
'C) cryo-medium. Cells were then split at a ratio of 1: 2 and 1: 6 for 25 cm" and 75 CM2 
flasks respectively into pre-cooled cryovials to give Iml volumes. The cryovials were 
then placed in a Nalgene freezing container, which was placed in a -80 OC freezer for a 
minimum of 4 hours in order to provide a cooling rate of -1 OC. min-1. The cryovials 
were then quickly transferred to liquid nitrogen storage. 
2.4.6. Resurrection of cryopreserved cell cultures 
Method: Cells were removed from liquid nitrogen storage and rapidly defrosted in a 37 
T water bath. Pre-warmed complete medium (10 ml) was then added drop-Wise to the 
cells prior to centrifugation at 200 g for 10 minutes. The supernatant was then discarded 
and the pellet resuspended in 5 ml of complete medium. This was then transferred to a 
3 25 cm tissue culture flask and the cells incubated under standard conditions. 
2.5. Basic histological techniques 
2.5.1. Tissue harvesting for paraffin embedding 
Materials: Ethanol, xylene and paraffin were obtained from VWR International. 
Methods: Tissue samples were placed in 20 ml of formalin solution for one hour, 
before being placed in 20 ml. of 70 % (v/v) ethanol until ready for further processing. 
Tissues were then dehydrated through graded alcohols and xylene. This involved first 
replacing the 70 % (v/v) ethanol with 20 ml 90 % (v/v) ethanol and 
leaving the samples 
overnight. The tissues were then placed in 20 ml absolute ethanol 
for one hour, before 
the ethanol was replaced for a second hour. This was then repeated with xylene and 
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- liquid paraffin. Tissues were then embedded in liquid paraffin before it was cooled and 
solidified. 
2.5.2. Tissue sectioning and slide 
tissues 
preparation of parafflin-em bedded 
Materials: The hotplate was purchased from Raymond A Lamb (London, UK). 
Superfrost Plus slides were obtained from VWR International. 
Method: Tissue sections were made by sectioning the paraffin block at a thickness of 4 
pm on a microtome. Sections were then melted onto Supeirfrost Plus slides by leaving 
Al- 
the slides on a hotplate set at 56 T for 10 minutes. 
2.5.3. Dewaxing and rehydrating paraffin-em bedded tissue sections 
Materials: Ethanol, xylene and paraffin were obtained from VWR International. 
Method: This was carried out by sequentially immersing the cells in two lots of 100 ml 
of xylene for ten minutes each followed by three changes of 100 ml absolute ethanol for 
I minute each, followed by 100 ml 70 % (v/v) ethanol for I minute and finally rinsing 
the slides in running tap water. 
2.5.4. Dehydration and mounting of tissue sections 
Materials: Ethanol,, xylene, DPX mountant and 22 MM2 coverslips were obtained from 
VWR International. Slide racks were purchased from Raymond A Lamb Ltd. 
Method: Once sections had been stained, the slides were transfeffed to a metal slide 
rack. This was then sequentially immersed in 70 % (v/v) ethanol then three changes of 
ethanol for I minute at a time. The ethanol was then 
followed by two changes of xylene 
for I minute each. Slides were then individually removed 
from the xylene, a drop of 
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DPX mountant placed over the tissue section, and a coverslip carefully placed over the 
section. 
2.5.5. Tissue harvesting for cryo-embedding 
Materials: Cryo-embed was purchased from VWR intemational. 
Methods: Tissues requiring cryo-embedding were first lightly dried using tissue paper. 
A drop of Cryo-embed was then placed on a cryostat chuck in the freezing chamber of 
the cryostat. The tissue section was then placed into the cryo-embed drop before more 
cryo-embed was added to cover the tissue. The sample was then left to freeze for 10 
minutes. Frozen blocks were then stored at -40 T. 
2.5.6. Tissue sectioning and slide preparation of cryo-embedded tissues 
Methods: Tissues were sectioned at a thickness of 5 pm on a cryostat and the section 
transferred to Superfrost Plus slides and allowed to air diy. Prior to any histological or 
immunohistochemical staining, sections were rehydrated by immersing the slides in 5 
ml of PBS for 5 minutes. 
2.5.7. Haematoxylin & eosin Staining 
Materials: Modified Mayer's haernatoxylin consisted of 3g of haematoxylin 
(Raymond A Lamb) added to 20 ml absolute ethanol (VWR International) This was 
then mixed with 850 ml distilled water containing 0.3 g sodium iodate 
(Fisher 
Scientific), Ig citric acid (VWR Intemational), 50 g chloral hydrate (Fisher Scientific) 
and 50 g aluminium potassium sulphate (VWR Intemational). 
Once mixed, 120 ml of 
glycerol (Sigma-Aldrich) was added and the solution 
filtered before use. Eosin was 
obtained from Raymond A Lamb. 
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Method: Paraffin sections were first dewaxed and rehydrated through graded alcohols. 
Sections were then dipped in 100 ml Modified Mayer's Haematoxylin for I minute, 
rinsed in tap water, and immersed in 100 ml eosin for 3 minutes. Sections were then 
dehydrated and mounted. 
2.6. Immunohistochemical labelling 
2.6.1. Immunoperoxidase labelling of paraffin-e m bedded sections 
Materials: Citric acid buffer consisted of 10 mM citric acid (Sigma-Aldnch) adjusted 
to pH 6.0 using NaOH pellets (Sigma-Aldrich). A streptavidin/biotin blocking kit, 
rabbit serum and ready-to-use streptavidin horseradish peroxidase were purchased from 
Vector Laboratories Ltd. Tris-buffered saline (TBS buffer) consisted of 25 ml 2M Tris 
(Sigma-Aldrich), adjusted to pH 7.6 using HCI (VWR International), 50 ml 3M NaCl 
(VWR International) and 925 ml distilled water. TBS azide consisted of TBS buffer 
containing 0.01% (w/v) sodium azide (VWR International). TBS azide BSA consisted 
of TBS azide containing 10% (w/v) bovine serum albumin (Sigma-Aldrich). Sigma Fast 
3,, 3'-diaminobenzidine tablets (I ml) were purchased from Sigma-Aldnch. Antibodies 
were obtained from various suppliers and were diluted according to the accompanying 
data sheet in TBS azide BSA prior to use. Biotinylated secondary antibody was diluted 
to according to the manufacturer's instructions in TBS azide BSA containing 10 % (v/v) 
pig serum. 
Method: Sections were first dewaxed and rehydrated prior to undergoing antigen 
retrieval and peroxide blocking if required. The slides were then placed into separate 
compartments of a slide box prior to covering the sections With 50 W of streptavidin 
block for 10 minutes. The slides were then washed three times in TBS buffer and 50 gI 
of biotin block added to each section for a ftirther 10 minutes. Again the sections were 
washed three times in TBS buffer and 50 pI of 20 % (v/v) rabbit serum 
(diluted in TBS 
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azide) added to each section for a further 5 minutes. This was then washed three times 
in TBS buffer and 50 gl of the appropriate diluted antibody added to each section (see 
Table 2.1). This was then left for I hour at room temperature before being washed three 
times in TBS buffer and 50 ýtl of secondary antibody was added to each section. Afler 
30 minutes, the slides were washed three times in TBS buffer and 50 gI of horseradish 
peroxidase streptavidin was added to each section for 45 nunutes at 37 T. This was 
then washed three times in TBS buffer. Sigma Fast 3,3'-diaminobenzidine tablets were 
dissolved in Iml of distilled water according to the manufactures instructions and 50 gl 
of the working solution was added to each section. After 10 minutes, the reaction was 
stopped by immersing the slides in running water. The sections were then 
counterstained by dipping the slides in haernatoxylin for 5 seconds, prior to dehydrating 
the sections through graded alcohols as previously described. Sections were then 
mounted in DPX mountant prior to viewing. 
2.6.2. Peroxide blocking 
Materials: Hydrogen peroxide (30 0, /0'; vIv) was Purchased from Sigrna-Aldrich. 
Method: For paraffin sections, slides were placed in 3% (v/v) 
H202 in distilled water 
for 10 minutes at room temperature, prior to being washed for 3x2 minutes in distilled 
water. For frozen sections, slides were placed in 0.6 % (v/v) 
H202 in methanol for 10 
minutes at room temperature prior to being washed for 3 x2 minutes in 
distilled water. 
2.6.3. Antigen retrieval 
2.6.3.1. Microwave treatment 
Materials: EDTA buffer was prepared using a solution of 
I m-M EDTA (Sigma- 
Aldrich) adjusted to pH 8.0 using NaOH 
(Sigma-Aldrich). Citric acid buffer was 
prepared using 10 rnM citric acid adjusted 
to pH 6.0 using NaOH pellets (Sigma- 
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Aldrich). The microwave was an 80OW model from Sanyo. The Pyrex dish and 
clingfilm were purchased from Wilkinson's. 
Method: Wbere indicated by the manufacturer of the antibody, microwave treatment 
was used to retrieve antigens on paraffin embedded tissue sections. The slides were 
placed in a Pyrex dish and covered in 400 ml of either EDTA or citric acid buffer 
accordingly. The dish was then covered with clingfilin and placed in a microwave, 
before being microwaved on full power for 10 minutes. The dish was then placed on ice 
and allowed to cool. 
2.6.3.2. Trypsin treatment 
Materials: Trypsin and CaC12were purchased from Sigma-Aldrich. 
Methods: Sections were incubated at 37 T in distifled water for 10 minutes. Water was 
then replaced with a solution containing 0.1 % (w/v) trypsin in 0.1 % (w/v) CaC12at pH 
7.8. Sections were then rinsed in running tap water prior to further processing. 
2.6.3.3. Hyaluronidase treatment 
Materials: Buffered hyaluronidase was prepared by dissolving 10 mg of bovine 
testicular hyaluronidase Type IV (Sigma-Aldrich) in 10 ml PBS). 
Method: Antigen retrieval was carried out by immersing each slide in 5 ml of buffered 
hyaluronidase enzyme for 3 hours at 37 T. 
2.6.4. Immunofluorescent labelling of cultured cells 
Materials: Slide boxes were obtained from Fisher Scientific. Antibodies were obtained 
from various suppliers and were diluted according to the accompanying 
data sheet (see 
Table 2.1) in TBS azide BSA prior to use. Fluorochrome labelled goat anti-mouse 
secondary antibody was obtained from Molecular 
Probes Europe BV and was diluted 
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11500 in TBS azide containing 10 % (v/v) pig serum (Vector Laboratories Ltd). Tween 
20 (polyoxethylene sorbiton monolaurate) was purchased from Slgma-Aldrlch. 
DABCO/glycerol solution consisted of 9: 1 solution of glycerol (VWR Intemational): 
2.5 % (w/v) 1,4-diazobicyclo-(2,2,2)-octane (DABCO, Sigma-Aldrich) in 0. IM 
NaHC03 (VWR International), adjusted to pH 9.0 using NaOH pellets (Sigma-Aldrich). 
Method: Multi-spot slides were placed into a 4-well slide box. The cells were then 
washed three times in TBS buffer. Antibody was diluted according to the 
manufacturer's instructions in TBS-azide BSA and 50 gl was added to each section and 
left for I hour at room temperature. The slides were then washed three times in TBS 
buffer prior to fixation in a 50: 50 solution of methanol and acetone for 2 minutes. 
Diluted fluorochrome-labelled anti-mouse secondary antibody (50 gl) was added to 
each section and the sections were incubated at room temperature for 30 minutes. The 
slides were then washed twice in PBS containing 0.25 % (v/v) Tween 20. The sections 
were then rinsed once with distilled water before being dried and stored in a dark box 
prior to viewing. Finally, the sections were mounted in DABCO/glycerol solution. 
2.6.5. Antibodies used for immunohistochemistry 
Where necessary, antibodies were diluted with TBS azide BSA as described in section 
2.6.1. Few antibodies were available that were known to bind to porcine antigens, 
therefore, antibodies to human antigens were frequently purchased and their sultability 
for porcine tissue assessed using porcine positive control tissue. 
ANTIGEN TYPE SUPPLIER ISOTYPE ANTIGEN DILUTION POSITIVE 
RETRIEVAL CONTROL 
Ki67 Mouse DAKO IgGI None 1: 75 Porcine 
anti- skin 
human 
-jgG I --Trypsin 1: 100 Porcine Elastin Mouse Vector 
small anti- 
bovine intestine 
n Mous Trypsin 
1-1100 Porcine Collagen Mouse Chemicon I ýIgGI skin I anti- 
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human T- ýj-oliajen Mouse Sigma Igm Hyaluron- 1.1500 --+Bovine 
anti- idase cartilage human 
e Mouse 1 Vec 
ýt- tor IgGI -Porcine None 1: 25 caspase- anti- 
tonsil 3 human 
Tau Mouse -Vector I g-G -I N--one 1: 100 Porcine anti- 
optic bovine 
nerve NSE Mouse Vector IgG2a Citrate 1: 50 Porcine 
anti- microwave optic human 
nerve ---ý-STAA Mouse Vector IgG2a None 1: 50 --Porcine 
anti- bowel human 
M wall HCMs Ouse Vector Iýgdi Citrate 1: 20 Porcine 
anti- microwave heart 
rabbit muscle -Vi7in-entin Mouse Vector -IgG-1- I Citrate 1: 50 Porcine 
antI-pIg microwave lymph 
node -de--smin Mouse Vector IgG-I Citrate 1.50 Porcine 
anti-pig microwave heart 
muscle X-gal Baboon Chemicon Poly- None 1.500 Porcine 
anti-pig clonal valve 
leaflet 
Alkaline Mouse DSHB Poly- None 1-10 Osteo- 
Phosphat anti- clonal sarcoma 
ase human 
_,, _cell 
line 
Osteo --F'ý ýtrate Mouse Vector IgGI 1: 40 Osteo- 
nectin anti- microwave sarcoma 
human cell line 
Osteo- Mouse V-ector IgGI Citrate 1: 25 Gall 
pontin anti- microwave bladder 
human 
CD3 Rat Caltag IgG-2a Not suitable 1: 4 Murine 
anti- for paraffin spleen 
mouse 
CD4 Rat Caltag IgG2a Not suitable L4 Murine 
anti- for paraffin Spleen 
mouse 
F4/80 Rat Caltag IgG2b Not suitable 1: 4 Munne 
for paraffin Spleen anti- 
mouse 
-lgG2-a-- 7 -Not suitabýle 1-20 Munne CD34 Rat BD 
for paraffin Spleen anti- Pharminge 
mouse n 
Table 2.1. Details of the primary antibodies used during the study. Antigen 
retrieval only required when paraffin sections used. 
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ANTIGEN TYPE SUPPLIER DILUTION 
2'Rabbit Biotin- DAKO 1: 200 
anti- ylated I mouse 
2' Goat FITC Molecular 1: 500 
anti- Probes 
mouse 
2'Rabbit Biotin- DAKO 200 
anti-rat ylated 
Table 2.2. Details of the secondary antibodies used during the study. 
ANTIGEN TYPE SUPPLIER 
Isotype Mouse DAKO 
control control 
IgGI 
Isotype Mouse DAKO 
control control 
IgG2a 
Isotype Rat Caltag 
control control 
IgG2a 
Isotype Rat Caltag 
control control 
_IgG2b Table 2.3. Details of the isotype control antibodies used during the study. 
2.7. Control cell lines and tissues 
A human osteosarcoma cell line (HOS38094) was obtained from The European 
Collection of Cell Cultures (ECACC), as a positive control for the alkaline phosphatase 
assay. Human smooth muscle cells obtained from saphenous vein explants were used as 
a negative control for the alkaline phosphatase analysis. All control cells were cultured 
in complete medium and under standard conditions as described in Section 2.4.1. 
Control tissues for immunohistochemistry are described in Table 2.1. Human aortic 
homograft valves were obtained ftom the National Blood Service for cell counting 
analysis and comparison with reseeded tissues. 
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2.7.1. Isolation of human smooth muscle cells from saphenous vein 
Materials: Saphenous vein samples were obtained with ethical approval (ethics 
number: 01/044) from Leeds General Infirmary from patients undergoing a coronary 
artery bypass. 
Methods: Isolation of human smooth muscle cells from saphenous vein was camed out 
by Dr Helen Wilcox. The tissue sample was placed into a petri dish and rinsed twice 
with PBS. The vein was then cut longitudinally and the internal surface (Intima) scraped 
with a scalpel in order to remove the endothelial cell layer. The outer adventItIal layer 
was then carefully peeled away from the remainder of the tissue and discarded. The 
remaining tissue was then finely diced before being transferred to a 25 CM2 tissue 
culture flask and the pieces spread out evenly on the base of the flask. Complete 
medium (I ml) was then carefully added to the flask so as not to disturb the tissue 
pieces, and the tissue cultured under standard conditions. Culture medium was replaced 
every other day at this point, and the migration of cells out of the tissue samples 
monitored using an inverted microscope. Once cells could be observed to be migrating 
out from the majority of tissue pieces, the flask was flooded with 5ml of complete 
medium and re-incubated for 24 hours. The flask was then gently tapped in order to 
dislodge the tissue pieces, which were then poured out of the flask. This was then 
replaced with 5ml of complete medium and the cells cultured using standard conditions 
and techniques, as described in Section 2.4.1. 
2.8. Leaflet decellularisadon and disinfection 
2.8.1. Leaflet decellularisation 
Materials: Aprotinin was purchased ftom the LGI pharmacy as 
Tyrasol. Sodium 
ethyldiaminotetraacetic acid, Tris, magnesium chloride, 
bovine serum albumin (BSA), 
RNase A and DNase I were purchased from Sigma-Aldrich. 
Hydrochlonc acid was 
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obtained from VWR International. Sodium dodecyl-sulphate was obtained from 
Calbiochern. An orbital plate shaker (IKA KS130 basic) was purchased from Jencons. 
Wash buffer consisted of PBS containing 10 KIU aprotinin and 0.1 % sodium 
ethyldiaminotetraacetic acid (EDTA). Hypotonic buffer consisted of 10 mM Tris with 
10 KIU aprotinin and 0.1 % EDTA adjusted to pH 8.0 using HCI. Reaction buffer was 
made by adding 10 mM magnesium chloride and 50 ug. ml-1 bovine serum albumin to 
50 mM Tris and adjusted to pH 7.5 using hydrochloric acid, 
Method: This technique was developed by Booth et aL (2002). Porcine hearts were 
obtained from a local abattoir and the aortic valve leaflets excised. Leaflets were then 
washed 3x3O minutes in wash buffer (5 ml per leaflet) on a plate shaker set at 300 rpm. 
Leaflets were then incubated for 16 hours in hypotonic buffer at 4T (5 ml per leaflet) 
before being incubated for 24 hours in hypotonic buffer containing 0.1 % (w/v) SDS (5 
ml per leaflet) at room temperature on a plate shaker set at 300 rpm. Leaflets were again 
washed in wash buffer (5 ml per leaflet) for 3x3O minutes in PBS (5 ml per leaflet) 
prior to enzymatic digestion. RNase (I U. ml-) and DNase (50 U. ml-1) were added to 
100 ml of reaction buffer and filter-sterilised and the leaflets incubated in 5 ml reaction 
solution per leaflet for 3 hours at 37 T with gentle agitation on an orbital plate shaker. 
Leaflets were then washed for 3x3O minutes in wash buffer. At this stage,, decellulansed 
leaflets were either cryopreserved and stored in liquid nitrogen prior to further use, or 
fonnalin fixed for histological analysis. 
2.8.2. Leaflet cryopreservation 
Materials: Cryovials and a Nalgene freezing container were obtained 
from Fisher 
Scientific. 
Methods: Once decellularised, leaflets were transferred to chilled 
(4 'C) cryo-medium. 
Two leaflets were then transferred to each cryovial in I ml of cryo-medium. 
The 
77 
,I 
CHAPTER 2 
cryovials were then placed in a Nalgene freezi I in a -80 ng conta ner, which was placed 
freezer for a minimum of 4 hours in order to provide a cooling rate of -1 'C. min-I 
The cryovials were then quickly transferred to liquid nitrogen storage. 
2.8.3. Thawing of cryopreserved leaflets 
Methods: Leaflets were removed from liquid nitrogen storage and rapidly defrosted in 
a 37 T water bath. The leaflets were then transferred to 20 ml complete medium until 
required for finiher manipulation. 
2.8.4. Tissue disinfection 
Materials: Aprotinin and imipenem were purchased from the LGI pharmacy as Tyrasol 
and Primaxin respectively. Amphotericin B, vancomycin, gentamicin, polymixin B and 
IPIB'S were purchased from Sigma-Aldrich. 
Method: Decellularised leaflets placed in PBS containing 25 gg. ml-1 amphotencin B, 
0.05 mg. ml-1 vancomycin, 0.5 mg. ml-1 gentamicin, 0.2 mg. ml-1 polymixin B, 0.2 mg. ml- 
1 imipenem, and 10 U. ml-1 aprotinin. Approximately 5 ml of solution was prepared per 
leaflet. Leaflets were then incubated on a plate shaker set at 300 rpm for 18-24 hr at 4 
OC. 
2.9. Statistical analysis 
2.9.1. Basic statistical terms 
Mean W=2: x 
n 
standard Deviation (S) 
I= sum of 
x= individual values 
n= the number of individual values 
ý(Y-X) 
n-I 
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Standard Error (SE) S 
ýn 
2.9.2.95 % Confidence limits 
Confidence values,, 95 %, were calculated for data with several replicates. The results 
were expressed as the mean ± 95 % confidence limits. 
95 % confidence limit = SE x t-value 
Statistical tables were used to calculate the t-value where: 
a probability level (0.05) 
v degrees of freedom (n-1) 
2.9.3. Arcsine transformation of data 
Where experimental data was expressed as percentages it was necessary to transform 
the data to arcsine values in order to generate 95 % confidence limits. Arcsine is also 
known as inverse sine. The percentage data (proportions) were converted to the angle 
whose sine was the given quantity. At the end of the analysis the value for 95 % 
confidence was back transfonned to a percentage and plotted as nonnal. 
1 
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Isolation and Characterisation of 
Porcine Mesenchymal Stem Cells 
Introducdon 
n any tissue engineering strategy involving living cells, an appropriate source of Icells 
ha's to be established that possess similar properties to the cells of the native 
tissue. The use of ten-ninally differentiated cells such as fibroblasts and smooth muscle 
cells for tissue engineering an aortic heart valve is potentially beset with cell-age related 
problems as it is widely known that terminally differentiated cells become senescent 
after prolonged culturing in vitro [Hayflick, 19651. For a tissue-engineered product in 
which cells would ultimately be derived from the recipient of the construct to 
circumvent rejection, it is likely that a relatively small number of cells isolated from a 
simple biopsy would have to be expanded to large numbers in vitro prior to reseeding 
and subsequent implantation of the construct. Since these cells would already have aged 
in situ within the patient, subsequent in vitro culture could yield cells possessing only a 
limited lifespan. This could lead to seeded cells becoming senescent before host cells 
were able to infiltrate the tissue engineered implant, leaving a period of time in which 
the implant would not have cells needed for repair and remodelling of the tissue. This 
could be particularly problematic for a heart valve since the tissue is continually 
subjected to strong sheer forces and flexion fatigue in vivo Pavila, 1989; Schoen, 19991 
and is consequently highly susceptible to damage. Also, whilst fibroblasts and smooth 
muscle cells may have properties similar to the native cells, 
differences Will remain. 
Since these cells are tenninally differentiated, their capacity to adapt to the new 
environment will be limited and they may have 
limited capacitý, for chang-ling 
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phenotype, therefore they would be potentially suboptimal until host cells infiltrate the 
new tissue. 
Adult stem cells, such as mesenchymal stem cells, have two distinct advantages over 
tenninally differentiated cells. One of the definitions of any stem cell is that they are 
thought to be immortal in their undifferentiated state [Till & McCulloch, 19611. This 
immortality could enable large numbers of cells to be grown in vitro Without loss of 
proliferation capacity or age-related deterioration of the cells which is seen when 
terminally differentiated cells are cultured for prolonged penods [Hayflick, 1965]. 
Although it has been found that hMSC do not posses any telomerase activity [Banfi et 
aL, 2002] this could be a result of inappropriate culture conditions. Improving the 
culture conditions could pen-nit the cells to maintain the immortality that the cells 
should in theory possess in vivo, allowing large cell expansion without loss of function. 
, rl%-- 
Once sufficient cells are available, differentiation into the appropriate required 
lineage(s) could then either be induced biochemically or mechanically in vitro by 
culturing the cells in a bioreactor. This latter route could be advantageous as it has been 
shown that mechanical stimulation can differentiate MSC and can even enhance matrix 
production and cell orientation of some terminally differentiated cells [Streppeti et al., 
1993; Banes et al., 1995; Sato et al., 1995; Butt & Bishop (1997); Eastwood et aL, 
1998; Hishikawa & Li1scher, 1997; Sirols et aL, 1998; Breen, 2000; Grinell, 2000; 
Altman et aL,, 2002]. In tissue engineering an aortic heart valve, it is likely that the 
environment created in a bioreactor and later in situ within the patient would provide the 
correct mechanical and biochemical stimuli necessary to differentiate the cells into a 
phenotype more closely related to the native heart valve cells than could otherwise 
be 
achieved. 
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In order to perform pre-clinical assessment of a tissue engineered living heart valve, a 
large animal model would be required. Since only inbred pigs were available at the start 
of the project, this was the model of choice. Isolation and identification of porcine 
mesenchymal stem cells would provide a source of cells ultimately capable of being 
used to create a valve that could be tested in a large animal model. This construct could 
then be implanted into pigs to assess the in vivo functionality of the construct, which 
would be a vital step in the development of a tissue-engineered product suitable for 
human implantation. 
At the beginning of the project, no work had been published regarding porcine MSC. It 
was therefore necessary to derive methods for isolating and identifying pMSC from 
investigations on MSC from other sources. An increasing number of groups have shown 
that it is possible to isolate and differentiate both human and murine MSC into a variety 
of cell lineages, including osteogenic, adipogenic and chondrogenic lineages [Caplan, 
199 1; Pereira et aL . 1995; Wakitani et aL, 
1995; Cassiede et aL, 1996; Prockop, 1997; 
Feffari,, et al, 1998; Johnstone et aL, 1998; Nevo et aL, 1998; Makino et aL., 1999,, 
Pittenger et aL, 1999; Deans & Moseley, 2000; Emura et aL, 2000; Minguell et aL, 
2000; Pittenger et aL, 2000; Fukuda, 2002; Hakuno et aL, 2002; Reyes et aL, 2002]. 
Thus methods for isolating the MSC from both sources are widely documented and 
essentially follow the same principle of centrifuging whole bone marrow on a 
continuous gradient (usually Ficoll or Percoll) and culturing the adherent cells from the 
uppermost fraction under standard conditions. The first medium change is left until 4 or 
5 days after isolation to allow the MSC to attach, and the non-adherent haematopoietic 
cells can be easily poured off and discarded. Since this method 
has been shown to be 
effective for isolating murine and human MSC, it was 
decided to attempt the same 
protocol using porcine bone marrow. 
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Once cells are isolated , it would 
first be necessary to try to identify the cells as being 
MSC prior to investigating their potential In tissue engineenng an aortic heart valve. 
Currently there are no definitive markers available specific for MSC of any origin. and 
so their identification has to be based on virtue of their differentiation capacity. 
However, this requires manipulation of the cell, which in turn changes the cells' 
properties. So in practical terms, the differentiation capacity has to be assessed using 
populations of MSC derived from a single cell. In identifying cells in this way, it would 
be important to try to differentiate the cells into a number of different cell lineages in 
order to rule out the possibility of multiple cell lineage precursors being present in the 
bone marrow and to demonstrate the multipotential differentiation capacity of the cells. 
I-%-- 
Once differentiation had been attempted, a range of markers would be used to identify 
the cells. The myogenic lineage would be identified using markers to a-smooth muscle 
actin (aSMA), desmin and heavy chain myosin slow (HCMs). Measuring alkaline 
phosphatase activity would identify the osteogenic lineage. The adipogenic lineage 
would be identified by looking for the accumulation of Oil Red 0 stain in the lipid 
vesicles. The chondrogenic lineage would be identified using markers to collagen 11, 
and the neurogenic lineage would be identified using markers to neurone speci ic 
enolase (NSE) and tau. 
When this work was started, it was noted that no successful attempts to perfon-n 
clonogenic analyses of the cells had been published in the literature and consequently It 
was decided to try to differentiate cells derived from a single 
bone marrow sample 
rather than a single cell, with the idea that clonogenic analyses could 
be perfonned at a 
later stage if evidence of a multipotent differentiation capacity could 
be found in these 
initial experiments. 
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3.2. Ahns &o1jectives 
The aims of this part of the study were to adapt methods developed for human and 
murine MSC to isolate and differentiate porcine mesenchymal stem cells into cells of 
the osteogenic, myogenic, chondrogenic, adipogenic, neurogenic and smooth muscle 
cell lineages. Success with at least three of these attempts would indicate the cells to be 
porcine mesenchymal stem cells and would enable investigation of their application in 
an animal model of a tissue engineered aortic heart valve. 
3.3. Materials& methods 
3.3.1. Isolation of MSC from porcine bone marrow 
Materials: Porcine shoulder bones were obtained from pigs recently slaughtered at a 
local abattoir. A Percoll gradient was prepared by centrifuging 22.05 ml Percoll, 
(Sigma-Aldrich), 2.45 ml 1.5 M NaCl, (Sigma-Aldrich) and 10.5 ml Tyrode's balanced 
salt solution, (Sigma-Alchich) at 20,000 g for 15 minutes. Centrifuge tubes (50 ml) were 
obtained from Fisher Scientific. 
Method: The bones were dissected and the bone marrow within each bone was scraped 
out into separate sterile centrifuge tubes containing 25 ml of complete medium, as 
described in Section 2.4.1. The tube was then inverted a number of times in order to 
disperse the bone marrow prior to being centrifuged at 600 g for 5 minutes. The 
supernatant and overlying fat layer were carefully removed leaving approximately 5 ml 
of medium to avoid aspirating the pellet. The pellet was then resuspended by repeated 
pipetting in the remaining 5 ml of medium, before the suspension was carefully layered 
onto a preformed Percoll gradient. The Percoll-marrow solution was centrifuged at 460 
g for 15 minutes before 14 ml of the upper fraction was removed and added to 25 ml of 
complete medium. The solution was then centrifuged at 
600 g for 5 minutes, the 
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supernatant removed, the pellet resuspended by repeat pipetting, and a ftirther 20 ml of 
complete medium added. The tube was then centrifuged at 600 g for a further 5 minutes. 
The supernatant was then removed and the cells resuspended in 5 ml of complete 
medium. The cell suspension was then transferred to a 25 CM2 tissue culture flask and 
the flask incubated under standard conditions as described in Section 2.4.1. Culture 
medium was first changed after five days and then every three to four days. If not 
immediately required, the cells were cultured this way until the first passage when they 
were cryopreserved as described in Section 2.4.5. Otherwise the cells were grown until 
required for a differentiation assay. Cells were counted as described in Section 2.4.2. 
3.3.2. Porcine mesenchymal stem cell differentiation assay I 
Materials: Osteogenic medium consisted of complete medium supplemented With 
2xlO-4 M ascorbic acid (Sigma-Alchich), 7x 10-3 M P-glycerophosphate (Sigma- 
Aldrich), and Ix 10-8 M dexamethasone, (Sigma-Aldrich). 
Chondrogenic medium consisted of complete mediurn supplemented with 2xIO-4 M 
ascorbic acid and I ng. ml-1 TGFOI (Product code T5050, Sigma-Aldrich). 
Adipogenic medium consisted of complete medium containing only I% (v/v) FCS, 
IX 10-7 M dexamethasone, and Ix 10-9 M insulin (Product code 15523, Sigrna-Aldrich). 
Plates (96-well) were obtained from Invitrogen. Multi-spot slides were obtained from C. 
A. Hendley Ltd. Square petri-dishes were obtained from Appleton and Woods. 
Methanol and acetone were purchased from VWR International. 
Cells ftom sample number pBNU were used as they were the first cells successfully 
isolated that did not succumb to contamination or other problems. Cells were used at 
passage 3 for the chondrogenic and adipogenic assays, and at passage 
5 for the 
osteogenic assay. 
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Method: At the third passage, 5x 105 cýells were transferred to each of four 75 CM2 flasks 
containing 10 ml of the three different differentiation media and a complete medium 
control, as established by Muraglia et aL (2000). The medium was changed every three 
to four days and the cells passaged when confluent. This continued until the cells no 
longeTdivided. At each passage the cells were resuspended in a total volume of 3 ml. 
Aliquots of Cells (I x 105 cells) were removed to 12 wells of a 96-well plate, and 2.5x 104 
cells were removed to 24 spots of multi-spot slides. Of the remaining cell suspension 
5x 105 cells were then passaged into a fresh 75 CM2 flask (Figure 3.1). The cells in the 96 
well plate, when confluent (usually 1-2 days), were assayed for alkaline phosphatase 
(AP) to establish the activity of this enzyme which is only thought to be expressed by 
cells of the osteogenic lineage. Multi-spot slides were cultured for a minimum of three 
hours to ensure that the cells had attached and were not washed off the slides prior to 
the slides being flooded with the appropriate culture medium. The cells were then 
grown until confluent (usually 2 or 3 days) and fixed in a 50: 50 methanol/acetone 
solution for 2 minutes prior to storage at -20'C until they could be analysed for 
phenotypic markers. 
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Figure 3.1. Diagram showing how the cells were divided at each passage. 
3.3.3. Porcine mesenchymal stem cell differentiation assay 2 
Materials: Osteogenic differentiation medium consisted of complete medium 
supplemented with 50 pM ascorbate-2-phosphate (Sigma-Aldrich), 10 mM 0- 
glycerophosphate (Sigma-Aldrich), and 0.1 pM dexamethasone, (Sigma-Aldrich). 
Myogenic differentiation medium consisted of complete medium supplemented with 
5% (v/v) horse ser-w-n (Invitrogen), 0.1 gM dexamethasone and 50 ptM hydrocortisone 
(Sigma-Aldrich). 
Smooth muscle cell differentiation medium consisted of serum-free DMEM 
supplemented with 100 ng. mI_1 platelet-derived growth factor (PDGF) [P8953, Sigma- 
Aldrich]. Plates (96-well) were obtained from Invitrogen. Multi-spot slides were 
obtained from C. A. Hendley Ltd. Square petri dishes were obtained from Appleton and 
Woods. Methanol and acetone were purchased from VWR International. 
Cells from sample number hBM2 were used at passage 5 as they were the first cells 
successfully isolated that did not succumb to contamination or other problems. 
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Method: Four 75 CM2 tissue culture flasks were seeded with 5x 105 cells (passage 3) 
each and the cells fed with the three different differentiation media and complete 
medium control conditions,, as established by Reyes & Verfaillie (1999) and Zuk et aL 
(2001). The medium was changed every three to four days and the cells passaged when 
confluent, approximately every 2 weeks. At each passage the cells were resuspended in 
a total volume of 3 ml. Aliquots of cells (I x 10 5 cells) were removed to 12 wells of a 96- 
well plate, and 2.5 x 104 cells were removed to 24 spots of multi-spot slides. Of the 
remaining cell suspension, 5x 105 cells were then passaged into a fresh 75 CM2 flask 
(Figure 4.1). The cells in the 96-well plate,, when confluent (usually 1-2 days), were 
used to detennine alkaline phosphatase (AP) activity. Multi-spot slides were flooded 
with the appropriate culture medium a minimum of 3 hours after cells were aliquoted to 
ensure that the cells had attached and were not washed off the slides. The cells were 
then grown to confluence (usually 2 or 3 days) and fixed in a 50: 50 methanol/acetone 
solution for 2 minutes prior to storage at -20'C until they could be analysed for 
phenotypic markers. 
3.3.4. Porcine mesenchymal stem cell differentiation assay 3 
Materials: Adipogenic medium consisted of 50 ml of adipogenic differentiation 
supplement (Stem Cell Technologies) added to 450 ml of human Mesencult medium 
(Stem Cell Technologies). 
Myogenic medium consisted of complete medium supplemented with 10 pM 5- 
azacytidine (Sigrna-Aldrich). 
Neurogenic induction medium consisted of complete medium containing 20 % FCS 
(Invitrogen) supplemented with I mM P-mercaptoethanol (Sigma-Aldrich). 
Neurogenic 
differentiation mediw-n consisted of serum-free DNIEM supplemented with 
10 mM P- 
mercaptoethanol (Sigina-Aldrich). 
Tyrode's balanced salt solution (TBSS) was 
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purchased from Sigina-Aldrich. Cells were grown on multi-chamber slides purchased 
from Bibby Sterilin. Methanol/acetone solution was made from 50: 50 methanol: acetone 
which were both purchased from VWR International. Polypropylene centrifuge tubes 
(15 ml) were purchased from Fisher Scientific. 
Cells isolated from sample number pBM9A were used at passage 3 for this 
differentiation attempt and were chosen randomly from the available cryopreserved cell 
stock. 
Method: For the adipogenic, myogenic and neurogenic differentiation assays, 5x 104 
cells (passage 3) were cultured in each well of four multi-chamber slides in complete 
medium for 24 hr to enable the cells to become fully attached. 
For adipogenic differentiation, complete medium was then removed and replaced with 
adipogenic medium. Cells were then fed adipogenic differentiation mediurn twice 
weekly for up to four weeks with two slides fixed at 2 weeks, and two slides fixed at 4 
weeks in formalin solution for 30 minutes. Slides were then stored at -20'C. Upid 
vesicles were Visualised by staining the cells with Oil Red 0. 
The myogenic differentiation assay was derived from Wakitani et aL (1995). Briefly, 
complete medium was replaced with myogenic medium for 24 hr before this was 
replaced with complete medium again. Cells were then fed complete medium twice 
weekly for up to four weeks with two slides fixed at 2 weeks, and two slides fixed at 4 
weeks in methanol/acetone for 2 minutes. Slides were then stored at -200C prior to 
Phenotypic evaluation using immunofluorescence. Immunofluorescent staining as 
described in Section 2.6.4 using antibodies to a-smooth muscle actin, myosin heavy 
chain-slow and desmin was used to show if differentiation had taken place. 
The neurogenic differentiation assay was derived from Woodbury et aL 
(2000). Briefly, 
complete medium was first replaced with neurogenic 
induction medium for 24 hr. The 
cells were then briefly rinsed in TBSS, before this was replaced with neurogenic 
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differentiation medium. Slides were then fixed for 2 minutes in methanol/acetone at 2, 
4,6 and 8 hours after differentiation medium was introduced before being stored at -20 
T prior to phenotypic evaluation. Immunofluorescent staining using antibodies to tau 
and NSE was used to show if differentiation had taken place. 
3.3.5. Alkaline phosphatase assay 
Materials: Tyrode's balanced salt solution, ready to use alkaline phosphate colour 
substrate, p-nitrophenyl phosphate, and sodium hydroXide were obtained from Sigma- 
Aldrich. 
Method: Culture medium was removed from cells grown to confluence in wells of a 
flat-bottomed 96-well plate and the cells rinsed in Tyrode's balanced salt solution. p- 
nitrophenyl phosphate (200 gl) was added to each well and the plate incubated at 37 T 
for 20 minutes. NaOH (50 gl, 3 M) was then added to each well to stop the reaction. 
The supernatant (200 gl) was then removed to wells of a second flat-bottomed 96-well 
plate and the absorbance read in a microtitre plate reader at 405 nm. 
3.3.6. Oil red 0 staining 
Materials: Isopropanol was obtained ftom VWR International. Oil Red 0 Stock 
solution consisted of 300 mg Oil Red 0 (Sigma-Aldrich) added to 99 % (v/v) 
isopropanol. This was stable for up to 6 months. Working solution was made by mixing 
3 parts oil red 0 stock solution with 2 parts distilled water and 
filtered using a number 5 
filter purchased from Whatman International. This was stable 
for I hour. 
Methods: Cells cultured for Oil Red 0 staining were fixed in formalin solution 
for 
30min. Formalin solution was then removed and the slides rinsed with distilled water. 
Sufficient isopropanol (60 % v/v) was then added to cover each slide and 
let stand for 3 
minutes. This was then replaced with oil red 
0 working solution for 10 minutes. This 
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was then carefully removed and the slides rinsed again with distilled water. Sufficient 
haernatoxylin was then added to cover each slide and let stand for I minute. This was 
then poured off and the slides carefully rinsed 5 times using distilled water. Cells were 
then viewed wet under phase contrast microscopy. 
3.4. Results 
3.4.1. Cultured porcine mesenchymal stem cells 
A growth curve was plotted using the first successfully isolated putative pMSC (pBM2,. 
Figure 3.2) and the cell doubling time (CDT) was calculated as described in Section 
2.4.3. Typically, IX106 porcine mesenchymal stem cells formed a confluent monolayer 
in a 25 CM2 tissue culture flask, and 3x 106 cells in a 75 CM2 tissue culture flask., which 
was when the cells were passaged. The CDT was calculated to be approxiMately 106 
hours initially, although by the sixth passage, this had risen to approximately 136 hours. 
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Figure 3.2. Growth curve of porcine mesenchymal stem cells. Each point on the 
line represents a cell passage. The original cell number could not be calculated due to 
difficulties in seeing the cells through other bone marrow debris. 
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The apparent reduction in proliferation rate was matched by a change in cell 
morphology. Images of cells freshly isolated ftom the porcine bone marrow of a 
recently slaughtered pig are shown in Figure 3.3. The cells were seen to be fibroblastic 
in appearance. Observation of cell morphology at different passages showed that the 
cells could generally be categorised into three age-related morphologies based on their 
appearance: 
1. Cells one week after isolation (passage 0) are shown in Figure 3.3a. Cells 
were relatively small, becoming confluent in approXimately 2 weeks. 
2. Cells at an intennediate stage (passage 4) after which their rate of 
proliferation had decreased slightly and the cells were beginning to take 
on a more flattened and spread morphology are shown in Figure 3.3b. 
3. Quiescent cells (passage 6) are shown in Figure 3.3c. At this stage, cells 
were largely quiescent and divided very slowly., if at all. Cells became 
highly flattened and spread with prominent filaments visible in the cell 
cytoplasm, and typically took over 4 weeks to become confluent. 
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Figure 3.3. Porcine mesenchymal stem cells at different ages. A- Proliferating 
primary morphology (PO); 13- Secondary intermediate morphology (N); and C- 
Quiescent tertiary morphology (P6). 
During the course of the investigation, a number of cell isolations were made and are 
listed in Table 3.1. There was a long period between February and November 2001 
when cells could not be isolated due to a national outbreak of Foot & Mouth disease 
restricting access to the abattoir. The yield of cells was observed to vary from bone to 
bone, however it was impossible to accurately count the number of cells initially 
isolated because of the large amount of debris still present after the isolation procedure. 
Although seemingly healthy cells were isolated in the first few attempts, during 
February and November 2001, later attempts between January and December 2002 
resulted in cells that rapidly ceased proliferation and broke away from the culture flask. 
Cryopreserved samples were retained as a cell bank for future studies and analysis. 
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SAMPLE DATE PASSAGES NOTES 
-- 
T", 
pt5M2 
I 
12/02/01 PI 07/03/01 Used in differentiation assay 1, 
P2 14/03/01 chondrogenic and adipogenic at P3, 
P3 21/03/01 osteogenic and control at P5. Used in 
P4 30/03/01 differentiation assay 2 at P5. Samples 
P5 10/04/01 cryopreserved at each passage. 
P6 19/04/01 
pBM5 21/02/01 PI 12/03/01 
_qnýopreserved 
12/03/01 
_pBM6_ 
21/02/01 PI 12/03/01 Cryopreserved 12/03/01 
_pBM7 
21/02/01 P1 14/03/01 Cryopreserved 14/03/01 
-nTIMR 1) 1 /1Y) MI /n I 
-Mi 
pBM9A 15111101 PI 04/12/01 Cryopreserved 10/12/01. Thawed 
P2 10/12/01 08/01/03, used in differentiation assay 
3 at P3. 
pBM9C 15111101 P 126/11 /01 Cryopreserved 20/12/01 
P2 04/12/01 
P3 20/12/01 
pBM9D 15111101 PI 10/12/01 Cryopreserved 0 1/02/02 
pBMIOA 06/12/01 PI 20/12/01 Cryopreserved 20/12/01 
pBM OB 
pBMII 11/01/02 Discarded 21/01/02, too few cells 
12 22/01/02 Discarded 0 1/03/02, cells died 
pBM13 _ 27/02/02 Discarded 18/03/02, too few cells 
pBM14 04/03/02 Discarded 12/04/02, cells di_ed____ 
pBM15 04/03/02 cells 
pBM16 11/03/02 ------ 
iscarded 09/04/02, cells died ý 
PM17 p 20/03/02 Discarded 12/04/02, cells died 
pBM18 09/04/02 Discarded 26/04/02, cells died___ 
"B ýýI 9 17/04/02 Discarded 29/04/02,, cells 
died 
_ P13M20 23/04/02 Discarded 13/05/02. ) cells 
died 
pBM21 02/05/02 Discarded 13/05/02, no cells 
- pBM22 21/05/02 Discarded 10/06/02, cells died 
- pBM23 28/05/02 Discarded 01/07/02, too few cells 
pBM24A 24/06/02 Discarded 24/07/02, cells died 
pBM24B 
pB 4C 
pBM24D - 24/06/02 PI 12/07/02 Discarded, 12/08/02, cells 
died- 
pBM25 04/07/02 Discarded 24/07/02, cells 
di-ed 
pBM26 09/07/02 Discarded 26/07/02,. cells 
died 
- pBM27 16/07/02 Discarded 
09/09/02, cells died 
- pBM28 01/08/02 Discarded 
09/09/02, cells 
_died - d ll d pBM29 08/08/02 _ 
ie s Discarded 09/09/0_2, ce 
pBM32 - 03/10/0 Discarded 
10/12/02, cells 
- 
died 
ll d d /03 6 
pBM33A ie s , ce 
1 18/10/02 Discarded 06/ 
p4M3 3ýý 18/10/02 
---- -P1 08/11/02 Discarded 06/01/03, cells died 
--- _ M33D pB Lýded 
06(0ý/03, cells died /0 18/10/02 P-I- 01/11 
ý ý4 ý3 22/10/02 Discarded 0 1/ 11/02 , no - 
cells 
_p ý 5 -- -- -- 11 tf cells died 29/10/02 Discarded 06/01/03 -, -- -t 7 
IDBM36A iscarded 
06/01/03, cells died F2 Ii 
L_04/11/02 
PI 19/1 
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pBM3ý6-B------- -0-4-411/02 -13/11-/02 --Dis-- carded 06/01/03, cells died 
pl3M36C 04/11/02 
pBM36D 
__ppMý6E - pBM36F 04/11/02 
pBM37A 03/12/02 
_pBM37B 
_ 
-j--q3/12/02 pBM37C 03/12/02 
pBM37F 
pBM37D 03/12/02 
_TAM37E p. DM38A 24/02/03 
P2 22/11/02 
Discarded 06/01/03, cells died 
P1 13/11/02 
P2 25/11/02 
P1 13/12/02 
IP1 13/12/02 
PI 10/03/03 
P2 18/03/03 
Discarded 06/01/03, cells died 
Discarded 06/01/03, cells dled 
Discarqed 06/01/03, cells died 
Cryopreserved 13/12/02 
Discarded 20/12/02,, too few cells 
Cryopreserved 18/03/03 
iBM38B , 24/02/03 1 PI 14/03/03 ý Cryopreserved 14/03/03 Table 3.1. Putative porcine mesenchymal stem cell isolations. Each isolation 
attempt tried to isolate putative pMSC from four porcine shoulder bones. Unless 
otherwise stated, one sample number corresponds to all four bones. A number 
followed by a letter indicates individual bones. 
When the success in isolating pMSC began to deteriorate, a number of factors in the 
procedure were investigated to try to establish why this was happening, This involved 
systematically checking individual components of both the solutions used to isolate the 
cells and also those used in the complete medium used to culture the cells. This was 
carried out by sequentially replacing each reagent with freshly bought reagents and 
attempting to isolate cells to assess whether there was an improvement. Despite this 
process revealing potential sources of problems, such as ageing reagents, no changes 
were observed in the success of isolating the cells. Consequently, the source of the 
reagents used was investigated. This revealed the problem to be a change of supplier of 
DMEM. Samples from pBM1 to pBM12 and pBM38 were Isolated and cultured using 
DNEM supplied by Invitrogen, whereas samples from pBM13 to pBM36 were isolated 
and cultured in DNIEM supplied by Sigma-Aldrich. Sample pBM37 was isolated and 
cultured in Mesencult, supplied by Stem Cell Technologies, with supplements 
designed 
specifically for hMSC. Invitrogen and Sigma-Aldrich 
DMEM were both reported to be 
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identical, however, a comparison of their specific ingredients revealed numerous small 
differences in components and concentrations which ultimately seemed to affect the 
isolation and growth of the cells. Human Mesencult medium was used to grow the cells 
to see what happened before it was realised that the DMEM itself was the problem. This 
also seemed to support the cells adequately, despite being aimed specifically at human 
MSC. However, this was a very expensive mediurn,, which was why attempts at using 
Invitrogen DNIEM were resumed once the source of DMEM was suspected as being the 
source of the problem. 
3.4.2. Porcine mesenchymal stem cell differentiation 
3.4.2.1. Differentiation assay 1 
Once putative MSC had been successfully isolated, it was decided to try to differentiate 
the cells into multiple phenotypes in order to show their multipotentiality. A review of 
the literature provided the conditions thought necessary to try to differentiate the pMSC 
initially into cells of the osteogenic, chondrogenic and adipogenic lineages. The 
differentiated cells were then identified by measUnng alkaline phosphatase activity for 
the osteogenic lineage, immunohistochemical staining for collagen 11 for the 
chondrogenic lineage, and oil red 0 staining for the adipogenic lineage. The results of 
the alkaline phosphatase, (AP) of the cells grown in each of the differentiation media are 
shown in Figure 3.4. A human osteosarcoma. cell line was used as a positive control for 
AP activity and human smooth muscle cells as a negative control. The AP activity of 
cells grown in the osteogenic medium increased initially, and then decreased again at 
each subsequent passage. The cells grew very slowly at this point, and it was not 
possible to transfer ftirther aliquots from the flask to the multi-spot slides as the cells 
became senescent and failed to attach to the slide surface after trypsinisation from the 
tissue culture flask. More intriguingly was the huge amount of AP activity demonstrated 
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by the cells grown in the chondrogenic medium. These cells had a low activitv initialIN', 
but cells from the third passage had an extremely high activity, producing an absorbance 
over four times greater than the osteosarcoma cells used as a positive control for the 
assay. This had dropped by the fifth passage in the differentiation medium, but was still 
significantly higher than the positive control. Meanwhile, the cells grown in adipogenic 
medium had a level of AP activity comparable to the negative control smooth muscle 
cells. 
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Figure 3.4. Alkaline phosphatase supernatant absorbance of pMSC from 
differentiation assay 1. HOS= human osteosarcoma cell line; SMC= human smooth 
muscle cell; CO= control undifferentiated pMSC; OS= pMSC grown in osteogenic 
differentiation medium; CH= pMSC grown in chondrogenic differentiation medium; AD= 
pMSC grown in adipogenic differentiation medium. Two bars for each sample represent 
repeat samples. P number refers to the passage number of the cells. Number in 
brackets represents the number of passages since differentiation medium was 
introduced. Results are expressed as mean (n=6) ±95 % confidence limits. 
Attempts to differentiate the putative MSC into cells of the adipogenic and 
chondrogenic lineage both failed. The cells in adipogenic medium 
failed to produce 
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fatty vesicles that could be stained and visualised with Oil Red 0. The cells in 
chondrogenic medium failed to produce collagen 11, which is the principle marker for 
chondrogenic differentiation. Bovine cartilage was used as a positive control for the 
collagen 11 antibody (Figure 3.5). 
Cells Cartilage 
Oro'. "' 
negative control; B: positive control. Bar represents 100 pm. 
3.4.2.2. Differentiation assay 2 
The resulting failure of the first differentiation assay resulted in the development of new 
methods from the literature to try to differentiate pMSC into cells of the osteogenic, 
myogenic, and smooth muscle cell lineages. Alkaline phosphatase activity was 
measured as a mark of osteogenic differentiation, decreased immunohistochemical 
staining for a-smooth muscle actin (aSMA), increased heavy chain myosin slow 
(HCMs) staining and increased desmin staining was measured as a marker for myogenic 
differentiation and aSNIA, HCMs, desmin and vimentin was measured as a marker for 
the smooth muscle cell lineage. The results of the alkaline phosphatase (AP) activity of 
the cells grown in each of the differentiation media is shown in Figure 3.6. A human 
osteosarcoma cell line was used as a positive control for AP activity and 
human smooth 
muscle cells as a negative control. The AP activity of cells grown m the osteogenic 
medium increased initially, and then decreased again at subsequent passage. 
The cells 
grew very slowly at this point, and it was not possible to transfer 
further aliquots from 
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the flask to the multi-spot slides as the cells became senescent and failed to attach to the 
slide surface after trypsinisation from the tissue culture flask. More intriguingly was the 
huge amount of AP activity demonstrated by the cells grown in the myogenic medium. 
The activity of the AP seemed to fluctuate between the sampies at each passage, and 
then 7 passages after the differentiation medium was added,, one flask of cells showed 
an AP activity equivalent to the negative control, whilst the other flask showed an 
increasing activity up to 5 times greater to that of the cells grown in osteogenic 
differentiation media. 
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Figure 3.6. Alkaline phosphatase supernatant absorbance of plVISC from 
differentiation assay 1. HOS= human osteosarcoma cell line; SMC= human smooth 
muscle cell; CO= control undifferentiated pMSC, OS= pMSC grown in osteogenic 
differentiation medium; MY= pMSC grown in myogenic differentiation medium. Two 
bars for each sample represent repeat samples. The P number refers to the passage 
number of the cells. The number in brackets represents the number of passages since 
differentiation medium was introduced. Results are expressed as mean (n=6) ± 95% 
confidence limits. 
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Attempts to differentiate pMSC into other lineages were unsuccessful. Cells grown in 
myogenic medium failed to label with antibodies to ct-smooth muscle actin, slow heavy- 
chain myosin and desmin. However, they did show one change from freshly isolated 
cells, which were a-smooth muscle actin positive (Figure 3.7). Porcine heart muscle was 
used as a positive control for the myogenic antibodies. Cells grown in smooth muscle 
cell medium changed morphology within a few days of the change in differentiation 
medium, however as there was no serum or equivalent substitute included in the growth 
medium,, the cells became quiescent and died before any further phenotyping or analysis 
could be carried out. 
Positively 
stained cells 
differentiation mediurn. A: control human smooth muscle cells (hSMC); B- control 
pMSC; C: pMSC grown in myogenic differentiation medium 
3.4.2.3. Differentiation assay 3 
The lack of success of the first two differentiation assays lead to the 
development of 
further methods to try to differentiate the putative pMSC into cells of the adipogenic, 
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myogenic and neurogenic lineages. Oil Red 0 stain was used to identify cells of the 
adipogenic lineage, decreased immunohistochemical staining for (x-smooth muscle actin 
(aSMA), increased heavy chain myosin slow (HCMs) and increased desmin indicated 
myogenic differentiation and immunohistochernical staining for tau and neurone 
specific enolase (NSE) was used to identify cells of the neurogenic lineage. Porcine 
heart muscle and porcine optic nerve were used as positive controls for myogenic and 
neurogenic differentiation attempts respectively. Attempts to differentiate pMSC into 
cells of the myogenic lineage were unsuccessful, as the cells were negative when 
stained with antibodies to a-smooth muscle actin, slow heavy-chain myosin, and desmin 
although again this did represent one change in that freshly isolated pMSC stained 
positive for a-smooth muscle actin. Attempts to differentiate pMSC into cells of the 
neurogenic lineage were also unsuccessful as the cells were negative when stained with 
fluorescent antibodies to tau and neurone- spec i fic enolase. However, the results of the 
experiment to differentiate the cells into cells of the adipogenic lineage can be seen in 
Figure 4.8 below. Oil Red 0 is a lipid soluble dye; therefore the areas stained pink mark 
lipid deposits made by the cells. The lipid could only be seen using the oil red 0 stain 
and seemed diffuse across the cells,, especially when compared with the adipogenic 
differentiation assay carried out on hMSC (see Figure 3.2). It was observed that only 
approximately 20 % of cells differentiated successfully. 
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Figure 3.8. Differentiation of porcine mesenchymal stem cells into adipogenic 
A 
lineage. Oil red 0 staining of lipid vesicles. A: x10 magnification; 13: x40 magnification. 
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3.5. Discussion 
Since there was no literature available on pMSC at the start of this study, methods used 
for human cells were adopted. The isolation method developed for isolating pMSC 
yielded cells with a fibroblastic appearance. Some isolation methods examined had 
passed the bone marrow material through sequentially narrower hypodermic needles to 
break apart cell clumps prior to centrifugation [Friedenstein et aL, 1987]. However, this 
was not included in the final developed method as it proved difficult to pass porcine 
bone marrow through even the highest calibre needles. This was probably due to the 
fact that porcine bone marrow was observed to contain a lot of fat, which was very solid 
in texture. 
Attempts at isolating putative pMSC met with mixed success over the course of the 
investigation. Although initially successful, cell yields became reduced and cells 
frequently died during the initial incubation period before a confluent monolayer could 
be obtained. After much thought, discussion and investigation, it was deduced that the 
unexpected change was due to a change in supplier of DNIEM. The supplier had been 
changed from Invitrogen to Signia-Aldrich during the course of isolating the cells 
during February 2002, essentially because of a change in the prices from the supplier. 
Although the suppliers each sold the DNEM as the same product, analysis of the exact 
contents of the media revealed numerous differences in concentrations of constituent 
components. A return to Invitrogen DMEM during December 2002 resulted in 
improved cell yields that survived to the point of cryopreservation. 
The cells isolated appeared to become senescent with prolonged culturing, in a manner 
similar to terminally differentiated cells. The cell doubling time also slowed 
from 106 
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hours initially to 136 hours with older cells. This was in contrast to the notion that stem 
cells are immortal and compared well With reports by others which have shown that 
human MSC do not possess telomerase activity [Banfi et aL, 2002], which is thought to 
be an important enzyme involved in maintaining telomere length and consequently cell 
immortality. However, it may well be that the in vitro conditions used to grow the cells 
could not sustain the immortal capacity of the cells and instead exerted a selective 
environment that preferentially encouraged the cells to become terminally 
differentiated. 
A number of attempts to differentiate the cells were made using biochemical 
supplements to complete medium and serum-ftee medium. The methods for the first 
differentiation assay were derived from Muraglia et aL (2000). Reyes & Verfaillie 
(1999) and Zuk et aL (200 1) provided the conditions for the second differentiation assay 
and Stem Cell Technologies, Wakitani et aL (1995), Woodbury et aL (2000), and Jones 
et aL (2002) provided the conditions for the third differentiation assay. In differentiation 
assay 1, osteogenic differentiation medium consisted of complete medium 
supplemented with 200 pM ascorbic acid, 7 mM P-glycerophosphate and 10 nM 
dexamethasone. Ascorbic acid is a free radical scavenger and can also act as a reducing 
agent. Furthermore, it functions as a co-factor in the hydroxylation of lysine and proline 
residues in collagen and is essential for its normal synthesis and secretion [Beresford & 
Owen, 1998]. Therefore its role in matrix production and consequently cell 
differentiation is clear. P-glycerophosphate is an organic phosphate donor which, in the 
presence of ascorbate, can enhance the formation of minerallsed matrix in vitro, 
consequently it Is role in osteogenic clifferentiation is clear [Beresford & 
Owen, 1998]. 
Dexamethasone is a glucocorticoid steroid with numerous effects, including its role as a 
broad-spectnnn transcription inducer. So here its role could be to switch on genes that 
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were previously inactive in order to induce differentiation of the cells. Although the 
effects on specific osteogenic-related genes are unknown, used in combination with a 
phosphate donor such as P-glycerophosphate, it is possible that osteogenic 
differentiation could be induced. The osteogenic differentiation medium in the second 
differentiation assay contained essentially the same components, but at different 
concentrations. Here, ascorbic acid was replaced by 50 W ascorbate-2-phosphate, 
which is a more stable form of ascorbic acid, P-glycerophosphate was increased in 
concentration from 7 to 10 mM, and dexamethasone, was increased in concentration 
from 10 to 100 nM. This variation in concentrations producing apparently the same 
effects clearly demonstrates the unknown nature of what is really required to 
biochemically induce cell differentiation. 
In differentiation assay 1, chondrogenic differentiation medium consisted of complete 
medium supplemented with 200 pM ascorbic acid, along With 10 ng. mYI transforming 
growth factor beta- 1 (TGFO 1). There are three forms of mammalian TGFP and they can 
be found in a variety of developing and regenerating tissues and in pathological 
responses. They have a variety of ftuictions including attracting inflammatory cells to a 
wound site., stimulating the release of cytokines and also regulating the extracellular 
matrix by stimulating fibroplasia and collagen deposition whilst inhibiting proteases 
[O'Kane & Ferguson, 1997]. It is likely that its function in promoting collagen 
production is its role in inducing chondrogenic differentiation here. The main problem 
here is that it is widely known that if chondrocytes are cultured in the 2-dimensional 
, enviromnent of a tissue culture 
flask, they rapidly de-differentiate and stop producing a 
collagen 11 extracellular matrix. Therefore, trying to induce the differentiation of 
MSC 
into chondrocytes in a tissue culture flask has this problem to overcome as well. 
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The adipogenic differentiation medium used in the first differentiation assay consisted 
of complete medium with the serum content reduced to I% (v/v) FCS and then 
supplemented with 100 pM dexamethasone and I nM insulin. As previously discussed, 
dexamethasone is a glucocorticoid steroid which can act as a wide-ranging transcription 
inducer. Insulin plays a major part in the uptake of glucose by cells and stimulates 
glycogen synthesis. This in turn increases the synthesis of fatty acids and therefore 
lipids. Consequently, the combination of a transcription inducer With a molecule which 
controls lipid synthesis is likely to promote adipogenic differentiation. Also, the 
reduction in serum content from the standard 10 % to I% (v/v) in this differentiation 
medium could have mimicked starvation conditions for the cells, thereby encouraging 
them to store fat. The Stem Cell Technologies adipogenic differentiation supplement to 
Mesencult used in differentiation assay 3 did not state its constituent components, 
however, it is likely to contain similar biochemicals to those already described, although 
perhaps at different concentrations since the second adipogenic differentiation attempt 
was successful. 
The myogenic. differentiation medium used in differentiation assay 2 consisted of 
complete medium supplemented with 5% (v/v) horse serum, 100 nM dexamethasone 
and 50 gM hydrocortisone. The horse senun was likely to be expected to contain 
unknown factors thought to have an effect on myogenic differentiation, much the same 
as FCS contains unknown factors that readily support cell growth in vitro. As previously 
discussed, dexamethasone is a glucocorticoid steroid, and hydrocortisone is another 
member of the same family. Consequently, their role would 
be to induce gene 
transcription with each steroid presumably affecting different genes. However why they 
would induce differentiation into the myogenic 
lineage over any other lineage remains 
unclear, perhaps it is factors in the 
horse serum that are expected to drive the 
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differentiation in this direction. The myogenic differentiation medium used in the third 
differentiation assay took a different approach and consisted of complete medium 
supplemented with 10 pM 5-azacytidine. The cells were exposed to this differentiation 
medium for 24 hours before it was replaced with complete medium and the cells 
cultured under standard conditions for up to 4 weeks. 5-azacytidine is an analogue of 
cytosine and is consequently incorporated into DNA during the cell division cycle. 
However,, unlike cytosine, it cannot be methylated. Methylation of cytosine is a 
common occurrence that changes how the DNA is read by protein synthesising 
nbosomes. Therefore, when 5-azacytidine is incorporated into new DNA.,, its 
transcription is altered, leading to changes in gene activation and therefore 
differentiation of the cells, although why this would induce differentiation into the 
myogenic lineage over any other lineage remains unclear. 
The smooth muscle cell differentiation medium consisted of serum-free medium 
supplemented with 100 ng. ml-1 platelet-derived growth factor (PDGF). PDGF is a factor 
released by platelets upon clotting. It is a ubiquitous mitogen which has the function of 
stimulating the proliferation, differentiation and migration of predominantly connective 
tissue cells [Qiu & Ferguson, 1995]. Therefore its role in differentiating MSC into 
smooth muscle cells is clear. However, without FCS in the culture medium, the medium 
was not capable of fully supporting cell growth and the cells quickly became senescent 
and died before any analysis could be carried out. 
The neurogenic differentiation medium used in differentiation assay three consisted of 
complete medium containing 20 % (v/v) FCS supplemented with I mM 
0- 
mercaptoethanol in the induction medium and 10 mM P-mercaptoethanol 
in serum free 
medium for the differentiation medium. P-mercaptoethanol is a reducing agent and 
free 
100 
CHAPm 3 
radical scavenger that is used in the culture of some cell types to protect the cells. It Is 
possible that its function here was to change the properties of cell surface proteins, 
thereby changing receptor sites and changing the binding of proteins, which could 
ultimately affect gene activation and therefore induce the cells' differentiation. 
Although why this would result in differentiation into the neurogenic lineage over any 
other lineage remains unclear. 
Despite the method derived for isolating porcine MSC yielding fibroblastic cells 
morphologically similar to human MSC, attempts to differentiate them only produced 
adipogenic cells intentionally, with mixed results for the osteogenic assay and negative 
results for all the other assays. Since the methods for differentiating the cells were 
derived from papers in which the work was carried out on human MSC,, the 
combination of the lack of success of the different differentiation assays, combined with 
the aberrant results of the osteogenic assays, suggested that porcine MSC did not 
respond in the same manner as human MSC when exposed to the same biochemical 
stimuli, or perhaps were not MSC to begin with. Thus it may be the case that pMSC 
require different combinations or concentrations of biochemical supplements in order to 
differentiate the cells into different lineages. However, the success of differentiating 
pMSC into adipogenic cells using a supplement designed for use on hMSC suggests that 
there are some similarities in cell signalling susceptibility. 
Ringe et aL (2002) have since shown that it is possible to differentiate pMSC into cells 
of the osteogenic, adipogenic and chondrogenic lineages using methods commonly 
available for differentiating hMSC. It is difficult to say why they succeeded when this 
work failed. It is possible that the reagents they used to differentiate their cells were 
slightly different to the ones used here, being fTom different sources. However, it is 
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difficult to compare the work since the paper in which the work was published [Ringe et 
aL, 2002] did not give clear methods for differentiating the cells, but merely referenced 
to other papers for each differentiation assay attempted. 
Mechanical stimulation has been shown to be capable of differentiating hMSC into a 
ligament cell lineage [Altman et aL, 2002], and is also known to affect other cell 
lineages such as fibroblasts and aortic endothelial cells [Streppeti et aL, 1993; Banes et 
aL. 1995; Sato et aL, 1996; Butt & Bishop (1997); Eastwood et aL, 1998; Hishikawa & 
Liischer,, 1997; Sirois et al., 1998; Breen, 2000; Grinell, 2000]. Consequently, future 
experiments could try to differentiate pMSC into aortic valve interstitial cells by seeding 
undifferentiated cells onto a matrix and then exposing the construct to the mechanical 
conditions found in the heart by culturing the construct in a pulsatile-flow bioreactor 
without the need for biochemical stimuli. Other future experiments could further 
investigate the growth conditions of the cells in vitro. Some researchers have suggested 
that certain lots of foetal calf serum are more effective at supporting MSC [Lennon et 
aL, 1996]. Also, an investigation to create a more defined medium to culture the cells in 
could be carried out by replacing the serum component with other biochemicals such as 
ascorbate and insulin transferring sodium selenite, or adding specific growth factors to 
assess their effects on the cells. Also, the cells could be grown in a pellet culture as 
described later in Section 4.3.2 to try to aid their differentiation into the chondrogenic 
lineage and also to see what effect this system might have on the properties of the cells. 
in conclusion, putative porcine MSC were isolated using methods adapted 
from 
techniques to isolate human and murine MSC. However, whilst the cells were 
morphologically similar to human MSC isolated by others, attempts to 
differentiate the 
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cells were only partially successful. As such, it was not possible to conclusively state 
that the cells isolated were in fact porcine MSC. 
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Introduction 
In tandem With isolating and identifying porcine MSC as a potential cell source for 
inclusion in an animal model for tissue engineering an aortic heart valve, it was also 
important to investigate e potential of hui-nan MSC as this would ultimately be the cell 
source used in the clinical setting. If successful, the isolation, identification and 
reseeding of a decellularised matrix with hMSC and culturing the construct in a 
pulsatile-flow bioreactor would show the in vitro potential for using hMSC in a tissue 
engineering application. 
Although much of the initial work on MSC was carried out on mUnne MSC, 
investigations of hMSC are now far more prevalent and have already led to clinical 
trials using hMSC for stem cell therapy purposes [Wakitani et aL, 1994; Grande et aL. 
1995; Saito et aL, 1995; Kadiyala et aL, 1997; Yoo et aL, 1998; Young et aL, 1998; 
Wang et al., 2000; Tomita et al., 2002]. In these investigations, hMSC have been 
isolated and expanded in culture and then reintroduced back into the patient directly 
into an injury site. Local environmental cues were then thought to have differentiated 
the cells into the appropriate lineages required to repair and regenerate the damaged 
tissues. 
Despite the positive findings of these experiments, identification of the isolated hMSC 
has frequently been based on the assumption that the cells must be MSC since no other 
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cells in the bone marrow are thought to be adherent. Many attempts have been made to 
produce a monoclonal antibody specific for hMSC to facilitate rapid identification of 
these cells, [Simmons & Torok-Storb, 1991; Barry et aL, 1999; Caplan & Haynesworth, 
2000], however almost as soon as they were produced, the monoclonal antibodies were 
found to cross-react with other non-MSC lineages. Many groups have used panels of 
antibodies to identify and phenotype isolated hMSC [Galmiche et aL, 1993; Conget et 
aL , 
1999; Fontes & Thomson,, 1999; Pittenger et aL, 1999; Zvaifler et aL, 2000; Jones et 
aL. 2002; Lodie et al, 2002], however, there is currently no agreed set panel that every 
group uses and each seems to have their own ideas regarding which markers are 
necessary to accurately identify hMSC. A group working at St James Hospital, Leeds, 
have used a panel of antibodies to identify hMSC isolated from bone marrow and 
synovial lining (CD13, CD45, D7FIB, CD105, CDIO, LNGFR, CD55, BMP, AP) 
[Jones et aL, 2002]. 
Since there is no agreed panel of antibodies in general use to spec, fically distinguish 
hMSC from other cells, a more thorough identification of the cells had to be based on 
the differentiation potential of cell populations derived from a single source. In order to 
limit the possibility of multiple cell precursors being present in the bone marrow and to 
show the multipotentiality of the cells, it was decided that it would be necessary to 
differentiate the cells into at least three different lineages. It was decided to try to 
differentiate hMSC derived merely from the same source initially, with a view to then 
carrying out clonogenic analyses if multipotentiality was demonstrated from the results 
obtained. 
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4.2. Aims & objectives 
The aims and objectives of this chapter were to develop and carry out methods to isolate 
and differentiate hMSC into cells of the adipogenic, myogenic, chondrogenic and 
neurogenic cell lineages. Successful differentiation into at least three of these cell 
lineages would strongly indicate these cells to be hMSC. Furthermore, the antigen 
profile of the isolated cells was to be examined using fluorescence activated cell sorting 
(FACS) with a panel of antibodies to CD45, CD13, CDIO, CD55, CD105, D7FIB, low 
affinity nerve growth factor receptor (LNGFR), bone morphogenetic protein (BMP) and 
alkaline phosphatase (AP). Phenotypic analysis of the cells would enable a direct 
comparison with the work of Jones et aL (2002) and would further confinn the identity 
of the isolated cells. 
4.3. Materials& methods 
4.3.1. Isolation of MSC from human bone marrow 
Materials: Ethical approval was sought and obtained from the local ethics committee 
(Leeds General Infirmary) to obtain waste bone marrow from hip replacement 
operations at Leeds General Infirmary for use in these investigations. A Percoll gradient 
was made by centrifuging 22.05 ml Percoll, (Sigrna-Aldrich), 2.45 ml 1.5 M NaCl,. 
(Sigma-Aldrich) and 10.5 ml Tyrode's balanced salt solution, (Sigma-Aldrich) at 
20i'000 g for 15 minutes. Polypropylene centrifuge tubes (50 CM) were obtained from 
Fisher Scientific. 
Method: Once obtained from the patient, the bone marrow was placed in transport 
medium and collected from the operating theatre within 
4 hours of removal. The bone 
marrow and transport medium were then transferred to a 
50 ml centrifuge tube. The 
tube was then shaken in order to disperse the bone marrow prior to 
being centrifuged at 
600 g for 5 minutes. The supernatant and overlying fat 
layer were careftdly removed 
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leaving approximately 5 ml of medium to avoid aspirating the pellet. The pellet was 
then resuspended by repeated pipetting in the remaining solution before being carefully 
layered onto a preformed Percoll gradient. The Percoll-marrow solution was centrifuged 
at 460 g for 15 minutes before 14 ml of the upper fraction was removed and added to 25 
ml of complete medium as described in Section 2.4.1. The solution was then centrifuged 
at 600 g for 5 min, the supernatant removed, the pellet resuspended by repeat pipetting, 
and a further 20 ml of medium added. The tube was then centrifuged at 600 g for a 
further 5 minutes. The supernatant was then removed and the cells resuspended in 5 ml 
of complete medium. The cell suspension was then transferred to a 25 CM2 tissue culture 
flask and the flask incubated under standard conditions as described in Section 2.4.1. 
Culture medium was first changed after five days and then every three to four days until 
the cells were cryopreserved for later use or used in the differentiation assays. 
4.3.2. Human mesenchymal stem cell differentiation assay 
Materials: Adipogenic medium consisted of 50 ml of adipogenic differentiation 
supplement (Stem Cell Technologies) added to 450 ml of human Mesencult medium 
(Stem Cell Technologies). 
Myogenic medium consisted of complete medium supplemented with 10 pM 5- 
azacyti, dine (Sigina-Aldrich). 
Chondrogenic medium consisted of serum-free medium supplemented with 100 gg. ml-1 
sodium pyruvate, 40 gg. ml-1 L-proline, 50 Itg. ml-l L-ascorbic acid-2-phosphate, 
mg. ml-I bovine serum albumin (BSA), Ix insulin-transfemn-sodiurn selenite, 100 nM 
dexamethasone (all purchased from Sigma-Aldrich) and 10 ng. ml-1 TGFP3 (Catalogue 
number 243-B3-002, R&D Systems). Mouse anti-collagen H antibody was purchased 
from Sigma-Aldrich. 
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Neurogenic induction medium consisted of complete medium containing 20 % (v/v) 
FCS (Invitrogen) supplemented with I mM P-mercaptoethanol (Sigma-Aldrich). 
Neurogenic differentiation medium consisted of serum-free DMEM supplemented with 
10 mM P-mercaptoethanol (Sigma-Aldrich). Tyrode's balanced salt solution (TBSS) 
was purchased from Sigma-Aldrich. Cells were gown on multi-chamber slides 
purchased from Bibby Sterilin. Anti-tau, anti-neuron-specific enolase (NSE),, anti- 
desmin, anti-myosin heavy chain-slow and anti-a-smooth muscle-actin antibodies were 
all purchased from Vector Laboratories. Antibodies were diluted as described in Section 
2.6.5 prior to use. Oil Red 0 stain was purchased from Sigma-Aldrich. 
Methanol/acetone solution was made from 50: 50 methanol: acetone which were both 
purchased from VWR International. 15 ml polypropylene centrifuge tubes were 
purchased from Fisher Scientific. 
Method: For the adipogenic, myogenic and neurogenic differentiation assays, 5x 104 
cells (passage 3) were cultured in each well of four multi-chamber slides each in 
complete mediwn for 24 hr to enable the cells to become fully attached. 
For adipogenic differentiation, complete medium was then removed and replaced with 
adipogenic, medium. Cells were then fed adipogenic differentiation mediwn twice 
weekly for up to four weeks with two slides fixed at 2 weeks, and two slides fixed at 4 
weeks in formalin solution for 10 minutes. Slides were then stored at -20 T. Lipid 
vesicles could be visualised by eye as the cells were growing and were also stained 
using Oil Red 0 once fixed. 
The myogenic differentiation assay was derived from Wakitani et aL (1995). Briefly, 
complete medium was replaced with myogenic medium for 24 hr before this was 
replaced with complete medium again. Cells were then fed complete medium twice 
weekly for up to four weeks With two slides fixed at 2 weeks, and two slides fixed at 4 
weeks in methanol/acetone for 2 minutes. Slides were then stored at -20 T prior to 
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immunofluorescent evaluation. Immunofluorescent staining as descnbed in Section 
2.6.4 using antibodies to a-smooth muscle actin, myosin heavy chain-slow and desmin 
was used to show if differentiation had taken place. 
The neurogenic differentiation assay was derived from Woodbury et al. (2000). Briefly, 
complete medium was first replaced with neurogenic induction medium for 24 hr. The 
cells were then rinsed in TBSS., before this was replaced with neurogenic differentiation 
medium. Slides were then fixed for 2 minutes in methanol/acetone at 2,. 4ý 6 and 8 hours 
after differentiation medium was introduced before being stored at -20 T prior to 
immunofluorescent evaluation. Immunofluorescent staining using antibodies to tau and 
NSE were used to show if differentiation had taken place. 
The chondrogenic differentiation assay was derived from Jones et al. (2002). Briefly, 
2.5xIO 5 cells were centrifuged at 500 g for 5 min in each of 6 (15 ml) polypropylene 
centrifuge tubes. Four tubes of cells were then fed with chondrogenic differentiation 
medium three times a week for up to four weeks and incubated in the polypropylene 
tube with a loosened cap to allow gaseous exchange. The remaining cells were fed with 
complete medium three times a week for up to four weeks as a comparison. Cell pellets 
were harvested at 2 and 4 weeks and cryo-embedded for frozen sectioning prior to 
storage in liquid nitrogen until required for tolWdine blue staining and 
immunofluorescent evaluation using an antibody to collagen 11. 
4.3.3. Toluidine blue staining 
Materials: Methanol and isopropanol were purchased from VWR International. 
Toluidine blue was purchased from Sigma Aldrich. 
Method: Cryo-embedded chondrogenic differentiation pellets were cryo-sectioned at 5 
pm and fixed onto super frost slides by immersing them in 100 
% methanol for 2 
minutes. Sections were then stained by immersion for 30 minutes in I% 
(w/v) toluidine 
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blue solution in 50 % (v/v) isopropanol at 37 T. Slides were then rinsed extensively in 
isopropanol prior to being dehydrated and mounted through graded alcohols and xylene 
as previously described in Section 2.5.4. 
4.3.4. Fluorescence activated cell sorting (FACS) analysis 
Materials: FACS tubes were purchased from Beckton Dickinson. Anti-mouse IgG, 
anti-low affinity nerve growth factor receptor (LNGFR), anti-CD105, anti-CD45, anti- 
CD13,, anti-D7FIB and anti-CDIO antibodies were directly conjugated to phycoerythrin 
(PE), a red fluorescent marker. Anti-CD55 and anti-bone morphogenetic protein (BMP) 
were biotinylated and so were visuallsed using a secondary marker, streptavidin (STR), 
which was conjugated to PE and readily binds to biotin. Anti-alkaline phosphatase 
antibody (AP) was not conjugated and so was visualised using a goat anti-mouse 
(GAM) secondary antibody also conjugated to PE. Anti-mouse IgG, anti-LNGFR, anti- 
STR,, and anti-CD55 antibodies were obtained from BD Phanningen. Anti-CD105 and 
GAM antibodies were purchased ftom Serotec. Anti-BMP was obtained from RnD 
Systems. Anti-CD45, anti-CD13, anti-D7FIB, anti-CDIO and anti-AP antibodies were 
gifts from Elena Jones. All antibodies were diluted as described in Table 5.1 using TBS 
azide BSA as described in Section 2.6.1. Foetal calf serum (FCS) was obtained from 
Invitrogen. 
Methods: A confluent flask of hMSC (passage 6) was trypsinised. Cells 
(I X 105) were 
then added to each of 12 FACS tubes. FCS (I ml) was then added to each tube to 
inactivate the trypsin. The tubes were then centrifuged at 200 g for 10 minutes. The 
supernatant was discarded and the cells resuspended in the residual fluid. Antibody 
solution (10 jil) was then added to the respective FACS tubes and the tubes incubated 
for 15 minutes at room temperature. HIBSS (5 ml) was then added to each tube and the 
cells were centrifuged at 200 g for 10 minutes. The supernatant was then discarded and 
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tubes containing antibodies directly conjugated to PE were then resuspended and 
analysed. Tubes containing antibodies requiring a secondary PE-conjugated antibody 
were also resuspended and 10 gl of the respective secondary antibody was added to the 
tubes. These tubes were incubated for a further 15 minutes at room temperature before 5 
ml of HBSS was added and the tubes centrifuged at 200 g for 10 minutes. The 
supernatant was then discarded and the cells resuspended ready for FACS analysis. 
Each tube was then introduced into the FACS machine and 10,000 cells counted and 
analysed for the presence of the respective markers on the F2 channel. 
MARKER CONJUGATE SPECIFICITY DILUTION 
IgG PE Mouse immunoglobulin G negative control 1/2 
CD45 PE Leukocyte marker Neat 
CD13 PE Monocyte, granulocyte and myelocyte marker Neat 
D7FIB PE Fibroblast marker 115 
CD105 PE Vascular endothelial cell marker Neat 
CDIO PE Fibroblast and granulocyte marker 115 
LNGFR PE Low-affinity nerve growth factor receptor, found Neat 
on adventitial reticular cells of the bone marrow 
STR PE Streptavidin negative control 1/200 
CD55 BIO Synovial lining and fibroblast marker Neat 
BNW BIO Bone morphogenetic protein marker 1150 
GAM PE Goat anti-mouse negative control 1/10 
AP None Alkaline phosphatase marker for bone Neat 
differentiation 
Table 4.1. Antibody dilutions used for FACS analysis. PE: phycoerythdn; BIO: 
biotin. 
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4.3.5. Clonogenic analysis 
Materials: Tissue culture treated petri dishes (60 mrn diameter) were purchased from 
Fisher Scientific. Cloning rings were purchased from Sigma-Aldrich. Whilst growing 
sufficient hMSC for various other experiments, the waste medium removed when the 
cells were fed was retained and mixed 50: 50 with fresh complete medium to make 
hMSC conditioned medium. 
Methods: Sample hBM6 was used for the clonogenic assay as this sample was 
harvested from the youngest patient available and, therefore, represented the potentially 
healthiest source of cells with the highest potential to proliferate for longer. A confluent 
flask of hMSC was trypsinised and the cells counted as described in Section 2.4.2. 
Approximately 30 cells were then reseeded into each of twenty 60 min tissue culture 
treated petri dishes. Cells were returned to the incubator and allowed to attach to the 
dish for a minimum of four hours (fed on conditioned medium). The petri dishes were 
then viewed on an inverted microscope. A cloning ring was placed over each single cell 
that could be seen to have no other cells nearby. Once all the single cells on a dish were 
ringed, the tissue culture medium was removed from the dish, and then from within 
each of the rings. The individual cells were then trypsinised using 100 gl of HBSS to 
wash the cells, and then 50 pd of trypsin-EDTA solution to detach the cells. Once the 
cells had detached, 100 gI of conditioned medium was added to each ring before the 
contents of each ring were transferred to a separate well of 96-well tissue culture plate. 
A finiher 100 gl of conditioned medium was then added to each well and the cells 
cultured under standard conditions. The cells were then fed twice weekly With 200 gl of 
conditioned medium. Once the cells became confluent, they were trypsinised and 
transferred to a 48 well plate, followed by 24-well and 12-well plates. 
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4.4. Results 
4.4.1. Cultured human mesenchymal stem cells 
A growth curve was plotted for sample hBM1 (Figure 4.1) and the cell doubling time 
(CDT) was calculated as described in Section 2.4.3. hMSC between passages I and 2 
were found to have a CDT of approXimately 151 hours. However, between passages 8 
and 9,, this time had increased to approximately 438 hours. 
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Time (hours) 
Figure 4.1. Growth curve of human mesenchymal stem cells. Each point on the 
line represents a cell passage of hBM1. The original cell number could not be 
calculated due to difficulties in seeing the cells through other bone marrow debris. 
The apparent reduction in proliferation rate was matched by a change in cell 
morphology (Figure 4.1). The cells were seen to be fibroblastic in appearance. 
Microscopic observation of cell morphology at different passages showed that the cells 
could generally be categorised into three age-related morphologies based on their 
appearance: 
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1. Cells one week after isolation (passage 0) are shown in Figure 4.2a. Cells 
were relatively small and highly proliferative, becoming confluent in 
approximately 2 weeks. 
2. Cells at an inten-nediate stage (passage 5) whereby their rate of 
proliferation had decreased slightly and the cells were beginning to take 
on a more flattened and spread morphology are shown in Figure 4.2b. 
3. At this stage, cells were largely quiescent and divided very slowly, if at 
all (passage 9). Cells became highly flattened and spread with prominent 
filaments visible in the cell cytoplasm, and typically took over 4 weeks 
to become confluent. Cell morphology can be seen in Figure 4.2c. 
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Figure 4.2. Human mesenchymal stem cells at different ages. A: Proliferating 
primary morphology (PO); B- Intermediate secondary morphology (P5); and C: 
Quiescent tertiary morphology (P9). 
114 
10 
CHAPTER 
A number of attempts to isolate putative hMSC were made during the course of the 
investigation. These are listed in Table 5.2. The yield of cells was observed to vary from 
sample to sample, however it was impossible to accurately count the number of cells 
initially isolated because of the large amount of debris present after the I ion i solat' 
process. The cryopreserved cells were stored in liquid nitrogen as a cell bank for future 
studies. 
SAMPLE DATE SEx AGE PASSAGES NOTES 
hBMI 28/08/02 F 71 P1 16/09/02 Used in differentiation assay at P3 
P2 26/09/02 for adipogenic and myogenic. P4 
P3 11/10/02 for neurogenic. P8 for 
P4 25/10/02 chondrogenic. Cryopreserved 
P5 19/11/02 25/10/02. Cryopreserved 19/11/02. 
P6 20/01/03 P5 thawed 06/01/03. Used for 
P7 30/01/03 FACS at P6 
P8 17/02/03 
P9 18/03/03 
PIO 14/04/03 
P 11 16/05/03 
54 Pl 16/09/02 Cryopreserved 08/11/02 hBM2 28/08/02 
P2 30/09/02 
P3 22/10/02 
P4 08/11/02 
hBM3 25/09/02 F 61 P1 14/10/02 Cryopreserved 20/12/02 
1 P2 01/11/02 
P3 25/11/02 
P4 20/12/02 
hBM4 23/10/02 1F 81 PI 10/12/02 Cryopreserved 17/12/02 
P2 02/12/02 
P3 17/12/02 
72 P1 10/ 12/02 Cryopreserved 20/12/02 hBM5 28/11/02 M 
P2 20/12/02 
i Cryopreserved 17/12/02. Thawed hBM6 04/12/02 M 40 P1 17/12/02 
P2 18/07/03 11/07/03. Used for clonogenic 
assay at P3. Cryopreserved P3 04/08/03 
P4 27/08/03 27/08/03 
hBM7 05/12/02 M 67 PI 17/12/02____Cryopýreserv-ed__1_7/1_2/0_2 
hBMIO 15/01/03 F 71 PI 31/01/03 Cryopreserved 31/01/03 
- h-BM I-1 16/01/03 -preserved 27/01/03 55 PI 27/01/03 cryo 
-TPI 03/02/03 Cryopreserved 03/02/03 hBM12 16/01/03 F 54 
--ýBM13 -16/01/_03---ý---M-- 69 P-1 27/01/0_3 Cryopreserved 27/01/03 
-- hBM14 02/06/03 F 62 Pl 21/02/03 Cryopreserved 21/02/03 
hBM16 26/02/03 ? Pl 21/03/03 Cryopreserved 21/10/03 
h: 6M- 17 27/02/03 M 79 PI 14/03/03 Cryopreserved 14/03/03 
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hBM19 12/03/03 F 80 P1 11/04/03 CryopTeserved 11/04/03 
hBM2 0 12/03/0_3 
__ __F--- 
74_ 11-PI 11/04/03 qTyqpreserved II/ 0 4/03 
hBM21 12/03/03 F_ 
__75 
PI 11/04/03 Cryopreserved 11/04 - - - 03 
hBM22 20/03/03 M 47 PI 31/03/03 Cryopreserved 31/03/03 -- 
hBM24 
- -- 
02/04/03 F 68 PI 02/05/03 Cryopreserved 02/05/03 
hBM 26 24/04/03 F 67 PI 0-9-/-05-/O--3---- ---T-(C--'-iýo-pre-served 09/0-5/03 
hBM27 07/05/03 F 68 PI 30/05/03 Cryopreserved 30/05/03 
hBM28 07/05/03 F 79 PI 30/05/03 Cryopreserved 30/05/03 
hBM29 08/05/03 F 52 PI 30/05/03 Cgo preserved 30/05/03 
hBM30a 08/05/03 M 68 PI ---- 30/05/03 qTyo erve4 30/05/03 Tres c 
hBM30b 08/05/03 68 PI 30/05/03 Cr yopreserved 30/05/03 
hBM32 31/07/03 T F 95 PI 27/08/03 _ Cryopreserved 05/09/03 
P2 05/09/03 
hBM33 31/07/03 F 
-- 
87 
- 
PI 27/08/03 Cryopreserved 27/08/03 
hBM36 28/08/03 F] 74--T-pf -l-ý/0-9/03 Cryopreserved 15/09/03 
hBM38 11/09/03 F 85 PI 03/10/03 Cryopreserved 03/10/03 
Table 4.2. Putative human mesenchymal stem -cell isolations. Each isolation 
attempted to isolate putative hMSC from waste bone marrow obtained from a hip 
replacement operation at Leeds General Infirmary. Requested patient details were not 
always given. 
4.4.2. Human mesenchymal stem cell differentiation 
Once putative hMSC had been isolated, it was necessary to try to differentiate the cells 
in vitro into multiple cell lineages in order to demonstrate the multipotentiality of the 
cells. When the bone marrow samples were first received, the supply was somewhat 
irregular as the operating theatre staff were not familiar with what was being requested 
of them. Consequently, the differentiation attempts were carried out on the first sample 
received, hBMI. Once the differentiation assays were started, it was necessary to 
continue to use the same cell population throughout the experiments in order to show 
that differentiation into multiple lineages was possible from one cell population in order 
to rule out different cell precursors being present in different cell populations. 
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4.4.2.1. Adipogenic differentiation 
The assay was carried out sample hBMI at passage I Oil Red 0 is a lipid soluble dye; 
therefore the areas stained pink mark lipid deposits made by the cells (Figure 4.3). It 
was observed that only approximately 20 % of cells differentiated. 
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Figure 4.3. Differentiation of human mesenchymal stem cells into adipogenic 
lineage. Oil red 0 staining of lipid vesicles. 
4.4.2.2. Myogenic differentiation 
The assay was carried out on sample hBM I at passage 3. Once the differentiation 
procedure was complete, the cells were fixed and stained with fluorescent antibodies to 
a-smooth muscle actin (aSMA), desmin and heavy-chain myosin slow (HCMs, Figure 
4.4). Approximately 10 % of cells were seen to weakly express these markers, with the 
aSMA being greatly reduced from its normally high expression on freshly isolated cells. 
Porcine heart muscle was used as a positive control for the antibodies as no human heart 
could be obtained. 
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Figure 4.4. Differentiation of human mesenchymal stem cells into myogenic 
lineage. Fluorescent antibody staining to a-smooth muscle actin (aSMA), desmin 
(Des), heavy-chain myosin slow (HCMs), negative control (NEG). 
4.4.2.3. Chondrogenic differentiation 
The assay was carried out on sample hBMI at passage 8. After 24 hours of culture, the 
cells formed a spherical cell pellet that became detached from the centrifuge tube 
(Figure 4.5A). Blue regions of toluidine blue staining after 4 weeks of culture indicated 
extracellular matrix production by the cells (Figure 4.5B). The main marker for 
chondrogenic differentiation is collagen 11, however, immunoperoxidase staining of the 
pellet indicated no collagen 11 production by the cells. Human cartilage was used as a 
positive control for the collagen 11 antibody. 
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B 
moon Figure 4.5. Differentiation of human mesenchymal stem cells into chondrogenic 
lineage. A: cell pellet in culture; B: toluidine blue staining of the pellet. 
4.4.2.4. Neurogenic differentiation 
The assay was carried out on sample hBMI at passage 4. Once the culture period was 
complete, cells were fixed and stained using fluorescent antibodies to tau and neurone- 
specific enolase (NSE), both markers of the neurogenic lineage (Figure 4.6). The cell 
morphology was also seen to change to an appearance resembling a neurone-like 
morphology. Again, approximately 10 % of cells were positively stained. Porcine optic 
nerve was used as a positive control for the antibodies. 
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Figure 4.6. Differentiation of human mesenchymal stem cells into neurogenic 
lineage. Neurone-specific enolase (NSE) and tau are markers of the neurogenic 
lineage. The phase-contrast image shows cell morphology after 8 hours. NEG shows a 
negative control. 
4.4.3. Fluorescence activated cell sorting (FACS) analysis 
The analysis was carried out on sample hBMI at passage 6. The dotplots for each 
marker were gated using the region shown in order to discount cell clumps and other 
artefacts. These regions were then used to make the corresponding histograms (Figure 
4.7). The negative controls (IgGPE, GAMPE and STRPE) were used to establish the 
MI region. Peaks that fell within this region were caused by fluorescently labelled cells. 
The percentage of cells within this region was calculated and the results for each marker 
can be seen in Table 4.3. All the cells were negative for CD45 and BMP, but positive 
for 137FIB, CD13, CD55 and CD105. CDIO was partly positive and partly negative, 
with the peak falling between the positive and negative regions. LNGFR and AP 
showed 2 peaks merged together on the histogram, falling on either side of the MI 
region. 
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Figure 4.7. FACS analysis of isolated hMSC. Each of the pairs of dot-plot and 
histogram shows the marker used. Cells that fell within the M1 region of the histogram 
were positively stained with the antibody, and outside of that region were negatively 
stained (SS: side scatter; FS: forward scatter). 
MARKER CONJUGATE SPECIFICITY PERCENTAGE PEAKS 
POSITIVE 
IgG PE Mouse immunoglobulin G 0.48 1 
negative control 
CD45 PE Leukocyte marker 0.04 1 
CD13 PE Monocyte, granulocyte and 99.99 
myelocyte marker 
D7FIB PE Fibroblast marker 95.47 
CD105 PE Vascular endothelial cell marker 98.14 
CDIO PE Fibroblast and granulocyte 40.2 1 
marker 
LNGFR PE Low-affinity nerve growth factor 21.09 2 
receptor, found on adventitial 
reticular cells of the bone marrow 
STR PE Streptavidin negative control 0.66 
CD55 BIO Synovial. lining and fibroblast 97.58 1 
marker 
BMP BIO Bone morphogenetic protein 0.99 1 
marker 
GAM PE Goat anti-mouse negative control 0.51 1 
AP None Alkaline phosphatase marker for 41.12 2 
bone differentiation 
Table 4.3. Summary of the FACS analysis results. Table showing the percentage of 
positively stained cells for each cell marker. 
4.4.4. Clonogenic analysis 
Sample hBM6 was isolated from a 40 year old patient undergoing a hip replacement 
operation at Nuffield Hospital, Leeds. Despite 60 attempts being made to isolate 
individual cells from this sample, only II attempts successfully transferred an 
individual cell from the cloning ring to a 96-well plate. Of these 
II cells, only 3 cells 
proliferated sufficiently for enough cells to be grown to necessitate transfer to 
larger 
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wells. Two wells of cells reached a 24-well plate stage and one well of cells reached a 
12-well plate stage. However, at this point the cells stopped dividing and appeared to 
become senescent. By this time, the cells that had Teached the 12-well stage had 
undergone 13 cell doublings to give over 8400 cells from the original single cell. 
Interestingly, these 13 cell doublings had occurred in 50 days, giving a CDT of only 
approximately 92 hours compared to the CDT of 151 hours calculated from the 
normally cultured cells. However, in order for differentiation analysis to be carried out, 
over 21 cell doublings would have been required to give sufficient cells for analysis. 
Furthermore,, for investigation by FACS analysis, 10,000 cells were required per marker 
assessed, therefore a further 120,000 cells would have been required. Consequently, no 
further analyses could be carried out. 
4.5. Discussion 
Attempts were made to isolate hMSC using the same method that was adapted for 
isolating pMSC in Chapter 4. This method yielded fibroblast-type cells of a similar 
appearance to cells isolated by other groups. The CDT calculated for hBMI was shown 
to gradually slow with prolonged culturing, however, the CDT calculated during the 
clonogenic assay was shown to be considerably shorter. Since the cells used in the 
clonogenic assay were from a younger patient (hBM6, Male aged 40) than those used in 
the differentiation assays (hBMI, Female aged 71) it is possible that hMSC from older 
patients have a reduced proliferation capacity and may show other age related 
degeneration such as reduced differentiation capacity. However, full details of patient 
medication or reasons for surgery were not available and may provide a 
ftirther 
explanation. Conget et aL (1999) stated the 
CDT of hMSC to be approximately 33 
hours, significantlY faster than the findings here. However, their cells were sourced 
ftorn healthy individuals undergoing bone marrow harvests for allogeneic 
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transplantation. Although the paper did not specifically state the age of the donors, it is 
likely that they would have been much younger that those used to obtain human bone 
marrow for this investigation. Consequently, this again could represent an age related 
effect on hMSC proliferation capacity. 
The change in morphology and decreasing proliferation rates of the hMSC as they aged 
suggested that the cells might not be immortal, which is thought to be a prerequisite in 
the identification of any stem cells. This compared well with reports by others, which 
showed that hMSC, do not possess telomerase actiVity [Banfi et aL, 2002], which is 
thought to be an important enzyme involved in maintaining telomere length and 
consequently cell immortality. However, it may well be that the in vitro conditions used 
to grow the cells cannot sustain the immortal capacity of the cells and instead exert a 
selective environment that preferentially encourages the cells to become terminally 
differentiated. This also associated well with findings of the FACS analysis of the cells 
(discussed later) using an antibody to alkaline phosphatase (AP). AP is a marker that is 
thought to be specific to osteogenic cells. The histogram from the FACS analysis 
showed two peaks, one positive and one negative. This means that the cells were a 
mixed population of AP-" and AP- cells. This could be interpreted as being the result of 
the cells initially being AP negative, but gradually becoming positive as the cells aged, 
i. e. hMSC gradually differentiated into osteogenic cells in vitro. It may be that 
conditions for growing and maintaining cells in their undifferentiated state need to be 
improved beyond the standard techniques and conditions currently implemented by the 
majority of groups working on hMSC. Mso, the different morphologies of the cells 
could account for the frequently described heterogeneity of the cells when they are 
initially isolated from the bone marrow. The different cells seen could all be hMSC at 
different stages of differentiation as shown in Figure 1.11 earlier, which describes the 
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progression of the cells from long-term replicating MSC through to mature terminally 
differentiated cells. 
A number of attempts to differentiate the cells were made using biochemical 
supplements to complete medium and serum-free medium. The methods were derived 
from Stem Cell Technologies, Wakitani et aL (1995), Woodbury et aL (2000), and 
Jones et aL (2002). The adipogenic differentiation medium used consisted of an 
adipogenic differentiation supplement to Mesencult, the hMSC growth medium 
produced by Stem Cell Technologies. Although the contents were not stated , it is likely 
to have contained insulin as a major differentiation factor as insulin promotes the 
storage of glucose as glycogen and consequently the production of fatty acids and 
therefore lipids. 
The myogenic differentiation medium used 5-azacytidine to alter gene transcription as 
described in Section 3.5, however; again why myogenic differentiation would occur 
rather than differentiation into any other lineage is unclear. 
The chondrogenic differentiation medium consisted of serum-free medium 
supplemented with 100 ugy,,. ml-1 sodium pyruvate, 40 ýtg. rnl-' L-proline, 50 gg. ml-1 
ascorbate-2 -phosphate, I mg. mI-1 bovine serum albumin 
(BSA), and Ix insulin 
transferrin sodium selenite (ITSS) to replace the FCS and then 100 nM dexamethasone 
and 10 ng. ml-1 transforming growth factor beta-3 (TGFP3) as the 
differentiation agents. 
The more critical part of this method was culturing the cells in a three-dimensional 
pelleted micromass culture rather than the 2-dimensional culture system used 
to attempt 
the chondrogenic differentiation of pMSC in Chapter 
3. It is known that when 
chondrocytes are cultured in a 2-dimensionai environnient 
they rapidly de-differentiate 
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and stop producing a collagen matrix. Consequently, by trying to differentiate the 
hMSC whilst in a 3-dimensional micromass pellet, this method would be more likely to 
work than others where the cells are cultured in a tissue culture flask. 
Neurogenic differentiation medium used P-mercaptoethanol as a reducing agent, as 
described in Section 3.5. however, again why it would induce neurogenic differentiation 
over any other lineage is unclear. 
The success of three of the four differentiation assays, along with the demonstration of 
increased AP expression with cell age suggests that the isolated cells were in fact 
hMSC. The failure of the chondrogenic assay to give cells that produced collagen 11 
may well be related to the age of the patient from which the cells were isolated as a 
number of groups have reported decreased cell proliferation and differentiation capacity 
as donor age increases [Caplan, 1994; Digorolamo et al., 1999; Mendes et al., 2002]. 
Also, the cells used for this assay were at passage 8, therefore the cells had undergone 
more cell doublings than those used for previous differentiation assays and may have 
had a reduced differentiation capacity as a result of this. However, despite these 
findings, it is Still possible that the bone marrow contains multiple cell precursors and 
the differentiation media simply select for these cells. 
The results of the FACS analysis were comparable to those discussed in Jones et aL 
(2002), having a phenotype of CD45-, CD13+, D7FI13+,. CD105 
+ 
1. CDIO-,, 
LNGFR+'-,. 
CD55 +, BW-, and AP+'-. Caplan & Haynesworth (2000) described CD105 as being 
specific to hMSC- It has since been found to also be present on vascular endothelial 
cells, and therefore is not specific to hMSC. However, since the cells were shown 
to be 
]positively stained for this antigen, 
it further demonstrated another indication of the 
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hMSC phenotype. It is thought that CDIO is present on hMSC when first isolated, but 
that it is gradually lost with subsequent cell ageing. This associated well With results 
here that 40% of cells were positive for the marker as the cells used for this analysis 
were at passage 6. The histogram for LNGFR also showed two peaks, which indicated 
two populations of cells, one with and the other without this marker being present on 
the cell surface. This also suggested that this marker is gradually lost as the cell 
population ages. The alkaline phosphatase (AP) marker also produced two peaks on the 
histogram. AP is known to be specific to osteogenic cells, and the appearance of two 
peaks suggested that AP expression gradually increased with cell age. This indicated 
that the osteogenic lineage may be the default pathway for hMSC, i. e. if the cells do not 
receive signals to differentiate into an alternate lineage, they become osteogenic cells. 
Conversely, it may be that current culture conditions are selective for the osteogenic 
lineage or provide some form of signalling that encourages the cells to become 
osteogenic. All of the results of the FACS analysis were analogous With the findings of 
Jones et aL (2002). However, in their work, the FACS analysis had been carried out on 
cell populations which had been Isolated and grown from a single cloned cell. 
Therefore, comparable results here gave further support to the prospect that the cells 
isolated could be mesenchymal stem cells. 
The problem of the cells gradually differentiating into cells of the osteogenic lineage 
could also have been the reason behind the failure of the clonogenic assay. Although 
some of the single cells isolated went on to proliferate, they all became senescent before 
sufficient cell numbers were grown to assess their differentiation capacity. The low 
number of single cells that proliferated combined with other observations indicated that 
below a certain cell density, hMSC were not receiving sufficient cell signals and other 
factors to encourage their proliferation. Although some of these factors would have 
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been provided by the conditioned growth medium used to grow the cells, permitting 
some of the cells to proliferate, clearly the signals present were not sufficient for many 
of the cells, The presence of these factors could be increased by using a higher 
proportion of used cell growth medium in the conditioned medium used to feed the 
cells. Alternatively, other means could be used to support the cell growth more 
effectively such as using an irradiated hMSC feeder layer to grow the cells on. Also, as 
previously mentioned, the problem may lie with some other part of the culture 
conditions which may actively encourage the cells to become terminally differentiated, 
leading to their rapid senescence before any further investigations could be camed out. 
The large numbers of cells isolated and cryopreserved during the course of the 
investigation were stored as a cell bank for future experiments. For example, the vaned 
age of the patients from whom the cells were harvested would enable investigation of 
whether the proliferation and/or differentiation capacities of the cells are affected by the 
age of the patient. The cells would also be a cell source for future clonogenic studies 
and reseeding experiments. 
Clearly, any future investigation of hMSC must first focus on providing the optimal 
culture conditions to consistently maintain their multipotential differentiation and 
immortality capacities. Some researchers have suggested that certain lots of foetal calf 
serum are more effective at supporting MSC [Lennon et aL, 1996]. Also, a chemically 
defined medium could be established, as described in Section 3.5. Furthermore, an 
irradiated feeder layer may assist in providing the correct chemical signals to maintain 
MSC in an undifferentiated state. Other experiments could investigate the use of 
mechanical stimulation to differentiate hMSC as previously discussed in 
Section 3.5. 
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In conclusion, putative hMSC were successfully isolated using a common method 
trequently described in the literature. These cells were morphologically comparable to 
those of others and their differentiation into multiple cell lineages was successfully 
achieved. Furthermore,, FACS analysis of the cells enabled a direct positive comparison 
with clonally isolated hMSC as described by Jones et aL (2002), further adding to the 
evidence that the cells were hMSC. However, an attempt to grow the cells in a 
clonogenic manner in order to show that cells from a single source were capable of 
differentiating into multiple cell lineages was unsuccessful as the cells became 
senescent before their differentiation capacity could be investigated. As a result of these 
findings, the cells were confidently, though not conclusively, believed to be hMSC and 
their potential as a cell source for use in tissue engineering an aortic heart valve was 
investigated. 
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0 CHAPTER 5, 
Biochemistry and Biocompatibility of 
Decellularised Valve Leaflets 
Introducdon 
T he basic principle of tissue engineering involves seeding cells into a matrix 
scaffold which then interact to produce a viable replacement tissue. However,, 
there are a number of ways of creating a suitable matrix scaffold. Essentially, the matrix 
can be one of two varieties: either synthetic or natural. Synthetic scaffolds can be made 
from a number of materials,, such as polyglycolic acid (PGA), fibrin and collagen. 
11- 
Flowever, whilst these have their advantages in that they can be readily mass produced 
and can be highly defined in composition, they ftequently lack the mechanical strength 
found in natural tissues. Developing a heart valve tissue substitute from a naturally 
occurring decellularised biological matrix is an alternative strategy that would provide a 
ready-made scaffold, which already possesses optimal mechanical and biochemical 
qualities and characteristics. There is also an immediate distinct advantage in that there 
should be minimal host response to a naturally occurring extracellular matrix provided 
decellularisation is adequately carried out [Badylak, 2002]. Methods for producing 
acellular matrices typically use a combination of enzymes and detergents to remove the 
cells from an allogeneic or xenogeneic tissue [Bader et aL, 1998; Booth et al., 2002]. 
This approach could offer an unlimited source of valve matrices, which could then be 
reseeded with autologous cells from the valve recipient to give a non-immunogenic 
living product. The difficulty with this technique, however, lies in the decellularisation 
process: all of the cells must be completely removed without damaging the tissue matrix 
so that mechanical and structural properties are fully maintained. Any chemicals used in 
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this process must be completely removed to ensure biocompatibility with cells and host 
tissue upon implantation. Remaining cell proteins could result in rejection of the tissue, 
and remaining fragments could lead to calcification, resulting in rapid stiffening and 
iffeparable damage to any implanted tissues [Dohmen et aL, 2002b]. 
A patented method has been developed at the University of Leeds for the 
decellularisation of porcine aortic heart valve tissue using the detergent sodium dodecyl 
sulphate (SDS). Histological analysis has shown matrix components to remain intact 
[Booth et al., 20021, whilst mechanical testing has demonstrated that the SDS treatment 
produced valves With equal strength, competence under physiological pressures 
(120mmHg) and greater extensibility than untreated fresh valves [Korossis et aL, 2002]. 
However, histological assessment alone is only a qualitative means of showing that 
cells have been completely removed whilst the matrix is maintained. Consequently, it 
was deemed necessary to further confirm these findings by quantifying the collagen, 
glycosaminoglycan (GAG) and DNA content of the tissues before and after 
decellularisation by the use of quantitative biochemical assays. 
Collagen exists in at least 12 different forins and is the major protein in the tissue 
matrix. Types 1,11, and III are the most abundant. The amino acids in the chains are 
predominantly glycine, proline and hydroxyproline. Hydroxyproline is Critical for 
collagen stability and consequently it can be used to determine the levels of collagen in 
tissues using a conversion factor of 7.14 [Harding & Wesley, 1968]. 
Glycosaminoglycans (GAGs) are also an important component of the valve leaflet as 
they make up the large majority of the spongiosa layer [Schoen, 1999]. They are long, 
unbranched, highly negatively charged polysaccharides with extended conformation, 
high viscosity and low compressibility; properties that confer excellent lubrication and 
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shock absorbance. This enables the fibrosa and ventricularis layers to slide easily over 
one another and also absorb and dissipate the forces endured by the leaflet during 
different stages of the cardiac cycle. The GAG content can be assessed by 
colourimetrically measuring the amount of sulphated proteoglycans present in the 
tissue. Furthennore, analysis of the DNA content of the leaflets before and after 
decellularisation would further indicate that all cellular material had been removed 
during the process. This can be carried out by using a fluorescent marker specific to 
DNA. 
It was important to determine whether the decellularised matrix would induce an 
inflammatory and/or immune response once implanted in vivo from either remaining 
cell debris or remaining reagents used in the decellularisation process. Many 
bioprosthetic valve replacements calcify after extended periods in vivo, which leads to 
their deterioration and eventual failure [Butany & Leask, 200 1 ]. In the case of these 
implants, it is thought that the gluteraldehyde cross-linking of cellular elements 
provides focal Points in the tissue ftom which calcification can develop and spread 
throughout the tissue. It was possible that inadequate removal of cellular fragments 
during the decellularisation process and/or failure to wash out the reagents used could 
also lead to calcification. However , if it is carried out adequately, no calcification 
should occur. Similarly, only a minimal immunogenic response should occur, as the 
constituent components of porcine heart valve tissue are all common to human tissues. 
5.2. Aims& objectives 
The aims of this chapter were to analyse the major biochemical components and assess 
the biocompatibility of a decellularised porcine valve tissue matrix for use as a scaffold 
for stem cell seeding. The specific objectives were to a) determine the levels of 
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collagen, GAGs and DNA both before and after decellularisation of valve tissue; and b) 
implant the decellularised porcine tissue matrix into mice and determine the 
calcification and inflammatory/immunogenic potential. 
5.3. Materials& methods 
5.3.1. Biochemical analysis 
5.3.1.1. Acid hydrolysis of tissues' 
Fresh and decellularised tissues were hydrolysed using strong acid in order to break 
down the tissue so that the hydroxyproline could dissolve into solution and be measured 
by means of a colourimetric assay. 
Materials: Porcine hearts were obtained form a local abattoir within 4 hours of 
slaughter. Hydrochloric acid and sodium hydroxide were purchased from VWR 
Intemational. An Edwards Freeze Drier Modulyo was used to freeze-dry tissues. The 
bench-top autoclave (Duromatic Pressure Cooker) was purchased from SLS. 
Method: Heart valves were excised and the valve leaflets dissected out. Leaflets were 
decellularised as described in Section 2.8.1. Whole fresh (n--6) and decellularised (n=6) 
leaflet samples (approx. 2xI cm) were freeze-dried to constant weights (45 T, vacuum) 
and the dry weights detennined prior to being finely chopped using a scalpel and placed 
in 5 ml of 6M HCI. The samples were then autoclaved for 2 hours in a bench top 
autoclave. After cooling, an equal volume of 6M NaOH was added to each sample 
solution and the pH was finely adjusted to 7.0 using IM NaOH. Samples were then 
centrifuged for 20 minutes at 2000 g and the supernatant aliquoted and stored at -20 'C. 
' The biochemical assays were carried out by Ms Natalie Beveridge, undergraduate 
student, under my supervision. 
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5.3.1.2. Enzymatic digestion of tissues 
Tissue samples for the DNA assay had to be digested enzymatically as strong acid 
would destroy the DNA. This then enabled the DNA to go into solution where it was 
free to react with a colourimetric marker. 
Materials: All reagents were purchased from Sigrna-Aldrich except hydrochloric acid, 
which was obtained from VWR International. The water-bath was purchased from 
Fisher Scientific. Papain solution was made from 125 gg-ml-1 papain in sterile PBS With 
5 mM cysteine-HCI and 5 mM sodium ethyidiaminotetraacetic acid adjusted to pH 6.0 
using hydrochloric acid. 
Method: Papain solution (5 ml) was added to weighted and recorded freeze-dried 
leaflets (fresh, n=6; decellularised, n=6) and incubated for 16 hours in a 60 T water- 
bath. Samples were centrifuged for 20 minutes at 2000 g and the supernatant aliquoted 
and stored at -20 T. 
5.3.1.3. Hydroxyproline assay 
Materials: Trans-4 hydroxyproline, p-dimethylaminobenzaldehyde and chloramine T 
were purchased from Sigma-Aldrich. All other reagents were purchased from VWR 
Intemational. 
Hydroxyproline buffer solution consisted of 13.3 g citric acid, 3.2 ml glacial acetic acid, 
32 g sodium acetate, 9.1 g sodium hydroxide, 80 ml propan-l-ol made up to 300 ml 
with distilled water. This solution was then adjusted to between pH 6.0 and pH 6.5 
using 0.2 M sodium hydroxide before being adjusted to a final volume of 400 ml using 
distilled water. 
Oxidizing solution consisted of 1.41 g chloramine T dissolved in 100 ml of distilled 
water. 
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Ehrlich's reagent was made by adding 7.5 g p-dimethylaminobenzaldehyde to 30 ml 
propan-l-ol and 13 ml 62 % (v/v) perchloric acid. This was then made up to 50 ml 
using distilled water. 
Method: This method was derived from Edwards & O'Brien (19 80). Standard solutions 
of 0,21,4ý, 6 and 8 gg. ml-1 of hydroxyproline dissolved in hydroxyproline buffer were 
prepared. Standard solutions (50 ýd, n--6) and test solutions (50 gl, n--6) were aliquoted 
into wells of a flat-bottomed 96-well plate. Oxidising solution (100 ýtl) was then added 
to each test well and the plate was gently shaken for 5 minutes. Ehrlich's solution (100 
was then added to each well and mixed thoroughly, before the plate was incubated at 
60 T for 45 minutes. The absorbance of the wells was then measured on a plate reader 
set at 570 nm. A curve of hydroxyproline (gg. ml-1) versus absorbance was constructed 
using the standards and the hydroxyproline content (pig. ml-1) of the test samples 
interpolated from the standard curve. The levels of hydroxyproline (gg. ml-1) were 
divided by their dry weight (mg) of each tissue sample and data for each sample 
expressed as [tg. mg-1. 
5.3.1.4. Sulphated proteoglycan assay 
Materials: All reagents were purchased from Sigma-Aldrich except ethanol, which was 
obtained from VWR International. 
Phosphate buffer was made by adding 137 ml of 0.1 M sodium di-hydrogen phosphate 
to 63 ml of 0.1 M di-sodium hydrogen phosphate. 
Dimethylene blue dye solution was made by dissolving 16 mg of 1,9-dimethylene blue 
in 5 ml ethanol. This was then added to 2 ml formic acid and 2g sodium formate before 
being made up to 1000 ml using distilled water. 
Method: This method was derived from Famdale et aL (1986). Standard solutions of 0, 
3.125,6.25,12.5,251,50,100,150 and 200 ýig. ml-l chondroitin sulphate were made b. y 
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dissolving chondroitin sulphate in phosphate buffer. Standard or test solution (80 pl, 
n=6) and dimethylene blue dye solution (500 gl) were added to I ml glass cuvettes and 
the absorbance read at 525 nm on a spectrophotometer within a fixed time of 60 
seconds. A curve of sulphated proteoglycans (gg. ml-') versus absorbance was 
constructed using the standards and the sulphated proteoglycan content (gg. ml-1) of the 
test samples interpolated from the standard curve. The levels of sulphated proteoglycans 
(gg. ml-1) were divided by their dry weight (mg) of each tissue sample and data for each 
sample expressed as gg. mg-1 
5.3.1.5. Fluorometric DNA assay 
Materials: All reagents were purchased from Sigma-Aldrich, except hydrochloric acid, 
which was obtained from VWR International. Plastic cuvettes were purchased from 
Fisher Scientific. 
Hoechst dye was stored as a stock solution at I mg. ml-I in distilled water. A working 
solution was made immediately before use by diluting this solution to 0.1 gg. ml-1 in dye 
buffer. 
Dye buffer consisted of I Om. M Tris, I mM sodium ethyldiaminotetraacetic acid, and 0.1 
M sodium chloride,, adjusted to pH 7.4 using hydrochloric acid. 
Method: This method was derived from that described by Kim et aL (1988). Standard 
solutions of 0,, 5ý, 10,151,209 25,30,35,40,45,50 and 100 gg-ml-1 calf thymus DNA 
dissolved in PBS were made. Test sample or standard (100 gl, n=6) was aliquoted into a 
plastic cuvette and mixed manually with 2 ml Hoechst-33258 dye solution by repeated 
pipetting. The fluorescence intensity was recorded with excitation set at 365 nm and 
emission at 458 mn. A curve of DNA (gg. ml-1) versus absorbance was constructed 
using the standards and the DNA content (gg. ml-1) of the test samples interpolated 
from 
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the standard curve. The levels of DNA (gg-ml-') were divided by the dry weight (mg) of 
each tissue sample and data for each sample expressed as gg. mg-1. 
5.3.1.6. Analysis of data 
Data for hydroxyproline, GAG and DNA content in the tissues before and after 
decellularisation were analysed using the students t-test. 
5.3.2. Biocompatibility study 
5.3.2.1. Preparation of tissue samples 
Materials: Hypotonic buffer consisted of 10 mM Tris with 10 KIU aprotinin and 0.1 % 
JIUEDTA adjusted to pH 8.0 using HCI. Porcine hearts were obtained from a local abattoi I. J ir. 
Method: Porcine hearts were dissected and the valve leaflets removed. The following 
tissue samples were prepared in blinded groups: 
1) Hypotonic-buffered leaflets; 
2) Decellularised leaflets. 
Samples were prepared by Dr Helen Wilcox according to methods described in Section 
2.8.1. Hypotonic-buffered treatments involved harvesting the tissues and storing them 
in hypotonic buffer prior to implantation. Once prepared, tissue samples were cut into 
3MM2 pieces for implanting. 
In the initial experiment n=3 for each group. At this point it was the intention that when 
the samples were excised the sections would be cut in three using a scalpel. This would 
provide replicates and would enable one tissue piece to be used for haematoxylin and 
eosin staining and Von Kossa's calcification staining, one for cell phenotype analysis 
using immunoperoxidase labelling and one could be digested and used for atomic 
absorption spectroscopy to quantitatively analyse the amount of calcium present. 
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The experiment was later repeated, this time using n==4 for each group. Of the four 
implants for each group it was intended that 3 be used for paraffin embedding as 
described in Section 2.5.1. These samples could then be used for haematoxylin and 
eosin staining and Von Kossa's calcification staining and also for cell infiltration 
analysis using antibodies to CD3, CD4, CD34 and F4/80. The fourth sample was cryo- 
embedded,, as described in Section 2.5.5 in the event of problems With the antibodies 
working effectively on paraffin embedded tissues. 
5.3.2.2. Subcutaneous implantation of tissues into mice 
The biocompatibility of the tissues was tested in a growing mouse subcutaneous implant 
model. Short term anaesthesia was induced using a mixture of halothane and oxygen. 
The mid dorsum of the mouse was aseptically prepared using 70 % methanol. Tissue 
samples (3 mm 2) were implanted subcutaneously between the mid-dorsal line with the 
aid of a sterile trochar. Mice were allowed to recover in an incubator and returned to 
their cages. Mice were fed food and water ad libitum and left for a period of 12 weeks. 
Mice were then killed by schedule (1) and the implanted tissues retrieved for analysis. 
All animal procedures were carried out by Professor E Ingham under Home Office 
licences PPL 40/2409 and PIL 50/00027; 1 assisted. 
5.3.2.3. Haematoxylin and eosin staining 
Haematoxylin and eosin staining of implanted tissues was carried out as described in 
Section 2.5.7. 
141 
CHAPTER 5 
5.3.2.4-Von Kossa's calcification staining 
Materials: Silver nitrate and sodium thiosulphate were purchased from Sigrna-Aldrich. 
Saframn 0 stain was purchased from Raymond A Lamb. 
Method: Tissue sections were dewaxed and rehydrated as described in Section 2.5.3. 
Slides were then transferred to 200ml I% (w/v) silver nitrate solution and left on a 
window ledge for I hour. Slides were then rinsed by immersing the slides in deiorused 
water for 3xI minute prior to being transferred to 200 ml 2.5 % (w/v) sodium 
thiosulphate for 5 minutes. Slides were then rinsed by immersing the slides in deionised 
water for 3xI minute. Slides were counterstained by immersion in Safranin 0 solution 
for I minute prior to being dehydrated and mounted as described in Section 2.5.4. 
5.3.2.5. Cell infiltration phenotyping 
Materials: CD3, CD4,, CD34, F4/80,, and biotinylated rabbit anti-rat, goat anti-rat and 
donkey anti-rat antibodies were purchased and used as described in Section 2.6.5. 
Methods: Immunoperoxidase was carried out on the cryo-embedded explanted tissues 
using the antibodies described above to examine the T-cell. (CD3, CD4), endothelial cell 
(CD34) and macrophage (F4/80) infiltration into the tissue by the host immune system. 
Images were then taken at 400x magnification of the capsule around the implant, at the 
edge of the implant and in the centre of the implant. The numbers of positively labelled 
cells were then counted in a known area with 6 replicates for each area. A 7-point 
scoring system was then developed (Table 5.1) and the scores used to assess the 
infiltration of the cells into the implant. 
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CELL No. SCORE 
0 0 
1-5 1 
6-10 2 
11-15 3 
16-20 4 
21-25 5 
26< 6 
Table 5.1. Scoring system for positively labelled cells in implanted tissues. 
5.3.2.6. Absorption of secondary antibodies 
Despite attempting the immunoperoxidase labelling with all three secondary antibodies 
listed above, all produced high amounts of background staining which made it 
impossible to gain any useful results. Consequently, the antibodies were absorbed 
against pig tissues as follows. 
Materials: Porcine hearts were obtained from a local abattoir within 4 hours of 
slaughter and the aortic valve leaflets dissected out. Secondary antibodies were acquired 
-0--- from companies as described in Section 2.6.5. A blood tube rotator was purchased from 
Fisher Scientific. Centrifugation was carried out using an MSE Micro Centaur 
microcentrifuge (Fisher Scientific). 
Methods: One valve leaflet per antibody per day was finely minced using a scalpel. 
This was then added to the antibody after 1: 5 dilution (to give a volume of 5 ml) using 
TBS azide BSA buffer as described in Section 2.6.1. Antibody/leaflet samples were 
then placed on a blood tube rotator for 24 hours at 4 T. After this point, samples were 
centrifuged at 200 g for 10 minutes in a microcentrifage and the supernatant was 
removed. Further minced leaflets were then added to each antibody sample and returned 
to the rotator for a further 24 hours. This was then repeated for a third incubation. The 
samples were then centrifuged again and the supernatant removed. 
Antibodies were 
then stored at 4T prior to use in immunoperoxidase labelling, as 
described in section 
2.6.1. 
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5.3.2.7. Atomic absorption spectroscopy analysis 
Sample were acid hydrolysed as described in Section 5.3.1.1 before being sent for 
atomic absorption spectroscopy analysis by Dr Ken Newton at Leeds General Infirmary 
Pathology Department, 
5.4. Results 
5.4.1. Biochemical analysis 
5.4.1.1. Hydroxyproline assay 
Decellularised and fresh leaflet samples were hydrolysed and assayed for their 
hydroxyproline content. The results indicated a slight, proportional Increase In the 
amount of hydroxyproline present in decellularised tissue (Table 5.1) 
The results were compared using a student's t-test, which showed there was no 
significant difference between the hydroxyproline content of cellular and acellular 
porcine aortic valve leaflets (Figure 5.1) 
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Figure 5.1. Hydroxyprolline content of fresh and decellularised acid hydrolysed 
porcine aortic tissue. Bars denote 95 % confidence limits 
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Fresh samples (n=6) Decellularised samples (n=6) 
'I: 
DRY WEIGHT MEAN MEAN 
(pg) ABSORBANCE HYDROXYPROLINE 
(470nm) (pg. mg-, ) 
FRESH SAMPLES 5.86e-4 0.9445 41.075 
(n=6) 
DECELLULARISED 3.98e-4 0.8235 53.095 
SAMPLES (n=6) 
Table 5.2. Hydroxyproline content of fresh and decellularised acid hydrolysed 
porcine aortic tissue. 
5.4.1.2. Sulphated proteoglycan assay 
Decellularised and fresh leaflet samples were hydrolysed and assayed for their 
sulphated proteoglycan content. The results demonstrated a slight, proportional increase 
in the amount of sulphated proteoglycan present in decellularised tissue (Table 5.2). 
The results were compared using a student's Mest this showed there was no significant 
difference between the levels of sulphated proteoglycans present in fresh and 
decellulansed porcine aortic valve leaflets, (Figure 5-2). 
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Figure 5.2. Sulphated proteoglycan levels of fresh and decellularised acid 
hydrolysed porcine aortic tissue. Bars denote 95 % confidence limits. 
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Fresh samples (n=6) Decellularised samples (n=6) 
CI HAP IER J 
DRY MEAN MEAN SULPHATED 
WEIGHT ABSORBANCE PROTEOGLYCAN 
(11g) (525nm) (pg. mg-, ) 
FRESH SAMPLES 5.86e-4 0.735 77.80 
(n=6) 
DECELLULARISED 3.98e-4 0.712 105.21 
SAMPLES (n=6) 
Table 5.3. Sulphated proteoglycan levels of fresh and decellularised acid 
hydrolysed porcine aortic tissue. 
5.4.1.3. Fluorometric DNA assay 
Decellulansed and fresh leaflet samples were digested with papain and assayed for their 
DNA content. The results showed a decrease in the amount of DNA present in the 
decellularised tissue (Table 5.3). 
The results were compared using a student's t-test, which showed there was a 
significant difference between the DNA content of cellular and acellular porcine aortic 
valve leaflets, (Figure 5.3). 
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Figure 5.3. Total DNA content of fresh and decellularised papain digested 
porcine aortic leaflets. Bars denote 95 % confidence limits. 
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DRY LUMINESCENCE MEAN 
WEIGHT (Excitation 365nm, DNA 
(lig) Emission 458nm) (pg. mg-1) 
FRESH SAMPLES 4.05 711.19 9.6 
DECELLULARISED 2.07 61.86 1.76 
SAMPLES (n=6) 
Table 5.4. Total DNA content of fresh and decellularised papain digested porcine 
aortic leaflets. 
5.4.2. Biocompatibility study 
5.4.2.1. Morphological and histological examination of implants 
After the initial implantation period, it was realised that cutting each leaflet into three 
pieces for different analyses was problematic. Essentially, the tissue pieces were just too 
small for practical use. The pieces were difficult to manipulate for paraffin embedding 
and then were near impossible to section adequately. Consequently, the experiment was 
repeated using whole tissue samples (n--4) for sectioning and analysis. As described in 
Section 5.3.2.1., of the four implants for each group it was intended that 3 be used for 
paraffin embedding. The fourth sample was to be cryo-embedded in the event of 
problems with the antibodies working effectively on paraffin embedded tissues. 
However, upon explantation of the tissues, only three of the four implants could be 
found in each group, therefore, 2 were paraffin-embedded and the third was cryo- 
embedded 
Hypotonic-buffered leaflet explants 
Implant I (Figure 5.4A) was easily located under the skin of the mouse. Gross 
morphological examination indicated that the tissue had shrunk considerably compared 
to the 3mm 2 tissue size implanted. Also, the tissue itself appeared white in colouring. 
Haematoxylin and eosin staining revealed that the implanted tissue had become highly 
vacuolated and had a necrotic appearance. The remains of a fibrous capsule could be 
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seen around the edge of the implant. Relatively few cells were present in the centre of 
the implant. Those that had penetrated into the tissue appeared to have a varied 
morphology; however, the majority had a fibroblastic appearance. 
Von Kossa's calcification staining indicated that histologically no calcification had 
occurred in this implant (Figure 5.5). 
Implant 2 (Figure 5.4B) was also easily located under the skin of the mouse and was 
also noticeably smaller compared to the 3mm2 tissue size Implanted. Again the tissue 
was white in appearance. 
Haematoxylin and eosin staining showed the remains of a fibrous capsule and that the 
tissue was also vacuolated, although not to the same extent as implant 1. This again 
gave the tissue a necrotic appearance, although in this implant the cell infiltrate was 
more prominent, with cells possessing fibroblastic, polymorphonuclear and 
mononuclear morphologies being present. 
Again, Von Kossa's calcification staining indicated that histologically no calcification 
had occurred in this implant (Figure 5.5). 
Decellularised leaflet explants 
Implant I (Figure 5.4C) could be visualised under the skin of the mouse. Gross 
morphological inspection indicated that the implant had shnmk considerably compared 
to the 3MM2 tissue size implanted and it was also white in appearance. 
Haematoxylin and eosin staining showed that there was no obvious fibrous capsule 
present around the implant and the tissue did not show any vacuoles. The matrix of the 
implant was healthy in appearance and had a prominent cell infiltrate which extended 
into the centre of the implant. Closer examination revealed the presence of cells With 
mononuclear and polymorphonuclear morphologies and also fibroblastic cells. 
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Furthermore, there was evidence of vascularisation of the tissue in the form of 
numerous blood vessels. 
Von Kossa's calcification staining indicated that histologically no calcification had 
occurred in this implant (Figure 5.5). 
Implant 2 (Figure 5AD) was also easily located under the skin of the mouse. Again, 
gross examination revealed that the implant itself was white in appearance and was 
visibly smaller in comparison to the size of the tissue implanted. 
Haematoxylin and eosin staining showed that there was no fibrous capsule present 
around the edge of the implant and the tissue matrix appeared healthy,, without any 
necrotic or vacuolated areas being present. Again cells had infiltrated into the centre of 
the tissue, although they were fewer in number compared to implant I and the cells 
appeared less dense. Both polymorphonuclear and fibroblastic-type cells could be 
observed. Again, vascularisation appeared to have resulted in the formation of some 
new blood vessels in the implant. 
Von Kossa's calcification staining indicated that histologically no calcification had 
occurred in this implant (Figure 5.5). 
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Figure 5.4A. Morphology and histology of tissue implanted subcutaneously for 
12 weeks. A- Hypotonic-buffered leaflet. Top image: location of implant at explantation, 
Lower images. - haernatoxylin and eosin staining. 
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Figure 5.413. Morphology and histology of tissue implanted subcutaneously for 
12 weeks. B. Hypotonic-buffered leaflet. Top image: gross morphology of implant at 
explantation; Lower images: haernatoxylin and eosin staining. 
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Figure 5.4C. Iýlorphology and histology of tissue implanted subcutaneously for 
12 weeks. C: Decellularised leaflet. Top image: location of implant at explantation, 
Lower images: haernatoxylin and eosin staining. 
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Figure 5.413. Morphology and histology of tissue implanted subcutaneously for 
12 weeks. D: Decellularised leaflet. Top image: gross morphology of implant at 
explantation, Lower images: haernatoxylin and eosin staining. 
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Figure 5.5. Von Kossa's calcification staining of aortic valve tissues 
subcutaneously implanted into hairless mice. A&B: Hypotonic-buffered leaflet; C 
& D: Decellularised leaflet; E: mouse skull positive control 
5.4.2.2. Atomic absorption spectroscopy analysis 
Despite repeated attempts, no meaningful data could be obtained from analysing the 
hydrolysed tissue samples by atomic absorption spectroscopy. This was thought to be 
due to the high sodium content of the samples which was present as a result of using 
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hydrochloric acid to hydrolyse the tissues followed by sodium hydroxide to neutralise 
the acid. 
5.4.2.3. Cell infiltration phenotyping 
Initial attempts to immunolabel the paraffin embedded tissues met with no success, 
despite repeated attempts. This was likely to be because the antigens had been cross- 
linked by the formalin fixation and antigen retrieval techniques were unable to retrieve 
the antigens. Consequently, the cryo-embedded tissues were sectioned and cell labelling 
attempted. The initial labelling attempts using a goat anti-rat secondary antibody 
resulted in a high degree of background labelling (Figure 5.6). This was then repeated 
with the washing steps prolonged and after the primary and secondary antibody steps 
the Tween 20 solution used for immunofluorescent labelling (Section 2.6.4) was used 
instead of TBS. This failed to yield any improvement. The procedure was again 
repeated and the incubation period used for blocking the sections with whole serum was 
increased. This also made no improvement, consequently staining was repeated using 
several test sections where different stages were missed out during the labelling 
procedure in order that the point at which the background labelling was occurring could 
be ascertained. This showed that the background staining was due to the secondary 
antibody binding non-specifically to the tissue. Subsequently,, immunolabelling was 
repeated using rabbit anti-rat then later donkey anti-rat secondary antibodies. However, 
the background staining remained using both secondary antibodies. Consequently, it 
was decided to try to absorb out this cross-reactivity by incubating the antibodies with 
I ectively removed the non- minced valve tissue as described in Section 5.3.2.6. This eff 
specific binding, allowing full evaluation of the implanted tissues. 
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Cell 
nuclei 
False 
positive 
staining 
Figure 5.6. F4/80 immunoperoxiclase negative labelling of un-fixed hypotonic- 
treated valve leaflet implanted in mice for 12 weeks. This negative control gave 
brown positive labelling when primary antibody was replaced with buffer. 
Bar represents 25pm. 
Cryo-embedded tissue sections were labelled with antibodies to CD3 (pan-T-cell 
marker), CD4 (T-helper cell marker), CD34 (endothelial cell marker) and F4/80 
(macrophage marker). Images were then taken (example in Figure 5-7) and the cells 
counted and the count scored as described in Section 5.3.2.5 (Figure 5.8). 
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Figure 5.7. Examples of images used for cell scoring. A- overview of section; B: 
middle of tissue section; C: edge of tissue section. Six images were taken from each of 
these areas and the positively labelled cells counted and scored. Sections are from un- 
fixed hypotonic-treated tissue labelled with antibodies to CD3. Secondary antibodies 
were absorbed as described in Section 5.3.12. 
Hypoton ic- buffered leaflets (Figure 5.8A) 
No capsule had formed around this implant therefore only counts at the edge and centre 
of the implant were made. At the edge, F4/80+ cells were in the highest proportion 
(score 4) with fewer CD34+ (score 2) and CD4' cells (score 2). Only low numbers of 
CD3+ cells (score 1) were found here. In the centre, no CD3+ cells were noted with only 
low numbers of CD4+, CD34+ and F4/80+ cells (all score 
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Decellularised leaflets (Figure 5.8B) 
Again, no capsule had formed around this implant therefore only counts at the edge and 
centre of the implant were made. At the edge of the leaflet, low numbers of CD3+ and 
CD4+ were found (both with score 1), but much higher numbers of CD34+ and F4/80--'- 
cells (both with score 4). The proportion of cell types in the centre of the leaflet was 
also similar, this time with no CD3+ cells, low numbers of CD4+ cells (score 1) and high 
numbers of CD34+ and F4/80+ cells (again both with score 4). 
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Figure 5.8A. Average scoring of biocompatibility implants labelled with 
antibodies to CD3, CD4, CD34 and F4180. Hypotonic-buffered leaflet. Bars represent 
95% confidence based on arcsine conversion. 
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Figure 5.813. Average scoring of biocompatibility implants labelled with 
antibodies to CD3, C134, CD34 and F4/80. Decellularised leaflet. Bars represent 95 % 
confidence based on arcsine conversion. 
5.5. Discussion 
Biochemical assays were used to compare the hydroxyproline, sulphated proteoglycans 
and DNA content of digested porcine heart valve tissues both before and after 
decellularisation in order to assess the levels of collagen and glycosaminoglycans 
(GAG) respectively and to verify that all cell DNA had been removed from the tissue 
by the decellularisation procedure. It was found that there no was significant difference 
between the hydroxyproline, and sulphated proteoglycan content before and after the 
decellularisation procedure, indicating that the decellulansation procedure had not 
affected the levels of these components of the tissue. Analysis of the DNA content of 
the leaflet before and after decellularisation revealed that the DNA had been reduced to 
considerably lower levels. It is possible that the apparent remaining DNA was the result 
of a background anomaly (perhaps due to elastin which is known to autofluoresce), 
however,. further experiments with increased DNase treatment (time and/or 
concentration) or longer washing periods after the decellulansation itself would be 
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required to show this more conclusively. Together, these data provide further support to 
the histological analysis described by Booth et aL (2002) and demonstrate that the 
decellularisation procedure developed can remove cellular material without affecting 
the principle constituent components of the valve leaflet matrix. 
A biocompatibility assay was carried out on the valve tissue in order to: a) show that 
calcification had not occurred as a result of failure to remove the decellularisation 
reagents upon completion of the protocol; and b) assess whether the decellulansed 
tissue was immunogenic when implanted in an animal model. The results indicated that 
calcification did not occur in either of the implanted tissue samples, indicating that the 
decellularisation reagents were completely removed during the washing stages at the 
end of the procedure. Further experiments here could improve the acid-hydrolysis of the 
tissue in order to more precisely quantify the calcium content to compare the hypotonic- 
treated tissue with the decellularised leaflets by use of atomic absorption spectroscopy. 
This technique is capable of measuring very small quantities of calcium that might not 
be visible by histological evaluation and would further confirm that no calcification had 
occurred. 
An analysis of the phenotype of the cells that had infiltrated into the implanted tissues 
indicated favourable results. Here, high numbers of CD3+ and CD4+ cells would 
indicate a specific T-cell mediated response equivalent to rejection of the tissue. F4/80' 
cells would indicate the presence of macrophages, which could, in the absence of T- 
cells indicate a wound-healing type response, as these cells would provide signals 
for 
CD34 + endothelial cells, which are involved in vascularisation of the tissue. 
However, 
the numbers of macrophages should fall after a while as the tissue is incorporated and 
remodelled by the host. The principle tissue 
being investigated here, namely the 
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decellulan*sed leaflet, showed a low T-cell infiltrate with high numbers of macrophages 
and endothelial cells,, suggesting that the leaflet might be being remodelled by the 
mouse model. Furthermore,, the haematoxylin and eosin staining revealed that the centre 
of the implanted decellularised tissues appeared to be living and healthy. There was a 
prominent cell infiltrate consisting of both fibroblasts and mononuclear cells and some 
regeneration had occurred, as indicated by the presence of blood vessels in the 
implanted tissues. In contrast, the centre of the implanted hypotonic-buffered tissues 
appeared to be highly vacuolated and necrotic with no vascularisation and the remains 
of a fibrous capsule could be seen around the implants. This indicated that the 
implanted decellularised tissue was in the process of being remodelled and integrated 
whereas necrosis of the hypotonic-buffered tissue indicated that the tissue was starved 
of oxygen and dying. Further experiments here would need to show definitively that the 
decellularised tissue was biocompatible using more replicates and that the numbers of 
macrophages falls in the later stages of remodelling to show that the host immune 
response was not a continued presence in the tissue in a non-specific manner. However, 
this would require an implantation period of up to 6 months rather than the 3 months 
investigated here. 
In conclusion,, biochemical analyses revealed that the decellularisation procedure 
efficiently removed cellular material without damaging the principle matrix 
components, namely collagen and glycosaminoglycans. An examination of the 
biocompatibility of the un-fixed decellularised tissue indicated that the decellularisation 
reagents were efficiently removed at the end of the procedure and the tissue appeared to 
be in the process of being remodelled and incorporated by the host tissues. 
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CHAPTER 6: 
Study of the Capacity of hAMSC to 
Re--seed Decellularised Porcine Aortic 
Valve Matrices 
Introduction 
he decellularised porcine aortic valve tissue had been found to be biocompatible 
and did not lead to an adverse inflammatory response or calcification in vivo. 
The matrix structure was also retained after the decellularisation procedure. The next 
phase was to determine whether it was possible to re-seed the aortic valve matrix with 
hMSC in vitro. Prior to reseeding, however,, it was important to establish conditions for 
culturing the reseeded valve tissue. In order to determine whether the mass transfer of 
oxygen and nutrients into cells within valve tissue would be sufficient, freshly isolated 
porcine aortic valves were cultured in vitro. At this stage, a basic system of static 
culture was deemed the most appropriate to use, however, it was important to ascertain 
whether the cells could be maintained in this way and also what effect this system had 
on the matrix, i. e. whether it remained intact, or whether it degenerated since the in 
vitro environment lacked the mechanical and biochemical stimulation present in situ. 
The next step was to reseed hMSC into a decellularised aortic valve leaflet to assess 
how effective the cells were at repopulating the tissue without biochemical or 
mechanical stimulation. As a comparison, human smooth muscle cells were also 
reseeded in order to establish whether either cell type was more effective 
for 
repopulating the leaflets. The density of the re-seeded cells was then compared to the 
cell density found in a human aortic homograft valve as a means of measuring the 
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success of the re-seeding attempts. Once the reseeding culture period was complete. it 
was also necessary to compare the phenotype of the reseeded cells with that of native 
valve cells to ensure that the cells retained an appropriate phenotype, and also to ensure 
that the reseeded hMSC had not differentiated into an undesirable phenotype. 
6.2. Aims & objectives 
The aims and objectives of this chapter were to firstly devise a method for culturing 
freshly isolated valve tissue. This system could then be applied to decellularised porcine 
aortic valve leaflets reseeded with both human mesenchymal stem cells (hMSC) and 
human smooth muscle cells (hSMC) in order to establish the optimal cell concentration 
required for cell adhesion and migration/infiltration into the decellularised tissue. The 
cell phenotype would then be analysed to establish whether the reseeded cells had 
maintained their phenotype and whether it was comparable to native homograft valve 
cells. The specific objectives were to: 
9 Determine the capacity of aortic valves to maintain cells and matrix in culture 
9 Determine the cell number and distribution in fresh valve leaflets 
* Determine the degree of attachment and infiltration of the re-seeded cells 
e Determine the phenotype of the re-seeded cells as compared to native valve 
interstitial cells. 
6.3. Materials& methods 
6.3.1. Intact static leaflet culture 
6.3.1.1. Culture conditions 
Materials: Nunc 6-well tissue culture plates were obtained from Fisher Scientific. Steel 
rings and stainless-steel mesh were gifts from Mr Devon Darby. 
Prolene surgical 
sutures (size 4.0) were purchased from NHS Supplies. 
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Method: Aortic heart valve leaflets were dissected under aseptic conditions from pig 
hearts obtained from a local abattoir, Duplicate samples were then placed in individual 
wells of 6-well plates and 5 ml of complete medium was added. The leaflets were 
weighted down with sterile steel rings to ensure they were completely covered in 
medium. The medium was changed every two to three days, as required, and leaflets 
were harvested at 0,1 ýP 2, and 3.81,15 and 22 days in the first experiment. In a second 
experiment, leaflets were sutured to a stainless steel mesh for the duration of the culture 
period and were harvested at 0,7,14,21,28 and 35 days. Leaflets were then paraffin- 
embedded and sectioned as described in Section 2.5. 
6.3.1.2. Haematoxylin and eosin staining 
Haematoxylin and eosin staining was carried out as described in Section 2.5.7. 
6.3.1.3. Alcian blue staining 
Materials: Alcian blue and acetic acid were purchased from Sigma-Aldrich. Alcian 
blue stain consisted of Ig of alcian blue dissolved in 100 ml of 2% (v/v) acetic acid 
solution. 
Method: Sections were first dewaxed and rehydrated using xylene and graded alcohols 
as described in Section 2.5.3. Slides were then briefly dipped in 2% (v/v) acetic acid 
prior to being immersed in alcian blue stain for 20 minutes. Slides were then carefully 
blotted dry using tissue paper and counterstained by immersion in haematoxylin 
solution for I minute. Slides were then rinsed in running tap water for 5 minutes prior to 
being dehydrated and mounted as described in Section 2.5.4. 
164 
CHAPTER 6 
6.3.1.4. Antibody labelling of fresh-cultured leaflets 
Materials: Kj67,, collagen 1, and elastin antibodies were purchased and used as 
described in Section 2.6.5. 
Methods: Immunoperoxidase labelling of fresh-cultured valve leaflets was carried out 
as described in Section 2.6.1. 
6.3.1.5. Assessment of cell density 
Cell density was calculated by calibrating the haematoxylin and eosin images shown 
and placing a circle of known area randomly at different points (n=6). The number of 
cells in these areas was then counted and an average taken. The standard deviation and 
95 % confidence limits were then calculated. This was performed at the beginning and 
end of the culture period for both free-cultured and statically cultured leaflets. 
6.3.2. Re-seeding of decellularised leaflets 
6.3.2.1. Isolation of human smooth muscle cells from saphenous vein 
This was carried out according to the methods described in Section 2.7.1. 
6.3.2.2. Source of hMSC 
All hMSC used for osteogenic cell phenotyping and re-seeding of decellularised 
matrices were from sample hBMI at passage 8. 
6.3.2.3. Osteogenic cell phenotyping 
There was concern since the FACS analysis in Chapter 4 had revealed that a proportion 
of the hMSC were alkaline phosphatase positive Consequently, it was 
decided to assess 
the phenotype of the hMSC seeded into the matrix in relation to the osteogenic 
phenotype. 
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Materials: Osteonectin, osteopontin and alkaline phosphatase monoclonal antibodies 
were purchased and used as described in Section 2.6.1. Multi-spot slides were 
purchased from C. A. Hendley. Methanol and acetone were purchased from VWR. 
Method: hMSC (hBMI) at P8 were seeded onto multi-spot slides and cultured for 3 
days. The cells were then fixed for 2 minutes in methanol: acetone (50: 50, v/v) prior to 
being stored at -20 OC. Slides were thawed when required and immunoperoXidase 
labelling carried, out as described in Section 2.6.1. 
6.3.2.4. Assessment of adhesion and cell infiltration 
Materials: Nunc 6-well tissue culture plates were obtained from Fisher Scientific. 
Multi-spot slides were purchased from C. A. Hendley. Methanol and acetone were 
purchased from VWR. Porcine heart valves were obtained from a local abattoir and had 
been decellularised and cryo-preserved as described in Section 2.8. 
Methods: Previously decellularised porcine aortic heart valve leaflets (10 leaflets per 
cell concentration, per cell type) were thawed from cryopreservation as described in 
Section 2.8.3. Leaflets were then disinfected as described in Section 2.8.4 prior to being 
washed for 3x 30min in PBS on a shaker at room temperature. Leaflets were then placed 
into 6-well tissue culture plates, laid flat and 2 ml complete mediw-n added to each well 
to keep the leaflets hydrated whilst cells were counted and prepared. The relevant cells 
were then counted using a haemocytometer as described in Section 2.4.2 and sufficient 
cells were carefully added drop-wise in 2 ml of complete medium (as described in 
Section 2.4.1) at tbree concentrations of 
IX 104 
, 5x 
104 and Ix 105 cells. CM-2 after 
removal of the medium used to keep the leaflets hydrated. The hSMC used were seeded 
at passage 5 and the hMSC used were seeded at passage 8 and cultured under standard 
conditions as described in Section 2.4.1. After 24 hours, a 
further I m-1 of complete 
medium was added to each well. After 3 days of culture, 
leaflets were transferred to 
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new 6-well plates so those cells that had adhered to the tissue culture plastic rather than 
the leaflets did not consume the nutrients in the medium. Leaflets were then carefully 
fed twice weekly with 3 ml of complete medium. Two leaflets were harvested at 24 
hours for scanning electron microscopy (SEM) analysis and then 2 each at 1,25 3 and 4 
weeks after seeding for each cell type and were embedded and sectioned for 
visualisation using haematoxylin and eosin staining, as described in Section 2.5.7. The 
length of the free edge of the leaflets cultured for 4 weeks was measured before and 
_. rý after the culture period to ascertain the degree of leaflet contraction. This was then 
converted to a percentage reduction in area of the leaflet and this value was used to 
calculate the true cell density without contraction in order for a direct comparison with 
the native homograft leaflets to be made. 
6.3.2.5. Preparation of samples for scanning electron microscopy (SEM) 
Materials: A series 3 330BM CamScan scanning electron microscope was purchased 
from Obducat CamScan. Acetone was purchased from VWR. 
- Samples were fixed in formalin solution (Section 2.3.3) for 24 hours prior to Methods. 
being dehydrated in ascending acetone concentrations of 20,. 40,601) 80, and 100 % (v/v) 
for 30 minutes each. Samples were then critical-point dried before being sputter-coated 
in gold and viewed by SEM. The images captured were digitally scanned for computer 
manipulation using a Minolta Dimage Image Scanner attached to a personal computer 
using Adobe Photoshop 5.5 software. 
6.3.2.6. Antibody labelling of re-seeded leaflets 
Antibody labelling of the re-seeded leaflets was carried out in order to show that seeded 
hMSC had not differentiated once within the tissue into any of the lineages previousiv 
described. 
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Materials: Antibodies were purchased and used as described in Section 2.6.1. 
Methods: Both aortic homografts and hMSC reseeded leaflets were labelled using 
antibodies to aSMA,, vimentin, desmin, and HCMs, which are all markers of the smooth 
muscle cell phenotype, and tau, NSE, collagen 11, alkaline phosphatase, osteonectin and 
osteopontin. 
6.3.2.7. Cell counting of aortic homografts and reseeded leaflets 
Materials: Two aortic homograft valves that were no longer suitable for clinical use 
had subsequently become available for research purposes and were obtained from the 
National Blood Service. Image Pro Plus software was supplied by MediaCybernetics 
UK 
Methods: The leaflets were dissected from the homograft valves, and paraffin 
embedded as described in Section 2.5.1. Decellularised leaflets reseeded with both 
human smooth muscle cells (hSMC) and human mesenchymal stem cells (hMSC) and 
cultured for four weeks were also harvested and paraffin embedded. Serial sections of 
each of the leaflets with a thickness of 4pm were then made and every 15 th section for 
the homograft leaflets and every I Oth section for the reseeded leaflets were mounted 
onto a slide. Once 50 sections from each leaflet had been mounted, the sections were 
stained with haernatoxylin and eosin and photographed. Image Pro Plus software was 
then used to calibrate the images and draw three circles in each of the three tissue 
layers. The area of the circles was then measured, and the number of cells within each 
counted. This is illustrated in Figure 6.1. The number of cells per square micrometer 
was then calculated for each tissue layer in each image, and the average cell number per 
area was calculated for each of the tissue layers in each leaflet. A companson of cell 
number between the homografts and the reseeded tissues was then made as a measure of 
the success of the reseeding experiments. 
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Figure 6.1. Diagram showing areas used for cell counting in the homografts and 
re-seeded leaflets. Three circles of known area for each tissue layer were placed over 
the image and the number of cells in each circle counted. The count was then divided 
by the area of the circle and the mean number of cells per square micrometer 
throughout each leaflet established. Bar represents 100 pm. 
6.4. Results 
6.4.1. Assessment of cultured porcine aortic valve leaflets 
6.4.1.1. Haematoxylin & eosin staining of free-cultured valve leaflets 
Freshly dissected porcine aortic heart valve leaflets were statically cultured in complete 
medium for up to 22 days. The leaflets were then embedded and stained with 
haematoxylin and eosin, as described in Section 2.5.7 in order to assess the overall 
tissue structure (Figure 6.2). By day 22 it appeared as though the cells had proliferated 
considerably as the cell density appeared visually to be much higher when compared to 
a time zero tissue sample. This was later verified in a comparison of cell densities at the 
beginning and end of the culture period (Figure 6.5), which showed that there was a 
significant difference in the cell density at the beginning and end of the culture period. 
T: \\\ :: 
169 
CH. 4p TER 6 
Sol. 
Is. 
41b 
w VA 41 - 
jo 
,"0., 
Al 
Do 
- ,,, , 
qt I. 1; 0. %4 
'1 4p .4 
I' 16 4 
10 
V Ot I 041, -. 4"-1 .4,1. '0 -ý L 
Sr 
,0, "NI 'r .4",. ItIIý 1-; 10 "I ý' J, I, -. r. - %, -. 
"t ý, at ,9 
Figure 6.2. Haernatoxylin and eosin staining of statically cultured heart valve 
leaflets. A: t=1 day, B. t=22 days. Purple shows the haernatoxylin-stained cell nuclei, 
pin s ows the eosin-stained cytoplasm/matrix (x200). 
6.4.1.2. Ki-67 Labelling of free-cultured valve leaflets 
The cells were stained using an antibody specific for the Ki67 antigen (Figure 6.3). 
Histological examination revealed only a low number of positive cells. The number of 
nuclei positively labelled was highest at time zero, but after 5 weeks, few positively 
stained cells could be seen on the leaflets. 
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F- igure 6.3. Ki67 antibody labelling of statically cultured heard valve leaflets. A: 
t=O (x200); B: t=22 days (x1OO). Arrows highlight the brown Ki67 positive nuclei, purple 
corresponds to haernatoxylin counterstain. 
6.4.1.3. Haematoxylin & eosin staining of suture-cultured valve leaflets 
In order to counteract the shrinkage of the leaflets observed previously, the 
leaflet 
culture was repeated, but this time the leaflets were cultured statically under standard 
conditions whilst sutured to a steel mesh. Tissues were then 
harvested at time zero, 7, 
1411 21,28 and 35 days. The morphology of the cultured leaflets was assessed using 
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haernatoxylin and eosin staining (Figure 6.4). In this case, the nuclei appeared to remain 
as spread as the time zero sample and no shrinkage of the leaflet was observed. To 
investigate this further, a comparison of the cell densities of the images shown 
demonstrated that the suture culture method had maintained the cell density at a 
constant level (Figure 6.5). 
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Figure 6.4. Haernatoxylin & eosin staining of suture-cultured valve leaflet. A: t= 
Owk; B- t= 6wk. 
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Figure 6.5. Comparison of cell density from before and after culture of leaflets 
cultured freely and sutured to steel mesh. Solid bar shows density at beginning of 
culture, patterned bar shows density at end of culture. Error bars show 95 
% 
confidence limits. 
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6.4.1.4. Ki67 Labelling of suture-cultured valve leaflets 
The cells were again stained using an antibody specific for the Ki67 antigen in order to 
establish whether the cells were actively proliferating (Figure 6.6). Labelling again 
revealed that only a small number of cells were positive for the antigen and by 5 weeks 
no positively stained cells could be found at all. 
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Figure 6.6. Ki-67 labelling of suture-cultured valve leaflets. A- t Owk; B: t 5wk. 
(x200). Arrows highlight the brown Ki67 positive nuclei, purple corresponds to 
haernatoxylin counterstain. 
6.4.1.5. Alcian blue staining of suture-cultured valve leaflets 
Alcian blue stains glycosaminoglycans (GAGs), an important constituent of the 
spongiosa layer of the valve leaflets which is thought to be responsible for dissipating 
the strong forces endured by the valve leaflet [Schoen, 1999]. The blue extracellular 
staining of the leaflets (Figure 6.7) showed how although initially there was a prominent 
band of GAGs in the central spongiosa layer, after 5 weeks this disappeared leaving 
only a weaker blue GAG staining throughout all the valve leaflet layers. 
172 
CHAPTER 
A 
11 - 
B 
Figure 6.7. Alcian blue staining of suture-cultured valve leaflets. A: t Owks, B- t 
5wks. Note prominent localised blue staining in A (arrows) compared to diffuse staining 
in B (x200). 
6.4.1.6. Elastin labelling of suture-cultured valve leaflets 
Elastin, present in the ventricularis layer, has a vital role in providing leaflet tissue with 
an elastic property which allows the leaflets to be stretched against the aorta when the 
valve is open, and pulls the leaflets back to occlude the valve when it closes. 
Consequently an antibody to elastin was also used to stain the leaflets to see whether 
this important flexibility-giving protein had been maintained during the culture period. 
The brown labelling of the leaflets (Figure 6.8) shows long elastin chains at time zero 
which degraded and fragmented during the course of 5 weeks of static culture. 
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Figure 6.8. Elastin labelling of suture-cultured valve leaflets. A: t Owk, B- t 5wk 
(x200). Brown staining shows elastin chains that became fragmented by 5 weeks. 
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6.4-1-7. Collagen I labelling of suture-cultured valve leaflets 
Collagen I is the major strength-giving component in aortic heart valve leaflets where it 
features most prominently in the fibrosa layer. Here it forms macroscopically crimped, 
densely packed fibres which are arranged parallel to the leaflet's free edge. These 
crimps expand during backpressure to ensure the valve is fully occluded. Thus it was 
also necessary to assess how the collagen I was affected during static culture. The 
brown staining (Figure 3.8) indicated that the collagen was unaffected during the 
culture period and remained histologically intact. 
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Figure 6.9. Collagen I labelling of suture-cultured valve leaflets. A- 3 week culture-, 
B: 6 week culture. Brown staining shows presence of collagen 1, purple shows 
counterstained cell nuclei. Bar represents 50 pm. 
6.4.2. Re-seeding of decellularised leaflets 
6.4.2.1. Scanning electron microscopy (SENI) analysis of decellularised aortic 
valve leaflets reseeded with human mesenchymal stem cells. 
Twenty-four hours after seeding was carried out, samples were harvested for SEM 
analysis to establish whether sufficient cells had been applied to the tissue to give a 
monolayer of cells on the surface of the leaflet. The results of the SEM analysis 
indicated that at Ix 104 cells CM-2, the cells were spread out over the surface of the 
leaflet and were frequently not in physical contact with neighbouring cells. At a 
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concentration of 5x 10 
4 
cel IS. CM-2 a monolayer of cells was observed which were mostly 
in direct contact with neighbouring cells. At a concentration Ix 105 cells CM-2, the cells 
could be seen to be piled on top of one another with the many cells not in direct contact 
4 -2 with the matrix itself Consequently, a concentration of 5x 10 cells cm was deemed 
the most appropriate concentration to use (Figure 6.10). 
cells. CM-2 ; B: cells seeded at 5x 
104 cells CM-2 ; C: cells seeded at 
1X105 cel IS. CM-2 
6.4.2.2. Haematoxylin and eosin staining analysis of decellularised aortic valve 
leaflets reseeded with human mesenchymal stem cells 
Samples were harvested after 1,2,3, and 4 weeks, paraffin embedded, sectioned and 
stained using haematoxylin and eosin as 
described in Section 2.5 in order to assess 
whether the cells had migrated 
into the leaflet. The results indicated that some cell 
migration into the tissue 
had occurred (Figure 6.11). Measurement of the length of the 
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Figure 6.10. Scanning electron microscopy (SEM) of decellularised aortic valve 
leaflets reseeded with human mesenchymal stem cells. A- cells seeded at 1 X104 
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free edge of the leaflets cultured for 4 weeks both before and after culture indicated that 
the free edge had shrunk from 21.5 mm to 10 mm on leaflet A, and from 20 mm to 9 
mm on leaflet B. This corresponded to an area reduction by 80 % for leaflet A and 78 % 
for leaflet B. 
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Figure 6.11. Haernatoxylin and eosin staining of decellularised aortic valve 
leaflets reseeded with human mesenchymal stem cells. Cells seeded at 5x1 04 
cells C; M-2, cultured for 4 weeks. 
6.4.2.3. Scanning electron microscopy (SEM) analysis of decellularised aortic 
valve leaflets reseeded with human smooth muscle cells. 
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Samples were harvested twenty-four hours after seeding for SEM analysis in order to 
establish whether sufficient cells had been applied to the tissue to give a monolayer of 
cells on the surface of the leaflet. The results of the SEM analysis indicated that at 
1XI04 cells CM-2 , the cells were spread out over the surface of the leaflet and were 
frequently not in physical contact with neighbouring cells. At a concentration of 5x 104 
cells CM-2 a monolayer of cells was observed which were all in direct contact with 
neighbouring cells. At a concentration Ix 
105 cells CM-2, the cells could be seen to be 
piled on top of one another with the many cells not in direct contact with the matrix 
itself Consequently, a concentration of 5x 104 cells CM-2 was deemed the most 
appropriate concentration to use (Figure 6.12). 
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leaflets reseeded with human smooth muscle cells. A: cells seeded at 1X104 
CM-2 04 CM-2. IS. CM-2 cells. ; B: cells seeded at 5xl cells. I 
C: cells seeded at 1x 105 cel 
6.4.2.4. Haematoxylin and eosin staining analysis of decellularised aortic valve 
leaflets reseeded with human smooth muscle cells 
Samples were harvested after 1,2,3, and 4 weeks and stained using haematoxylin and 
eosin as described in Section 2.5.4 in order to assess whether the cells had migrated into 
the leaflet. The results indicated that no cell migration into the matrix had occurred and 
instead, the cells had remained on the surface of the leaflets (Figure 6.13). Measurement 
of the length of the free edge of the leaflets cultured for 4 weeks both before and after 
culture indicated that the free edge had shrunk from 24 mm to 12 mm on leaflet A, and 
from 21 mm to II min on leatlet B. This corresponded to an area reduction of 75 % for 
leaflet A and 73 % for leaflet B. 
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Figure 6.12. Scanning electron microscopy (SEM) of decellularised aortic valve 
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Figure 6.13. Haernatoxylin and eosin staining of decellularised aortic valve 
leaflets reseeded with human smooth muscle cells. Cells seeded at 5xl 04 cells. cm- 
cultured for 4 weeks. In both images, no cells can be seen to have migrated into the 
valve tissue and instead remain on the surface. Bar represents 100 ýtm. 
6.4.2.5. Cell counting of human aortic homograft valves 
Two homograft valves were serially sectioned and the cells within each cell layer in 
each leaflet counted and compared (Figures 6.14,6.15 and 6.16). There was a slight 
overall difference between the cell numbers between the two valves: however, patient 
details were only available for the first valve, which was taken from a 46 yr old 
immunosuppressed male. 
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Figure 6.14. Cell counting of human aortic homograft valve 1. Cell number in each 
of the tissue layers is presented as the mean (n=1 50) ± 95 % confidence limits. 
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Figure 6.15. Cell counting of human aortic homograft valve 2. Cell number in each 
of the tissue layers is presented as the mean (n=150) ± 95 
% confidence limits. 
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Figure 6.16. Combined cell counting of both human aortic homograft valves. Cell 
number in each of the tissue layers in the two valves combined is presented as the 
mean (n=2) ± 95 % ronfidence limits. 
6.4.2.6. Cell counting of decellularised aortic valve leaflets reseeded with 
human mesenchymal stem cells 
Two leaflets reseeded with hMSC at a density of 5x 
104 cells. CM-2 were harvested and 
serially sectioned. The cells within each cell layer within each leaflet were counted and 
the cell densities determined, incorporating the reduction in surface area of the leaflets 
during culture discussed earlier (Figure 6.19). 
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Figure 6.17. Cell counting of aortic valve leaflet I reseeded with human 
mesenchymal stem cells. Cell number in each of the tissue layers is presented as the 
mean (n=1 50) ± 95 % confidence limits. 
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Figure 6.18. Cell counting of aortic valve leaflet 2 reseeded with human 
mesenchymal stem cells. Cell number in each of the tissue layers is presented as the 
mean (n=150) ± 95 % confidence limits. 
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Figure 6.19. Cell counting of two aortic valve leaflets reseeded with human 
mesenchymal stem cells. Cell number in each of the tissue layers is presented as the 
mean (n=2) ± 95 % confidence limits. 
6.4.2.7. Cell counting of decellularised aortic valve leaflets reseeded with 
human smooth muscle cells 
Despite serially sectioning the leaflets reseeded with human SMC in order to look for 
cell migration , it was 
found that none of the cells had migrated into the tissue and 
instead they remained on the tissue surface (Figure 6.13). Consequently no cell counting 
could be carried out on these leaflets. 
6.4.2.8. Comparison of cell density of reseeded valve leaflets compared to 
human aortic homograft valves 
A comparison of the combined cell densities of the homografts and hMSC reseeded 
valve leaflets was made (Figure 6.20). The percentage reseeding was then calculated by 
setting the mean cell density in the respective valve layers of the homografts as 100 % 
and comparing the reseeded valve leaflet layers to this level. This gave a reseeding level 
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of between 0.5 % and 2 %,, taking into account the reduction in leaflet area during the 
culture period. 
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Figure 6.20. Comparison of cell density of reseeded valve leaflets compared to 
human aortic homograft valves. Top graph: comparison of cell densities between 
homografts and hMSC reseeded tissues Cell number in each of the tissue layers is 
presented as the mean (n=1 50) ± 95 % confidence limits; Lower graph: percentage of 
cells reseeded relative to homograft valve. 
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6.4.2.9. Antibody labelling of hMSC used for re-seeding 
Prior to re-seeding the decellularised matrices, it was first deemed necessary to establish 
the phenotype of the cells used with reference to the osteogenic lineage. The FACS 
analysis carried out in Chapter 4 indicated that the cells were AP"-, which suggested 
that the cells could have been differentiating into cells of the osteogenic lineage. 
Therefore, to further determine if this was the case, the cells were also labelled with 
antibodies to osteonectin and osteopontin which were both deemed to be markers of the 
osteogenic lineage (Figure 6.21). 
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Figure 6.21. Immunoperoxidase labelling of hMSC at P8 with osteogenic 
markers. A: alkaline phosphatase labelling; B: osteonectin labelling; C: osteopontin 
labellin: D. negative control. Brown staining indicates positive antibody labelling, blue 
shows haematoxylin counterstaining of cell nuclei. Bar represents 25 pm. 
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6.4.2.10. Antibody labelling of reseeded valve leaflets 
Both the homografts and reseeded tissues were labelled with various antibodies to 
compare the cell phenotype and also to ensure that the seeded cells had not 
differentiated into undesirable lineages. The cells in the tissues were negative for 
neurone specific enolase (Figure 6.22), tau, heavy chain myosin slow, desmin, and 
collagen 11 (Figure 6.23. shows positive controls for these antibodies). 
A 
C 
B 
D 
leaflet reseeded with hMSC; C: leaflet reseeded with hSMC; D: Porcine optic nerve 
positive control. Brown staining indicates positive antibody labelling, blue shows 
haematoxylin counterstaining of cell nuclei. Bar represents 100 pm. 
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Figure 6.23. Positive controls used to for antibody labelling of homograft leaflets 
and reseeded valve leaflets. A: tau control on porcine optic nerve; B- heavy chain 
myosin slow control on porcine heart muscle, C: desmin on porcine bowel wall, D: 
collagen 11 control on bovine cartilage. Brown staining indicates positive antibody 
labelling, blue shows haernatoxylin counterstaining of cell nuclei. Bar represents 100 
pm. 
Labelling with antibodies to both (x-smooth muscle actin and vimentin revealed that 
both the hMSC and hSMC reseeded cells had a phenotype similar to the cells of the 
native homograft tissue (Figures 6.24, and 6.25. ). However, aSMA labelling of the 
reseeded hMSC revealed a mixed population of aSNLA+l- cells. 
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Figure 6.24. a-smooth-muscle actin labelling of a homograft leaflet and valve 
leaflets reseeded with hMSC and hSMC. A: homograft; B- leaflet reseeded with 
hMSC; C: leaflet reseeded with hSMC; D: negative control. Brown staining indicates 
positive antibody labelling, blue shows haematoxylin counterstaining of cell nuclei. 
4 
A 
187 
CH. 4p TER 6 
ks 
le I. I -s " 11 \, 0 tý . 
ft S, ýt ., ý. #-et, 1r;. 
, 
Figure 6.25. Vimentin labelling of a homograft leaflet and valve leaflets reseeded 
with hMSC and hSMC. A. homograft; B: leaflet reseeded with hMSC; C-. leaflet 
reseeded with hSMC; D: Negative control. Brown staining indicates positive antibody 
labelling, blue shows haernatoxylin counterstaining of cell nuclei. 
Immunoperoxiclase labelling with an antibody to alkaline phosphatase (AP) revealed 
that although the homograft cells and the reseeded hSMC were AP-, as would be 
expected, the reseeded hMSC were shown to be AP+ (Figure 6.26). Further analysis of 
the osteogenic phenotype of the cells was then carried out using antibodies to 
osteonectin and osteopontin. The reseeded cells appeared to be unifonnly positive for 
osteonectin. and osteopontin (Figure 6.27). 
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Figure 6.26. Alkaline phosphatase labelling of a homograft leaflet and 
decellularised valve leaflets reseeded with hSMC and hMSC. A- homograft; B: 
leaflet reseeded with hSMC; C: leaflet reseeded with hMSC; D: negative control. Brown 
staining indicates positive antibody labelling, blue shows haernatoxylin counterstaining 
of cell nuclei. 
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Figure 6.27. Osteonectin and osteopontin immunoperoxidase labelling of 
decellularised leaflet reseeded with hMSC. A: osteonectin; B: osteopontin labelling; 
C: negative control. Brown staining indicates positive antibody labelling, blue shows 
haernatoxylin counterstaining of cell nuclei. 
6.5. Discussion 
Leaflets were initially statically cultured by being weighted down in complete medium 
and cultured under standard conditions. However, with nothing restraining the tissue, 
shrinkage of the leaflets occurred. This gave the appearance that the cells had multiplied 
rapidly. However, qualitative histological analysis of the leaflets using an antibody to 
Ki67 indicated that few cells were positive for this marker. Ki67 protein expression is 
thought to be linked to cell proliferation as it has been found to be expressed during all 
the active phases of the cell cycle (GI, S, G2and mitosis) but not the resting phase (GO) 
[Scholzen & Gerdes, 2000]. Consequently, it was realised that shrinkage of the leaflet 
had merely brought the cells closer together and had given the appearance of an 
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increased cell number. This was later demonstrated by comparing the cell density 
before and after the culture period, which showed a significant increase in cell density 
after 4 weeks culture. Consequently, the experiment was repeated with the leaflets 
sutured to steel gauze to try to prevent shrinkage. Haematoxylin and eosin staining of 
these leaflets showed that shrinkage was being prevented and that the cells remained 
evenly spread throughout the leaflet. The cell density before and after the culture period 
was also not significantly different. Furthennore, histological analysis of M67 
immunoperoxidase labelling revealed few positive cells and therefore limited cell 
proliferation. Whether or not this is a typical finding of the level of proliferation of 
valve cells is not possible to assess as no-one else in the literature has assessed this 
feature of the cells. 
Alcian blue stain was used to stain the glycosaminoglycans (GAGs) present in the valve 
tissue and the results indicated that, although the centrally located sponglosa was 
stained most heavily before culturing, after 5 weeks the stain was more diffuse across 
all three layers of the valve tissue. This indicated that the predominantly GAG-based 
spongiosa had undergone some degradation. This may have been due to a lack of 
mechanical stimulation resulting in reduced GAG synthesis by the spongiosa cells. 
Similarly, maintenance of the elastin in the ventricularis layer may have been affected 
by the lack of mechanical stimulation and this corresponded well with elastin 
immunoperoxidase labelling which showed that the long elastin chains gradually 
degraded and fragmented as the culture period progressed. An antibody to collagen 1, 
however, indicated that histologically the collagen appeared not to have been affected 
during the culture period. 
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In conclusion, it was deemed that the conditions used to culture the freshly isolated 
valve leaflets were suitable for culturing reseeded valve tissue. Although leaflet 
shrinkage was prevented by suturing the leaflets to steel gauze, both elastin and GAGs 
appeared to have degraded during the culture period. Therefore this method was not 
used for the reseeded leaflets. It is likely that mechanical stimulation would have been 
necessary in order to provide the coffect conditions to induce the cells to maintain and 
remodel the tissue to ensure that the elastin and GAGs were maintained. However, this 
would form part of future detailed studies. 
Both human mesenchymal stem cells (hMSC) and human smooth muscle cells (hSMC) 
were seeded onto decellularised aortic valve leaflets at concentrations of Ix 104 , 5x 104 
and IxIO 
5 
cells. CM-2 . After 24 hours of culturing, SEM analysis for both cell types 
showed that a seeding density of 5x 10 
4 
cells. CM-2 resulted in a confluent monolayer 
forming across the surface of the leaflet. A monolayer was preferable at this stage 
because observations have indicated that hMSC grow poorly at low cell density and 
rapidly develop a flat, spread morphology with little cell proliferation taking place. In 
contrast, a high cell density would result in a more rapid consumption of nutrients and 
many cells would not be in contact with the matrix itself, which would be likely to 
result in cell death, leading to the release of toxins, which could harm other cells. 
Although cells were only seeded onto one side of the valve leaflets, histological analysis 
revealed cells on both side of the leaflets, indicating that the cells had migrated around 
the edge of the leaflet. However, although low numbers of hMSC had migrated into the 
tissues varying distances over the course of the culture period, reseeded hSMC 
remained entirely on the surface of the tissue and did not penetrate into the tissue at all. 
This indicated another potential advantage of hMSC over terminally differentiated cells 
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such as hSMC for tissue engineering purposes as this result suggests that hMSC may be 
more versatile at adapting to growth in tissue matrices; being capable of developing a 
migratory phenotype to assist cell penetration and repopulation of acellular tissues. 
A comparison of the cell counts of the leaflets reseeded with hMSC with the homograft 
tissue revealed that the leaflet had only been repopulated to between 0.5 and 2%. Cells 
had mainly only penetrated into the fibrosa and ventricularis layers with relatively few 
cells reaching the central spongiosa layer. Future experiments here could try to improve 
the repopulation of the tissue by treating the surface of the tissue to try to improve 
migration of seeded cells into the tissue. For example, the tissue could be briefly treated 
with enzymes or perhaps physically disrupted by sonication to try to open up the matrix 
in order to make it easier for the cells to migrate into it. Alternatively, it may be the case 
that the tissue has to be repeatedly reseeded with cells in order to encourage the cells to 
penetrate and also in order to achieve a desirable cell density comparable to the native 
valve, or at least sufficient cells to maintain the tissue whilst host cells infiltrate the 
tissue once it is implanted in vivo. A further option would be to seed a layer of 
endothelial cells onto the tissue after the hMSC in order to protect the tissue and assist 
in the differentiation of the cells already in place. Furthermore, biochemical and/or 
biomechanical stimulation may also assist in increasing the amount and rate of cell 
migration into the tissue. 
A major advantage of this work in comparison to the works of others who have carned 
out cell reseeding is the number of cells used. Relatively few cells were used, which 
keeps the in vitro cell expansion and hence cell age to a miMmum. In contrast, a number 
of others who have re-seeded both synthetic matrices and decellularised matrices have 
used huge numbers of cells that would not be feasible in the clinical setting. For 
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example, Zand et al. (199 8) re-seeded a synthetic scaffold measuring IxIx0.3 cm With 
3.4xlO 6 cells 8-10 times every 90 minutes. Seeding strategies for whole valve 
constructs have used similarly large cell numbers, for example Schenke-Layland et al. 
(2003) used 3xlO 7 fibroblasts followed by gx 106 endothelial cells on day 16. 
Significantly, both failed to make any quantitative comparison with the cell density in 
the native tissue, frequently only stating that histologically the re-seeded tissue appeared 
similar to the native valve. ., and 
therefore an accurate measurement of the success of the 
re-seeding cannot be made. It is likely that a quantitative cell count would reveal that 
fewer cells were present in the construct than were initially seeded. This information 
could then be used to optimise the techniques and reduce the number of cells required 
for the initial re-seeding. 
Immunoperoxidase labelling of the tissues reseeded with both hMSC and hSMC in 
comparison to a native human aortic homograft valve revealed that both cell types had a 
phenotype comparable to the native homograft valve cells. However, in the case of 
hMSC., aSMA labelling revealed that the cells had become a mixed population,, some 
positive and some negative for this antigen. This suggested that the hMSC may have 
been in the process of differentiating into a new phenotype. This is supported by the 
finding that the cells were AP+1- prior to seeding and became uniforinly AP+ in the 
tissue. Consequently, it is possible that the cells were in the process of developing an 
osteogenic phenotype. This was verified by labelling the hMSC prior to seeding with 
markers to osteonectin and osteopontin, which revealed the cells to 
be osteonectin+/- and 
osteopontin+. However, after reseeding, the cells became osteonectin+ and osteopontin+. 
This could be explained by the age of the cells used for the reseeding 
(passage 8), and 
gives further support to the suggestion that osteogenic 
differentiation is the default 
pathway for hMSC that are not instructed to 
differentiate into another lineage. 
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Moreover, it may be a further reflection of inadequate culture conditions, which perhaps 
induced differentiation by a currently unknown mechanism. However,, if the reseeded 
tissue is exposed to mechanical stimulation in a pulsatile-flow bioreactor, it Might be 
possible that this differentiation could be prevented and the enviroranent created could 
instead encourage the cells to differentiate into an appropriate interstitial cell phenotype. 
However, although originally defined as bone-specific markers, both osteonectin and 
osteopontin have since been found to be expressed on other tissues. Osteonectin is 
principally associated with tissue mineralisation and hence bone fonnation., but it has 
also been found to be expressed on certain tumours and is also related to angiogenesis 
and some wound healing responses [Yan & Sage, 1999]. Similarly, osteopontin was 
originally identified as a major component of the non-collagenous organic bone matrix,, 
but has also since been found to be expressed in relation to cell adhesion and migration, 
being present in the gastrointestinal tract, gall bladder, pancreas, unnary and 
reproductive tracts, lung, salivary and sweat glands [Brown et aL, 1992]. Furthermore, 
alkaline phosphatase has been found to be present in relation to the liver [Lawson et al, , 
1985] and has been reported to be present on bone marrow reticulum cells (Westen & 
Bainton,, 1979] and even embryonic stem cells [Draper et aL, 20021. Therefore, rather 
than its presence on MSC being regarded as a negative finding, it could actually be an 
encouraging finding as it would compare favourably with other findings in relation to 
stem cells. Another aspect of this is that osteogenic differentiation 
is likely to have 
many stages and therefore, different labelling with different markers may represent cells 
at different stages of differentiation for different periods of time. 
However, a full 
analysis would require an investigation of the temporal markers of osteogenesis. 
Overall, this indicates that the assessment of osteogenic lineage on the MSC is not 
conclusive for showing that the cells 
have developed an osteogenic phenotype. Further 
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characterisation would be required to aid the analysis of the osteogenic default 
progression of hMSC, perhaps using an antibody to another bone marker such as 
osteocalcin. 
The lengths of the free edge of the reseeded leaflets were measured both before and 
after culturing the reseeded leaflets for 4 weeks. Both seeded cell types were observed 
to reduce the surface area of the leaflet in static culture conditions by up to 80%. It is 
possible that this occuffed because without mechanical stimulation the seeded cells 
began to digest and degrade the matrix without replacing it. It is possible that given the 
correct mechanical stimulation the cells would instead remodel the tissue in an ordered 
manner and would hopefully produce an appropriate matrix to maintain the tri-laminar 
structure of the leaflet. Here,. the use of a pulsatile-flow bioreactor would provide an 
environment comparable to a native heart valve and would therefore be the ideal means 
to test this theory. However, a more preliminary study could investigate what happens 
when cells are seeded onto a matrix that is kept under tension, or perhaps under 
controlled biaxial strain. The matrix components of the leaflet could then be measured 
both histologically and biochemically (as described in Chapter 6) in order to quantify 
how the envirom-nent created by the bioreactor influenced the cells to maintain and/or 
remodel the valve tissue. Similarly the phenotype of the cells could be monitored by use 
of FACS analysis. 
Overall, the most important factor in aiding the cell migration and differentiation is 
likely to be the effect of culturing the reseeded tissue in a pulsatile-flow bioreactor. The 
physical environment created would closely mimIc the natural conditions of a 
heart 
valve and it is likely that the mechanical stimulation will greatly assist in 
the 
differentiation of the cells and may also encourage the cells to migrate into the tissue 
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and to assume a native interstitial cell role of repairing and maintaining the tissue 
matrix. By these means, it may be possible to produce a tissue-engineered valve with a 
cell density close to that of the native valve where the cells have differentiated into cells 
capable of producing and maintaining the appropriate tri-laminar structure and 
withstanding the forces found in the native valve. 
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General Discussion 
he aims of this study were to develop methods for the isolation and 
characterisation of mesenchymal stem cells as a cell source for re-seeding a 
decellularised aortic heart valve matrix in order to create a living valve that is capable of 
growth,, repair and regeneration. In addition, a previously developed decellularised 
porcine valve matrix was further characterised and its biocompatibility assessed prior to 
being reseeded with putative human mesenchymal stem cells. Overall, although the 
decellularised matrix was found to be biocompatible and biochemically equivalent to 
native valve tissue, mesenchymal cells isolated from both porcine and human bone 
maffows could not be conclusively labelled as stem cells. 
The most recent definition of a stem cell is that of a cell with the folloWing capabilities 
[Verfaillie, 2002]: 
1. The ability to self renew; 
2. The ability for a single cell to differentiate into cells of the tissue of origin and 
into at least one cell type different from the tissue of origin; and 
3. The ability to functionally differentiate in vivo into cells of the tissue of origin 
and at least one cell type of a tissue other than the tissue of origin. 
During the course of this investigation, neither the porcine or human putative 
mesenchymal stem cells isolated conclusively matched all of these criteria. 
No in vivo 
analyses were carried out, ruling out the third requirement, 
furthermore, it became 
apparent during the course of the investigation that although the cells were capable of 
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renewal, it was only for a limited time-span in vitro and the cells ultimately appeared to 
become senescent. Attempts were made to differentiate both porcine and human 
putative MSC into multiple cell lineages. For the pMSC, attempts were made to 
differentiate the cells into cells of the osteogenic, chondrogenic, myogenic, adipogenic, 
neurogenic and smooth muscle cell lineages. However, despite multiple attempts using 
different reagents and concentrations,, only adipogenic differentiation was achieved. 
Furthermore, attempts were made to differentiate hMSC into cells of the adipogenic, 
myogenic, neurogenic and chondrogenic lineages. Of these attempts, adipogenici. 
myogenic and neurogenic differentiation was achieved in up to 20 % of the cells. 
However,, despite repeated attempts, the hMSC could not be cloned. This failed to rule 
out the possibility that the cell populations used contained multiple cell precursors and 
that the biochemical cocktail used to "differentiate" the cells merely selected for cells of 
the appropriate lineage whilst perhaps discouraging growth of other cells in the 
population. Despite these findings, FACS analysis of hMSC indicated the cells to have a 
similar phenotype to those described by Jones et aL (2002) who were able to clone their 
cells prior to differentiation. Whilst this is far from conclusive, it does suggest that 
further time and investigation may have yielded successful cloning and further 
differentiation of both cells sources in vitro. Further areas of investigation here could be 
to use an irradiated cell feeder layer to culture the cloned individual MSC upon in order 
that they could continue to receive adequate cell signalling that would not be present 
when cells are otherwise cultured individually. Further differentiation attempts could 
vary the quantities of reagents used or use different differentiation supplements as used 
by other researchers. 
Comparing the work of one person with that of others, however, is increasingly 
difficult. Whilst there are currently no markers available specific for MSC of any 
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source, the majority of investigators rely on a panel of antibodies to phenotype their 
cells and rule out the possibility of other cell types being present. However, whilst this 
is a common method, the choice of antibodies to use in the panel is not. Each group of 
investigators has their own opinion as to which antibodies need to be used, and very 
little consensus exists behind the rationale for choosing these markers. Until a specific 
marker can be generated, if indeed one exists, it is of vital importance for a widely 
agreed antibody panel to be devised. Not only would this enable an easier comparison 
of work from different laboratories, but it would also help to clarify the true nature of 
the cells, ultimately ascertaining whether all the different names currently used by 
different researchers to name these cells (as discussed in Section 1.10) are in fact the 
same thing, or whether it is possible to isolate stem cells at different stages of lineage 
commitment as some groups claim to be doing [Reyes & Verfaillie, 1999]. Furthermore, 
this could then aid the possibility of isolating stem cells from animal tissues. This would 
enable the use of animal models for tissue engineering and other purposes, which is a 
vital developmental step for any application that is ultimately to result in a product 
suitable for human implantation. 
Another problem is that the cells do not appear to be immortal, as the theory suggests 
they should be. Different groups claim to have propagated the cells for differing lengths 
of time from anywhere between 8 or 9 to 120 cell doublings; however, almost all 
ultimately indicated that the cells became senescent [Bruder et aL, 1998; DiGirolamo et 
aL, 1999; Grompe, 2002; Jiang et aL, 2002]. This may be because in vitro culturing 
conditions are simply not close enough to the natural in vivo environment. Other cell 
sources have been shown to de-differentiate when transferred to in vitro conditions 
[Bennet et aL, 1991; Ma et aL, 2003], therefore it may be that something similaT 
happens to stem cells which could be overcome by the addition of the correct growth 
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factors to the culture medium, or perhaps by using an irradiated cell feeder-layer to 
supply growth factors and other signals to the cells. Indeed, the culture of embryonic 
stem (ES) cells has required feeder layers and also leukaemia inhibition factor (LIF) 
supplements to maintain cell pluripotency [Evans & Kaufman, 1981; Thomson et al., 
1998]. Another possibility is that standard culture medium is too good for keeping the 
cells in an undifferentiated state. Culture media are typically designed to carry a full, 
balanced range of nutrients and salts in such concentrations that would not necessarily 
be found in tissues in situ where competition for nutrients would greatly reduce 
availability for any given cell and local clianges in blood flow and blood oxygenation 
could lead to cells living in a less than optimum environment. Therefore, a more 
simplified culture medium could be preferential for maintaining a multipotent 
differentiation capacity. Alternatively, it could be something unknown present in the 
complete culture medium used by most groups which is influencing the cells by either 
gradually selecting for osteogenic cells, or in some other way encouraging the cells to 
differentiate into the osteogenic lineage. Foetal calf serum is routinely added to growth 
medium as a "growth" factor containing poorly defined components capable of 
sustaining cells. The variance from animal to animal of the serum used is frequently 
cited by a number of groups who actively screen sera in order to find samples capable of 
promoting proliferation whilst maintaining the multipotential capacity of their cells 
[Lennon et aL, 1996; Conget & Nfinguell, 1999; Caterson et aL, 20021. If the sera could 
be more accurately analysed, a highly defined serum-free alternative could be 
devised 
which would enable consistent concentrations of factors to 
be used which could 
consistently provide the optimal conditions for the cells and may 
help to prevent 
unwanted differentiation. Furthermore, a defined serum-free growth medium would 
be 
I or use in tissue engineered applications where the use of bovine highly preferentia f, 
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serum remains highly problematic due to the potential for disease transmission such as 
bovine spongiforin encephalopathy (BSE). 
Studies have shown that the nuinber of hMSC and differentiation capacity of the cells 
decreases with the age of the patient from which they are harvested [Mendes et al., 
2002]. One limitation of this study has been that the hMSC used have been obtained 
-r- - ITom the bone marrow of patients undergoing hip replacement operations. This 
operation typically occurs in those aged over 60, and therefore the cells used may 
already have been restricted in their potential as a result of the patient's age. It is 
possible that if hMSC from younger patients had been available then differentiating and 
cloning the cells may have met with more success. Furthermore, cell longevity may 
have been improved. However, in combination with the apparent default to differentiate 
into the osteogenic lineage with in vitro cell ageing and the cuffently limited cell 
proliferation, it is possible that no in vitro environment could maintain the cells 
adequately. Therefore, rather than concentrating on trying to improve the conditions so 
that multipotency and longevity can been maintained, it may simply be easier to use 
cells that have undergone only limited cell doublings prior to being used in a tissue 
engineering application. The application of adequate biochemical and/or mechanical 
stimulation could then encourage the cells to differentiate into an appropriate lineage for 
the tissue engineering application rather than into an inappropriate default lineage. 
Yj- 
Flowever, this could only be carried out if the cells were appropriately analysed with an 
antibody panel prior to use so that the cells were adequately characterised and purified. 
Other tissue engineering applications have met with similar problems in relation to the 
poor identification of the hMSC. However, since the cells seem to differentiate to the 
osteogenic lineage, this is providing a useful cell source for those researching 
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osteogenesis and related areas [Haynesworth et aL, 1992; Allay et al., 1997; Jaiswas et 
aL,, 2000]. Due to the similar location and the relation in functioning of the tissues in 
situ, differentiation of the cells into the chondrogenic lineage also seems to be relatively 
straightforward. As such people have made use of this cell source for investigating 
cartilage and the replacement of cartilage defects [Wakitani et al., 1994; Caterson et aL, 
2001]. In other tissues where the potential of MSC has been investigated as a cell 
source, investigators frequently fail to carry out any analysis of the MSC at all prior to 
use in their system. Young et aL (1998) investigated the use of MSC in a collagen 
matrix for Achilles tendon repair. However, their paper fails to mention any analysis to 
establish that the cells isolated were MSC and instead appears to assume that merely 
isolating the cells by a common method means that the cells must be MSC. 
Furthermore, they again failed to clone the cells and must therefore be using a poorly 
defined heterogeneous population. This assumption that the cells must be MSC and lack 
of analysis of the cells is extremely common in the tissue engineering literature. This is 
a very poor scientific approach and only serves to add to the confusion about the 
phenotype and capabilities of MSC rather than clarifying the common issues and is 
something that must be addressed if the full potential of these cells is ever to be realised. 
During the course of this investigation, other researchers have attempted to tissue- 
engineer cardiovascular constructs using mesenchymal stem cells. Perry & Roth (2003) 
have assessed the use of ovine mesenchymal stem cells for tissue engineering heart 
valves. They identified their MSC primarily using SH2 antibody (which is known to not 
be specific for bone marrow stem cells as it cross-reacts with endothelial cells; Fleming 
et aL, 1998) and smooth muscle actin, calponin and desmin, which in combination are 
more specific for myogenic cells by the researcher"s own admittance. 
Furthermore, the 
only differentiation assay attempted was the adipogenic 
lineage; however without first 
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cloning the cells, this fails to show whether they were merely selecting for adipogenic 
cells, or whether there were adipogemc progenitors present rather than MSC and does 
not provide any evidence of multipotency. Moreover, no cell characterisation was 
carried out after the culture on a PGA scaffold, therefore the effects of the culture 
system on the cell phenotype were not assessed, leaving the possibility that the cells 
could have differentiated into an undesirable lineage. Furthermore, a large number of 
cells were used (2x 106 cells. CM-2) making it clinically unfeasible. Kadner et al. (2002) 
have also investigated the use of MSC for cardiovascular tissue engineering, and found 
that the cells labelled positively for vimentin and smooth muscle actin and showed 
layered tissue formation of extracellular matrix with deposition of collagen fibrils. They 
concluded that MSC demonstrated myofibroblast-like characteristics and represented a 
promising cell source for cardiovascular tissue engineering. However, as is frequently 
the case, they failed to show that the cells they were calling MSC showed any stem cell 
properties as they did not attempt differentiation of the cells, and the FACS analysis 
carried out used only a few antibodies whicb were poorly cbosen, using only CD14 
(expressed on the surface of cells of the myelomonocytic lineage such as monocytes and 
macrophages) and CD31 (expressed on the surface of platelets, monocytes, granulocytes 
and B-cells), which would only serve to rule out contamination by haematopoietic cells. 
It is vital that more basic, fundamental investigations are carried out on MSC to more 
accurately identify and characterise them. There is a need to optimise the culture 
conditions and establish more precisely the biochemical factors involved in the 
maintenance of pluripotency and differentiation in order to fully control these cells and 
encourage them to do exactly what is required by the researcher 
in a manner comparable 
to how they are controlled in vIVo. Areas to investigate here could use chemically 
defined media supplemented with growth factors to culture the cells and the resulting 
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effects could be examined by assessing changes in gene transcription using reverse- 
transcriptase polymerase chain reaction (rt-PCR) or cell surface markers using FACS 
analysis. True control of stem cells at this level will make their application in tissue 
engineering strategies considerably easier and will have implications for the 
understanding of all cells throughout the body. Indeed, if the means by which the body 
recruits the normally quiescent, resting stem cells to injury sites could be ascertained, 
then enhancement of this signal could allow improved harvesting of the cells for in vitro 
manipulation, or perhaps could even abrogate the need for tissue engineering entirely in 
some applications as enhanced cell recruitment to specific locations could enable the 
I- 
body to repair itself more efficiently without the need for surgical or other intervention. 
Only by carrying out this fundamental research can the true potential of these cells be 
realised and their potential as an adequate competitor to embryonic stem cells, without 
the ethical nightmare associated with ESC, be assessed outright. 
With respect to the heart valve scaffold, the matrix developed by Booth et aL (2002) 
would appear to be extremely promising for use in tissue engineering a living aortic 
heart valve. Histological analyses have shown matrix components to remain intact 
[Booth et aL, 2002], whilst mechanical testing has demonstrated that the SDS treatment 
produced valves with equal strength, competence under physiological pressures (120 
mm 3 Hg) and greater extensibility than untreated fresh valves [Korossis et aL, 2002]. 
However,, histological assessment alone is only a qualitative means of assessing the 
procedure. Consequently, investigations were carried out in this study in order to make 
a quantitative biochemical comparison between fresh and decellulansed porcine aortic 
heart valve leaflets in order to ensure that the matrix was unaffected 
by the procedure. 
This was found to be the case as the biochemical analyses showed no significant 
changes in GAG or hydroxyproline content of the 
leaflet. Furthermore, analysIs of DNA 
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content indicated that the DNA had been removed by the decellularisation procedure. 
The biocompatibility of the decellularised tissue was assessed by subcutaneous 
implantation in a murine animal model for twelve weeks. This revealed that the 
decellularised tissue did not calcify and that the inflatninatory infiltrate was favourable, 
consisting mainly of macrophages and endothelial cells. Furthermore, histological 
examination indicated that the implanted decellularised tissue did not become necrotic 
and instead remained healthy in appearance. One possible further investigation here 
would be to implant tissues for a longer period. This is because although the presence of 
macrophages at 12 weeks seen here was deemed beneficial in order to attract 
endothelial cells required for remodelling of the tissue , if the tissue is fully accepted by 
the bost,, the number of macrophages sbould later decrease as a sustained persistence of 
macrophages in the tissue would suggest that the tissue was inflammatory. 
Decellularised valve leaflets were later re-seeded with hMSC and these were shown to 
penetrate into the tissue to up to 2% of a native valve. Although poor when compared 
to a native homograft, there are multiple options to explore which may enhance this re- 
cellularisation phase of the investigation. Mechanical stimulation of the re-seeded 
tissues alone may provide adequate conditions to improve cell infiltration into the 
tissue. Alternatively, treatment of the tissue by, for example, coating the tissue with 
fibronectin, could improve cell attachment and migration. The tissue could also be 
disrupted by use of, for example, sonication in order to provide more openings for the 
cells to migrate through. Analysis of the wound healing response in heart valve leaflets 
could possibly yield factors which could encourage cells to infiltrate into the tissue and 
once in vivo could aid the migration of host cells into the tissue engineered matrix. 
Other options include multiple cell seedings to try to increase the cell density. However, 
this would have to be balanced against the practicalities of growing sufficient cells 
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within an appropriate time frame to deliver the product to the patient. Furthermore, too 
many cell doublings in vitro could lead to cells with limited proliferation capacity 
unless the culture conditions could be adequately ILMproved to increase the longevity of 
the cells. Altematively, it may be possible to stimulate the seeded cells to divide in situ 
by the addition of growth factors. However, these would have to be carefully screened 
to ensure that they did not have an effect on the differentiation of the cells,, and also to 
ensure that once the stimulation is removed cell division would slow again to normal 
levels as too many cells could affect the mechanical properties of the tissue. It may also 
be the case that a layer of endothelial cells may be required to protect the tissues and re- 
seeded cells: The factors released by these cells may aid the migration and 
differentiation of the hMSC whilst protecting the tissues and preventing blood clot 
fonnation on the valve leaflets. 
Prior to re-seeding, the hMSC phenotype was assessed using osteogenic markers as it 
was suspected that the cells would default to the osteogenic lineage if no other cell 
signals were received. It appeared as though the cells were becoming osteogenic and 
this was further highlighted when the phenotype of the cells was analysed after re- 
seeding into the decellularised matrix using markers for alkaline phosphatase, 
osteonectin and osteopontin. However, the combination of results obtained from 
labelling cells with vimentin, aSMA, HCMs and desmin indicated that the re-seeded 
cells had a phenotype similar to valve interstitial cells and it was later found that the 
osteogenic markers used were not sufficiently specific to show conclusively that the 
cells were osteogenic in nature. Further analysis using a more specific bone marker such 
as osteocalcin could give ftuther indication to whether osteogenic differentiation did 
occur. However, it is likely that dynamic culturing of the leaflets in a re-seeded whole 
valve using a pulsatile-flow bioreactor would provide adequate signalling to prevent this 
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differentiation and would instead encourage the cells to develop an interstitial cell 
phenotype. The effects of mechanical stimulation on MSC have already been 
demonstrated by Altman et aL (2002) who have shown mechanical stimulation to cause 
a change in gene expression, resulting in cells of a ligament cell lineage. Similar results 
have also been achieved by stimulating fibroblasts and aortic endothelial cells, as 
described in Section 1.11.3. Furthermore,, as already discussed, using cells that have 
undergone fewer cell doublings may also circumvent this problem. 
The matrices currently being researched by other groups are most commonly of 
synthetic origin. Synthetic matrices have the problem that the matrix is usually 
mechanically weak in comparison to the native valve and relies upon rapid remodelling 
by seeded cells and host tissues in vivo to provide improved mechanical strength. In 
contrast, although remodelling will eventually occur in any tissue that is implanted, the 
use of a decellularised valve matrix would ensure that the mechanical requirements 
would be optimal at the point of implantation so there would be no period of 
remodelling that is essential for adequate valve ftniction. Synthetic matrices that have 
been tested in animal models have met with some promising results [Shinoka et aL, 
1996; Kim et aL, 2001; Rothenburger et aL, 2002], however, the investigators 
P-- - frequently failed to fully characterise the valves upon explantation, usually relying on 
basic histology alone for analysis, making it difficult to fully assess the degree of 
success. One use of decellularised porcine tissue has been in the acellular 
SYNERGRAFT'fm valve developed by Cryolife Inc. However, as discussed in Chapter 
1,, this failed very quickly and catastrophically in human trials [Simon et aL, 2003], 
suggesting a hyper-acute immune rejection. Others have investigated a decelludansed 
porcine aortic heart valve matrix re-seeded with autologous endothelial cells and 
implanted into an ovine model [Dohmen et aL,, 20011. The focus of this particular 
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research was to investigate the calcification potential of the implant and it was found to 
be comparable to a non-implanted valve tissue-engineered in the same manner. 
There are, however,, two fundamental problems with using porcine tissue: firstly Is the 
issue of adequate disinfection of the tissue prior to implantation. In the studies presented 
here,, the tissue was disinfected with an antibiotic cocktail prior to reseeding with cells. 
This means of disinfection was not intended to be a pennanent choice, but was merely 
an in vitro tool to produce a matrix for study. This study was part of a larger programme 
that aims to re-seed decellularised valves with terminally differentiated cells, and this 
programme is in collaboration with the National Blood Service Tissue Services (NBS) 
as a means of ultimately delivering the final product to patients through the NHS. 
Because of their familiarity with the legislation involved in delivering products to 
patients, the NBS took on the role of developing an appropriate sterilisation technique. 
Consequently, the antibiotic cocktail has now been superseded by the use of peracetic 
acid treatment of the tissues (0.1 % v/v for 3 hours) as a means of sterilising the tissue. 
The sterilising capabilities of peracetic acid have been known about for over 100 years 
and it has been widely used as a cold disinfectant for heat labile medical equipment and 
is also used widely in the food and agriculture industries [Lomas et aL, 2003; Kitis, 
2004]. It is believed to be active against bacteria, viruses, bacterial spores and protozoan 
cysts [Kitis, 2004]. Despite this treatment, the issue of porcine endogenous retroviruses 
(PERVs) potentially remains a problem [Patience et aL, 200 1; Blusch et aL, 20021. Pigs 
are known to carry these retroviruses asymptomatically,, but there are concerns that they 
could be transmitted to humans with unknown effects through tissue engineered 
products. Indeed, they have been readily detected in native porcine heart valves [Moza 
et al, 2001]. Since viruses are obligate intracellular parasites, if the porcine cells are 
completely removed, then so should any virus material that may 
be present. However, 
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the presence of PERVs needs to be fully assessed before and after decellularisation to be 
certain as they have been shown to infect human cells in vitro [Patience et aL, 1997; 
Martin et aL,. 1998; Wilson et aL, 1998; Specke et aL, 2001] and poorly Judged 
assumption could lead to catastrophic consequences for any recipient patient. In order 
for the efficacy of peracetic acid against these viruses to be tested,, ideally, tissues would 
have to be spiked with known concentrations of the virus prior to measuring the effects 
of the peracetic acid treatment and assessment of whether any infectious virus material 
remained. 
A second important potential problem With the transplantation of animal tissues into 
humans is the issue of the Galal-3Gal (a-gal) epitope. This is a sugar residue known to 
be present on the surface proteins and glycoproteins of all animal cells except humans 
and old-world non-human primates [Teranishi et aL, 2002]. Humans have developed a 
high-titre antibody response to antigens present on bacteria found in the human gut 
which cross-react with the a-gal epitope found on animal cells [Galili et aL, 1987]. 
Therefore, should an a-gal positive organ be implanted into a hwnan, antibody would 
bind to the antigen expressed on endothelial cells resulting in the rapid activation of the 
complement cascade which would lead to clotting and blockage of the vessels resulting 
in hypoxia followed by necrosis of the tissue in a process known as hyper-acute 
rejection. If an a-gal positive matrix were to be implanted into a human, again the 
antibody would bind to the antigen, but in this situation the subsequent inflammatory 
response would lead to a cascade of events that would give nse to the attraction of 
neutrophils and macrophages to the area, ultimately resulting in inflammation and the 
degradation of the implanted matrix. Indeed, a-gal has been shown to be implicated in 
the hyper-acute rejection of porcine organs transplanted into human recipients 
[Maruyarna et aL, 1999]. Whilst this in theory would not be a problem provided 
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complete decellularisation of the matrix is achieved, it is something that needs to be 
fully verified through research as the consequence of implanting tissues where this has 
not been investigated and dealt with accordingly could be devastating to the patient. 
Monoclonal antibodies against a-gal are now commercially available and therefore the 
presence of this antigen can be readily assessed by immunolabelling, thereby allowing 
techniques to remove the antigen to be developed. a-gal knock-out pigs have now been 
bred [Lai et aL, 2002], however, in order to provide a tissue-engineered living heart 
valve to the NHS through the NBS as a suitable alternative to currently available valve 
replacements, it would also have to be economically viable. Overcoming patents and 
similar legal issues relating to the knock-out pigs would greatly increase the overall cost 
of delivering a tissue engineered valve to a patient. Thus it is vital firstly to assess 
whether indeed this would be a problem in heart valves, as it has been suggested that it 
is not [Chen et aL, 2003], and secondly, if a problem exists, to develop a modification to 
the decellularisation procedure which could adequately remove a-gal residues. 
7.1 Future studies 
A vital issue is the cloning of the hMSC to more accurately demonstrate their 
multipotential capacity and to rule out the possibility of multiple cell precursors being 
present in the bone marrow. A method needs to be developed which enables this to be 
carried out in a relatively straightforward manner in order that it can be routinely carried 
out to ensure that all research is carried out on purified cell populations. Options here 
include the use of an irradiated cell feeder layer to culture the cells with in order that the 
individually cloned cells receive adequate stimulation from neighbounng cells whIch 
might prevent premature senescence. Alternatively, growth factors may 
be required to 
maintain the cells in an undifferentiated state in a way comparable to the culture of 
ES 
cells where LIF has been used to prevent differentiation 
[Evans & Kaufman, 1981 1, 
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Thomson et aL,, 1998]. One possibility would be fibroblast growth factor-2 (FGF-2),, 
which is known to stimulate endothelial cell proliferation [Bikfalvi et al., 1997] and has 
been shown to have encouraging effects on MSC from various sources [Tsutsumi et aL, 
2001]. The continued use of unpurified cell populations in research is particularly 
unhelpful for comparison between different laboratories, and also fails to show which 
cell population of the bone marrow is being used in the application, leaving a great deal 
of vagueness about the exact science of the whole process. 
Another interesting approach would be to investigate how mesenchymal stem cells 
change as the patient from which they are harvested ages and how this could affect their 
usefulness for tissue-engineering and other therapies. Whilst in younger patients MSC 
would be in optimal condition, making them ideal for tissue engineering applications, 
the same may not be true for cells of older patients. It is known that the differentiation 
capacity of MSC is reduced with patient age (Caplan, 1994; Digorolamo et aL, 1999; 
Mendes et aL , 
2002) and as discussed in Chapter 1, there is the possibility of a link 
between neoplasia and stem cells and the accumulation of a life-time of age-related 
degeneration and cell damage would be likely to reduce the regulatory control the body 
has over stem cells. Therefore the application of MSC from older patients in a tissue- 
engineered product, even if they are differentiated in vitro, could potentially create more 
problems than the tissue-engineered product might solve. 
Furthermore, as discussed previously, it is of absolute critical importance to investigate 
the means to remove both PERVs and a-gal residues if porcine tissue is to 
become a 
viable option for tissue engineering products for human implantation. 
Without this 
work, the progression to human studies simply cannot occur and 
it will hold back any 
tissue-engineered products using un-fixed animal tissues. 
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However,, without doubt, - the most 
important and exciting future study carrying on from 
this research will be the use of a pulsatile-flow bioreactor to culture the re-seeded valves 
in vitro. A number of groups have already created bioreactors for creatIng tissue- 
engineered heart valves, Both Hoerstrup et aL (2000) and Zeltinger et aL (2001) have 
n+n' created similar pulsatile-flow bioreactors. They are both relatively simple in design, 
being capable of culturing one valve construct at a time by re-circulating culture 
medium in a closed loop system at varying speeds and volumes to cause the valves to 
open and close. This simplistic approach, whilst providing mechanical stimulation, is 
undermined by the fact that only one valve can be cultured at a time, meaning that no 
replicates can be cultured simultaneously, making it impossible to carry out any 
statistically relevant analyses of the outcomes when the allotted culture time is 
completed. 
As part of the heart valve project, the construction of a pulsatile-flow bioreactor has 
recently been completed and is currently undergoing early-stage evaluation (Figure 7.1) 
[Ingham & Fisher, 2003]. The bioreactor has the capacity to culture between I and 6 
valves simultaneously, which are sutured into frames that sit Within transparent 
chambers to enable visual monitoring of the valves during culture. There is a central 
mitral valve incorporated into the system and the pump is capable of producing 
physiological pressures of up to 120 MM3 Hg with a varying stroke rate. There is a 
medium reservoir and a conditioning system able to maintain appropriate conditions by 
monitoring temperature, oxygenation and pH of the culture medium. It is hoped that 
with a primary static seeding stage to allow the cells to attach to the leaflet, reseeded 
valves could then be introduced into the bioreactor and the pressure and flow of the 
medium gradually increased to physiological conditions so as to avoid washing off the 
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cells. It is thought that the mechanical environment created during the culturing of re- 
seeded valves for up to 6 weeks would aid in the cell migration and differentiation and 
would encourage the cells to produce an appropriate matrix to create a fully functional 
tissue-engineered valve replacement. Re-seeding decellularised matrices with porcine 
smooth muscle cells and then implanting the pulsati le- cultured constructs back into a 
porcine animal model would show the potential for using the system for creating a valve 
re-seeded with human cells for use in clinical trials. 
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Figure 7.1. Pulsatile-flow bioreactor for tissue engineering a living heart valve 
[Ingham & Fisher, 20031. 
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Appendix 
APPENDIX 
Suppliers 
Amersham Pharmacia Biotech UK Ltd, Amersham Place,, Little Chalfont, Bucks HP7 
9NA. 
Appleton Woods Ltd, Lindon House, Heeley Road, Selly Oak, Binningham, B29 6EN. 
BD Biosciences, (fonnerly Becton Dickinson), 21 Between Towns Road,, Cowley, 
Oxford, OX4 3LY. 
Beckman Coulter UK Ltd, Oakley Court, Kingsmead Business Park, London Road, 
Fligh Wycombe, Buckinghamshire, IHPI I IJU. 
Bibby Sterilin Ltd, Tilling Drive, Stone, Staffordshire,, ST 15 OSA. 
Bio-Rad Laboratories Ltd, Life Science Research Division, Bio-Rad House,, Maylands 
Avenue, Hemel Hempstead, Hertfordshire, IHP2 7TD. 
Biowhittaker UK Ltd, I Ashville Way, Wokingham, Berkshire, RG41 2PL. 
BOC Ltd, The Priestly Centre, 10 Priestly Road, The Surrey Research Park, Guilford, 
Surrey, GU2 5XY. 
Bright Instruments Co Ltd, Margarets Way, Huntingdon, Cambridgeshire, PE29 6EU. 
C. A. Hendley (Essex) Ltd, Oakwood Hill Industrial Estate, Loughton, Essex, IG 10 
3TZ. 
Caltag-MedSystems Ltd, PO Box 6139, Silverstone, Towcester, NN12 8GN. 
Chemicon Europe Ltd, The Science Centre, Eagle Close, Chandlers Ford, Hampshire, 
S053 4NF. 
Corning Costar UK Ltdq I The Valley Centre, Gordon Road, High Wycombe, Bucks, 
IIP13 6EQ. 
DAKO Ltd, Denniark House, Angel Drove, Ely, Cambridgeshire, CB7 4ET. 
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Suppliers 
Developmental Studies Hybridoma Bank (DSHB), Department of Biological 
Sciences5 University of Iowa, 028 BBE, Iowa City, IA 52242-1324. 
DYNEX Technologies Ltd, Columbia House, Columbia Drive, Worthing, West 
Sussex, BN13 3HD. 
European Collection of Cell Cultures (ECACC), Centre for Applied Microbiology 
and Research, Salisbury, Wiltshire, SP4 OJG. 
Fisher Scientific UK Ltd, Bishop Meadow Road,, Loughborough, Leicestershire, LEI I 
5RG. 
Harlan UK Ltd, Shaw's Farm,, Blackthom,, Bicester, Oxon, OX2 51 TP. 
ICN Pharmaceuticals Ltd, Cedarwood, Chineham Business Park,, Crockford Lane, 
Basingstoke, RG24 MD. 
Invitrogen, (formerly Life Technologies Ltd), 3 Fountain Drive, Inchinnan Business 
Park, Paisley, Scotland, PA4 9RF- 
Jencons (Scientific) Ltd, Cherrycourt Way, Stanbridge Road, Leighton Buzzard, 
Bedfordshire, LU7 4UA. 
KI endro Laboratory Products, (formerly Heraeus Instruments and Sorvall), Sortford 
Hall Park, Bishops Stortford, Herts, CM23 5GZ. 
Leica UK Ltd, (formlery Leitz), Davy Avenue, Knowhill, Milton Keynes,, MK5 8LB. 
MediaCybernetics UK, Falcon Business Park, 40 Ivanhoe Road, Finchampstead, 
Berkshire, RG40 4QQ. 
Molecular Probes Europe BV, PoortGebouw, Rijnsburgerweg 10,2333 AA Leiden, 
The Netherlands. 
National Blood Service (NBS), Trent Regional Centre, Longley Lane, Sheffield, S5 
VN. 
NJIS Supplies Authority, NE Division, Foxbndge Way, Nonnanton Industrial Estate, 
Nomianton, WF6 I TL. 
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Nunc Inc, 200ON Aurora Road, Naperville, EL, USA 60566. 
_ 
upphers 
Olympus Optical Company UK Ltd, Great Western Industrial Park, Dean Way, 
Southall, Middlesex,, UB2 4SB. 
Oxoid (Unipath) Ltd, Wade Road, Basingstoke, Herts, RG24 OPW. 
John Penny & Son Abattoir, Low Green Farm, 40 Leeds Road,, Rawdon, West 
Yorkshire,, LS19 6NU. 
Pharmacia Biotech, 23 Grosvenor Road,, St Albans, Herts, AL I 3AW. 
Raymond A. Lamb Ltd, Units 4&5 Parkview Industrial Estate, Alder Close,, 
Lottbridge Drove, Eastbourne, East Sussex, 
' BN23 6QE. 
R&D Systems Europe Ltd, 19 Barton Lane, Abingdon Science Park, Abingdon, OX 14 
3NB. 
Roche Diagnostics Ltd, Bell Lane, Lewes,, East Sussex,, BN7 ILG. 
Sanyo Gallenca mp PLC, Monarch Way, Loughborough, LE II 5XG. 
Schleicher & Schuell UK Ltd, Unit 11, Brunswick Industrial Estate, London, NW II 
IJL. 
Scientific Laboratory Supplies Ltd, 26-27 Nottingham, South & Wilford Industrial 
Estate, Nottigham, NG II 7EP. 
Serotec Ltd, 22 Bankside, Station Approach, Kidlington, Oxford, OX5 I JE. 
Sigma-Aldrich Company Ltd. Fancy Road, Poole, BH17 3NH, Stevenage, Herts, SG I 
4QN. 
Starlab (UK-) Ltd, 4 Tanners Drive, Nfilton Keynes, MK14 5NA. 
Stem Cell Technologies, PO Box 35727, London, E14 9YE. 
Thermo Life Sciences Ul*' C, Unit 5, The Ringway Centre, Edison Road, Basingstoke, 
Hampshire, RG21 6YH- 
Triangle Bionledical Sciences Ltd, Unit 5, Gardiners Place, West Gillibrands, 
Skelmersdale, Lancashire, WN8 9SP. 
2-4 
Sup pliers 
Vector Laboratories Ltd. 3 Accent Park, Bakewell Road, Orton Southgate, 
Peterborough, PE2 6XS. 
VWR Internaltional Ltd, (fonnely Merck Eurolab), Hunter Boulevard, Magna Park, 
Lutterworth, Leicestershire, LE17 4XN. 
Whatman International Ltd, Whatman House, St Leonard's Road, 20/20 Maidstone, 
T. 1-1, - Kent, ME 16 OLS. 
Wilkinson's, 8/24 Albion Street, Leeds, West Yorkshire, LS I 6HX. 
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